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Abstract 
Vitamin A and its derivatives, collectively termed retinoids, are a group of natural and 
synthetic molecules that are structurally and/or functionally analogous. Retinoids are 
essential for many biologically important processes during mammalian embryogenesis 
and adult homeostasis. Consequently, retinoids are often used to modulate cell 
proliferation and differentiation of cultured stem and progenitor cells in the laboratory, 
and possess the potential for use in numerous clinical applications. For example, retinoids 
are already applied as treatments of dermatological disorders, and as part of 
chemotherapeutic programmes for certain types of cancer. 
The importance of optimal retinoid function in embryonic neural development is well 
known, and is now being realised in certain adult neural progenitor cell populations. It 
has been shown that all-trans-retinoic acid CATRA), which activates all retinoic acid 
receptor subtypes, is the main active natural retinoid, inducing neural differentiation in 
several cell model systems, including embryonic stem cells and adult neural progenitors. 
The in vitro study of A TRA, however, is complicated by its photo-isomerisation and 
degradation when used under standard laboratory conditions. This instability has obvious 
disadvantages, for example, in stem cell biology where the ability to control the 
development of cells and tissues in a predictable way is paramount. Human stem cells 
present the opportunity to produce tissues that can be used for basic research into health 
and disease, development of pharmaceuticals, toxicological tests and ultimately cell 
replacement therapy. Biologists require molecules that induce reliable and reproducible 
biological activity resulting in consistent modes of cell differentiation. To address this 
issue, a small library of synthetic retinoids have been designed and prepared and their 
biological activity investigated. This thesis focused on the synthesised A TRA retinoid 
analogues, EC 19 and EC23 and aimed to evaluate their biological activity in relation to 
A TRA on a number of different embryonic and adult model systems. Unlike ATRA, 
these compounds do not isomerise in response to light or heat. Data show that both 
compounds are effective at inducing differentiation. In moc!el embryonic stem and adult 
progenitor cell culture systems both neural and non-neural cell sub-types are induced 
after EC 19 or EC23 treatment. Specifically, EC23 elicited similar cellular responses to 
ATRA when tested in vitro, inducing significant neural differentiation in the model cell 
'systems and appears to do so via specific retinoic acid functional pathways. EC 19, 
however, induced different proportions of the cell-types observed after A TRA and EC23 
media supplementation, inducing differentiation towards predominantly non-neural, 
epithelial-like phenotypes in stem cell models, and enhanced glial differentiation in adult 
progenitor models. Interestingly, EC19 also appeared to enhance the proliferation of a 
neuroblastoma model, in stark contrast to both A TRA and BC23 which induced a degree 
of neural differentiation. 
Both synthetic retinoids induce an up-regulation of cellular proteins involved with 
retinoic acid metabolism and signalling, suggesting that they elicit their effects directly 
via these pathways. Therefore EC 19 and EC23 represent promising candidates as 
alternatives to A TRA for directing cell differentiation and investigating the molecular 
pathways involved in neural cell development and retinoid modes of action in vitro. It is 
anticipated that this work will enhance research into retinoid mediated neural 
differentiation. Finally, stable, synthetic modulators of cell-differentiation offer distinct 
advantages over existing technology and will be of significant commercial value. 
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1 Chapter 1: Introduction 
1.1 Literature review 
In 1960, the International Union of Pure and Applied Chemistry - International Union of 
Biochemistry (IUP AC-IUB) recommended the nomenclature of t~e three parent vitamin 
A compounds to be retinol, retinal and retinoic acid. By 1982, IUPAC-IUB had defined 
the term vitamin A as 'The generic descriptor for retinoids exhibiting qualitatively the 
biologicaJ activity of retinol,' and a retinoid as 'a class of compounds consisting of four 
isoprenoid units joined in a head-to-tail manner, formally derived from a monocyclic 
parent compound containing five carbon-carbon double bonds and a functional group at 
the terminus of the acyclic portion'. This nomenclature is still in part used today and 
incorporates both natural and synthetic analogues of retinol. The correct structure for 
retinoic acid (all-trans) (ATRA) was proposed in 1931 1. 
Natural retinoids are essential for all chordates, being involved in a wide variety of 
processes during embryogenesis and adulthood. In humans, vitamin A deficiency (V AD) 
is characterised by xerophthalmia (dry eyes), night blindness and impaired immune 
responses which, in clinical cases, can prove fatal. V AD is largely associated with 
developing countries where vitamin A fortified or rich foods are in poor supply. 
According to a report by the World Health Organisation (WHO) in 1995 2, VAD is a 
public health problem in over 120 countries. Over 1 million childhood deaths are 
associated with V AD annually and 3 million people are said to be clinically vitamin A 
.-
deficient. However, excessive .dietary or therapeutic intake of vitamin A 
(Hypervitaminosis A) can also give rise to a range of problems associated with skin, 
nervous system, circulation, bone formation and immune system and malformations of 
the foetus 3. Both of these conditions indicate the importance of the close regulation of 
retinoic acid up-take and metabolism. 
As retinoids are able to be transported to the central nervous system (CNS), an excess or 
deficiency can prove detrimental to normal mental development, being linked to various 
disorders such as retardation and depression. This literature review summarises work into 
retinoid function and biochemical pathways, and focuses on the roles of retinoic acid and 
/'07"-. 
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1 
its isomers in normal and abnormal neural regulation and differentiation. It also covers 
the instability of A TRA when used under standard laboratory conditions and the potential 
use of synthetic retinoid compounds to overcome this issue. This review also covers the 
potential therapeutic applications of synthetic retinoid compounds in treatment of 
numerous neurological disorders. 
1.2 Retinoid Function: 
-One of the earliest discoveries of a specific retinoid function was in 1968 4, when it was 
discovered that ll-cis-retinal was the chromophore component of the photoreceptors in 
the visual cycle. Since then, however, retinoids have been found to play key essential 
roles in numerous biologi~al processes, including vision 4, reproduction 5, immune 
competence 6, cellular regulation and differentiation in post-natal and adult organisms 7,8 
and embryonic growth and development 9. 
The importance of vitamin A during embryonic development was exemplified in studies 
of VAD and hypervitaminosis A during pregnancy. Both conditions resulted in 
embryonic/foetal malformations ranging from disorders of the skin, nervous system, and 
immune system (for a detailed review see Blomhoff and Blomhoff 2006 10). This need for 
a very defined and regulated concentration of retinoids during embryogenesis fitted with 
the discovery that A TRA was a potent morphogen during embryonic development II, 
involved in limb formation, body axis orientation and dorsal/ventral patterning of the 
eNS in vertebrates, which will be discussed in more detail below. 
The ability of certain tissues, and indeed whole organs, to regenerate under defined 
conditions is well-known and retinoic acid has been shown to playa key part. The 
specific pathways and genes involved have been shown to be the same as those activated 
during the initial development of the tissue in question 12. Therefore, any pathway which 
involved retinoic acid during development, would involve retinoic acid during adult 
regeneration, if it occurred. The ability of tissues to regenerate is classically illustrated in 
experiments of limb regeneration in urodele amphibians. During amputation studies in 
axolotls, it was shown that application of retinoic acid to the wound site induced a 
2 
concentration-dependent increase in the amount of tissue regenerated after exposure 13, 14. 
For example, at low concentrations of retinoic acid, an extra complete ulna and radius 
was regenerated, and at high retinoic acid concentrations a complete extra limb was 
regenerated from the amputation site. This ability to regenerate tissue is not exclusive to 
amphibians, but has been reported in many species including mammals, for example lung 
tissue regeneration after retinoic acid treatment of adult rat models of lung disease 15, 16. 
As retinoic acid is involved in many developmental processes, including lung and CNS 
development, retinoic acid induced regeneration has obvious therapeutic potential as a 
'self-repair' treatment for many different medical conditions. Unfortunately, in the case 
of spinal chord injury, the adult mammalian CNS has lost its ability to regenerate itself 
after damage or disease. However, as retinoic acid and the machinery required for gene 
activation are all present during the tissue's development, it can be assumed that adult 
regeneration does not occur as a result of one or more of these components either being 
inhibited or absent in the adult system 17. This feature has therefore become the focus for 
numerous research studies into spinal chord regeneration and neurodegenerative disorder 
treatment. 
1.3 Vitamin A Intake and Storage: 
Vitamin A cannot be synthesised by any animal species, and is obtained through diet, 
either in the form of pro-vitamin A carotenoids (such as ~-carotene) from plants or pre-
formed vitamin A, usually in the form of retinyl este:rs, from eating animal products 
(stores of ingested vitamin A). Once digested, all of these compounds are re-esterified, 
via enzymatic action, in the intestinal lumen and mucosa, and then packaged into 
chylomicrons and transported to the liver. The liver is the major site for storage and 
processing of these compounds within the body 18. Much of the retinol is stored as retinyl 
palmitate, which is formed after reversible enzymatic activity. When required, retinol is 
secreted from the liver and transported around the vascular system bound to retinol 
binding protein (RBP) 19. 
Circulating retinol is aided across the cytoplasmic membrane by the retinol binding 
protein receptor 20. Once retinol has entered the cell cytosol it can either be stored locally 
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for future use (as retinyl esters) or be converted into forms that activate certain cellular 
biochemical pathways leading to a modulation of gene transcription (Fig. 1.1a). 
The predominant active retinoid in the body is A TRA. A TRA is created from retinol via a 
two step reaction. Retinol is oxidised to retinal, catalysed by retinol dehydrogenases 
(ROLDH), then retinal is oxidised to ATRA catalysed by retinal dehydrogenases 
(RALDH) 1 8, (see Fig. 1.1b). The storage or breakdown of retinol occurs within the 
cytosol due to the presence of proteins which bind it with high affinity, called cellular 
retinol binding protein I (CRBP-I) and cellular retinol binding protein II (CRBP-II). 
CRBP-I is ubiquitously expressed throughout the organism, and appears to facilitate 
cellular uptake and metabolism of retinol into either its storage or active forms. CRBP-II 
is exclusively found in the villi of enterocytes where it is involved in the conversion of 
retinol into retinyl esters for chylomicron export to the liver 21. Within some cells there 
are also cellular retinoic acid binding proteins I and II (CRABP-I and CRABP-II). 
CRABP-I has been shown to playa key role in ATRA homeostasis, however, it was also 
shown to not be directly involved in activating the retinoic acid receptor signalling 
pathway 22, and later it was discovered that CRABP-I was involved in the storage and 
metabolism of free A TRA, thereby inhibiting the biological activity of the metabolite 23. 
Generally, it has been found that cells containing an excess of CRABP-I do not respond 
as readily to ATRA. The role of CRABP-II is less well understood and has only recently 
been validated. It has been shown that CRABP-II aids the transport of ATRA into the 
nucleus and interacts with receptor heterodimers 24, channelling ATRA to the receptors 
thereby sensitising cells to A TRA 25. The tissue specific expression of these important 
retinoid regulators indicates their complex nature of action and involvement in many 
biological processes. 
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Figure 1.1 A: Overview of retinoid action. 1: Ingested retinoids are converted to all-trans-retinol 
in the intestinal lumen and mucosa by enzymatic action. AII-trans-retinol is then packaged into 
chylomicrons and transported to the liver, which is the major site for storage and processing of 
this compound. Much of the retinol is stored as retinyl palmitate, which is formed after reversible 
enzymatic activity. 2: AII-trans-retinol is transported around the vascular system bound to retinol-
binding protein (RBP), and accesses target cells via the retinol binding protein receptor (RBP-R). 
3: The retinoid binds to the nuclear retinoic acid receptors (RAR & RXR) which act as signal 
transducers. 4: Activated ligand/receptor complexes modulate gene expression by binding to 
specific retinoic acid response elements (RARE) located in the regulatory regions of target genes. 
Diagram taken from Christie et al 2008 123 . 
Retinol Retinal 
Dehydrogenase Dehydrogenase 
~H~H_~CHO_ ~COOH 
All-trans retinol All-trans retinal All-trans retinoic 
acid 
Figure 1.1 B: Retinol is converted to the active form 'all-trans retinoic acid' via a two step reaction . 
Retinol is first reversibly converted to retinal, catalysed by retinol dehydrogenase. Secondly, retinal 
is irreversibly converted to all-trans retinoic acid, catalysed by retinal dehydrogenase . Diagram taken 
from Christie et al 2008 123 • 
1.4 Retinoic Acid Receptors: 
Retinoids elicit biological activity via retinoic acid receptors (RAR) which are located in 
the nuclear envelope. The molecular action of retinoic acid and RARs was first 
hypothesised during studies of steroid and thyroid hormone action 26, and has since been 
validated by the identification of the DNA- and ligand-binding domains within the 
receptors 27 alongside the identification of the receptors crystal structures 28. It was 
proposed that retinol entered the cell, was converted to A TRA via enzymatic action and 
was transported to the nucleus by CRABP-II, where it bound with high affinity to retinoic 
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acid receptors via a ligand binding domain. This interactio,n would lead to a conformation 
change to the receptor-ligand complex, enabling the binding of a specific retinoic acid 
response element (RARE) located upstream of the promoter region of a target gene via 
the DNA-binding domain (Fig. 1.2). The first nuclear retinoid receptor was 
independently discovered by two groups in 1987, now known to be RAR-a1 29,30. RARs 
can be divided into three sub-groups, RAR-a, RAR-P and RAR-y, which in tum can be 
sub-divided into multiple receptor isoforms (i.e. RAR-P1, RAR-P2 and RAR-P3). This 
heterogeneity is due to the fact that a separate gene that has multiple promoters encodes 
each subtype, and the products are also able to undergo differential splicing. The 
complexity of retinoid action is further complicated with the discovery of other nuclear 
receptors that also exhibit affinity for retinoids. These were termed retinoid X receptors 
(RXRs) 31. RXRs could also be divided into three isoforrris RXR-a, RXR-P, and RXR-y. 
RARs always bind to DNA as heterodimers, pairing up with an RXR. The RXRs are able 
to act as homodimers or heterodimers, pairing up with themselves, RARs or other 
receptor compounds 32. The RARs have the highest affinity for ATRA whereas the RXRs 
have higher affinity for other retinoid isoforms such as 9-cis-retinoic acid (9-cisRA) 33. 
The tissue expression of these numerous RAR and RXR subtypes and isoforms varies 
greatly throughout the organism, again an indication of the complex and varied role the 
retinoids play in adult and embryonic cell systems. For example, during neural 
development, RAR-y is found exclusively in the open neural folds, wheras RAR-P is 
found in the neural tube only after it has closed 34. 
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Figure 1.2: General overview of retinoid action. Retinol enters the cell via the retinol binding 
protein receptor and once in the cell is bound to cellular retinol binding proteins (CRBP I & II). 
These proteins aid either the breakdown of retinol for storage into retinyl esters, or the conversion 
to all-trans retinoic acid (ATRA). A TRA can be metabolised to more polar molecules catalysed by 
the CYP450 enzymes and cellular retinoic acid binding protein I (CRABP-I). Cellular retinoic acid 
binding protein II (CRABP-II) is thought to be involved in the delivery of ATRA to the nuclear 
envelope where it binds to the retinoic acid receptors (RARs). ATRA has high affinity for the 
RARs whereas other natural retinoids such as 9-cis retinoic acid (9-cisRA) has high affinity for the 
retinoid X receptors (RXRs). Once bound to the receptors the ligand/ receptor complex undergoes a 
conformational change rendering it active, and allows the binding of retinoic acid response 
elements (RAREs) of target genes. Diagram taken from Christie et al 2008123. 
Retinoic acid receptors are transcription factors that have a modular structure commonly 
associated with nuclear receptors, which contains six conserved regions, named A-F 
respectively (Fig.1.3). The N-terminal AlB region is the most variable in size between the 
RARs and the RXRs. The AlB region always consists of a ligand independent 
transcriptional activation function (AF-l) which contains several phosphorylation sites 
including those activated by MAP kinases 35. The C region is the most highly conserved 
between all RARs and RXRs (~66 amino acids long) and harbours the DNA binding 
domain (DBD). The domain is made up of two zinc-finger motifs which mediate 
sequence specific DNA recognition of target genes, two a-helices and a COOH-terminal 
extension 36, 37. At the base of the first zinc finger is located a three amino acid section 
termed the P-box, which plays a key role in determining the specificity of DNA 
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recognition for the receptor 38. This C-region also contains a small protein dimerisation 
surface (D-box), which allows the RAR to interact with an RXR when bound to 
particular types of DNA elements. The D region is a short linker region which allows the 
correct orientation of the DBD and the ligand binding domain (LBD) within DNA-bound 
dimers. The second most conserved region is region E (-200 amino acids long) which is 
multi-functional. Region E is made up of the LBD, containing the ligand-binding pocket, 
the main dimerisation surface (termed I-box), the ligand-dependent transcriptional 
activation function (AF-2), and also contains an area involved in transcriptional silencing 
in the absence of a ligand (NCoR box) 39. Region E is the main area of transcriptional 
regulation 40. Finally the C-terminal F-region has been shown to be present in RARs but 
absent in RXRs and its function is as yet unknown. 
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Figure 1.3 Schematic of RAR functional domains. Region AlB contains the ligand· independent activation 
function (AF·l) and is closest to the N terminal. Region C is the most highly conserved between the 
receptor subtypes and contains the DNA-binding domain (DBD), along with the P- and D-Box which are 
involved in DNA recognition and protein dimerisation respectively. The D region is the hinge, allowing 
correct orientation of the binding domains after the receptor dimers have bound DNA. Region E contains 
the ligand binding domain (LBD), the main dimerisation surface (I-Box), the ligand-dependent 
transcriptional activation function (AF-2), and the NCoR Box which is involved in transcriptional silencing 
in the absence ofligand. F-region is only present in RARs and its function remains unknown. 
There are three main types of classical RARE, all of which contain two direct repeats of a 
core hexameric motif, separated by a specific number of base pairs (bp) 41. The most 
common RARE is the direct repeated sequence separated by a 5 bp section, termed DR5. 
RARIRXR heterodimers are also able to bind to the direct repeated sequence separated 
by a 2 bp section (DR2) and a ! bp section (DR!). RXRIRXR homodimers are only able 
to bind to DR5 and DR! classical RAREs 42. Table 1.1 lists some of the classical RARE 
and their associated direct repeated sequence. The polarity of the receptor dimers when 
they bind to either DRS or DR2 is the RXR binds to the 5' hexameric motif and RAR 
binding to the 3' motif, whereas polarity is reversed in DR! binding, introducing an 
inhibitory effect in these receptor subtypes 43. 
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DR Gene Sequence Reference 
DR5 hRAR~2 AGGGTTCACCGAA \GTTCACT De The el. at. 44 
DR5 hCYP26 TTAGTI CACCCAA \GTrCA TC Loudig el. at. 45 
DR5 hHoxa-1 CAUU'ITCACCGAA \GTI"CAAG Dupe el. at. 46 
DR5 hHox-d-4 TAACiGTCJAAA TGC \GGTC \ CA Morrison el. at. 47 
DR2 mCRBP-I GT \GG I C \ AA \GCiTC AGA Smith el. al.48 
DR2 mCRABP-II CC \G ITT C \ CC \GG I C \ GG Durand el. al. 'IV 
DRl rCRBP-II ACAGG1CACAGG1C\CA Mangelsdorf el. al.--w 
Table 1.1 List of some of the classical RAREs. A RARE is a direct repeat of the hexameric motif spaced 
by 5 (DR5), 2 (DR2) or I (DR I) base pairs. Abreviations: RAR, retinoic acid receptor, CYP: Cytochrome, 
CRBP: Cellular retinol binding protein, CRABP: Cellular retinoic acid binding protein, h: Human, m: 
Mouse, r: Rat 
It is known that the receptor dimers are able to bind to the target DNA in the absence of 
any ligand, however the complexes are inactive. This was explained with the discovery of 
additional proteins that interact with RARs and either inhibit or enhance its 
transcriptional activity in a ligand-dependent fashion 51 (Fig. 1.4). In the absence of 
ligand, corepressor proteins such as nuclear receptor corepressor (NCoR)-1 and NCoR-
2/SMRT (silencing mediator of RAR and thyroid hormone receptor) would be bound to 
the RARlRXR heterodimer through the NCoR box. These corepressors recruit other 
factors including histone deacetylases (HDACs) which are involved in maintaining 
chromatin in its condensed state, leading to inhibition of transcription52, 53 . After ligand 
binding, the corepressor is released and coactivators such as CBP/p300, p3001CBP-
associated factor and p160 family members (including RlP140 and SRC) are recruited, 
binding through a motif containing the sequence LXXLL, where L represents lysine and 
X represents any amino acid 54. In tum, these coactivators recruit further proteins which 
contain histone acetyl transferase (HAT) activity to aid in chromatin decompaction 
leading to gene transcription 55. Many of these coactivators interact with the receptor 
through its AF-2 domain in region E. 
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Figure 1.4 Involvement of co-regulatory proteins which either inhibit or enhance receptor activity. (A) In 
the absence of ligand corepressor proteins (NCoR or SMRT) are bound to the RARlRXR dimers via the 
NCoR box domain, leading to inhibition of transcription. (B) Upon ligand binding, the corepressor proteins 
are released leading to a conformational change exposing the AF-2 site allowing coactivator recruitment, 
which in turn leads to chromatin decompaction allowing gene transcription. 
1.5 Retinoids and eNS Development in the Embryo: 
Experiments on retinoid function within the embryonic CNS are extensive (for a recent 
review see Clagett-Dame and DeLuca, 2002 56). ATRA is widely known to have potent 
teratogenetic effects, and as outlined above, experiments detailing the effects of V AD 
during pregnancy noted a wide range of birth defects, including several that occurred 
within the CNS and spinal chord, for example exencephaly and"various degrees of spina 
bifida 57. Furthermore, when retinoic acid was removed from either quail or rat embryos 
to generate retinoic acid-deficient embryos, the CNS showed several severe 
abnormalities, including no neurite outgrowth in the spinal chord 58, 59. Some of these 
types of neural tube defects were also witnessed if an excess of retinoic acid was 
administered 60. These in vivo experiments and those which revealed ATRA's ability to 
induce neural differentiation of embryonal carcinoma cultures in vitro, prompted the 
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hypothesis that retinoic acid must play an important role in the regulation and 
development of the developing eNS in the embryo 61. It was shown that cultures of 
embryonal carcinoma cells induced to differentiate with A TRA exhibited an increase in 
expression of the homeobox cluster of genes termed BOX. Predominantly an increase in 
the 4.2 kB transcript of BOX 5.1 was observed. This particular BOX gene is almost 
exclusively found in the eNS of the developing human embryo. Therefore this finding 
supported the notion that A TRA was inducing neural derivatives from embryonal 
carcinoma stem cells, and is important in eNS development in vivo 62. Backing up these 
findings were experiments using microinjection of dominant-negative retinoid receptors 
into Xenopus embryos 63, 64. These were administered to block retinoic acid receptor 
pathway signalling. It was reported that this inhibition lead to an expansion of anterior 
structures located in the eNS, and a decrease in posterior markers. The differentiation of 
sensory, motor, and interneurons was also inhibited. Finally, one of the first genes to be 
classified as a retinoid target gene was RAR-B2 44, and it was found to be regulated in 
neural cells and tissues 65. RAR-B mRNA expression is limited to the posterior hindbrain 
and spinal chord during early eNS development, however following exposure of the 
embryo to retinoic acid, the expression profile is expanded to the whole neuroectoderm 
66, outlining the importance of this receptor sub-type during neurogenesis. 
eNS development is initiated during gastrulation, briefly; the embryo divides into three 
distinct layers, namely the endoderm, mesoderm and ectoderm. The ectoderm gives rise 
to the outer epithelium of the body and the neural tube and neural crest. Neural tube and 
neural crest development is instigated by the release of specific growth factors, such as 
chordin, follistatin and noggin from the Spemann organiser 67. These molecules bind to 
bone morphogenetic proteins (BMPs) inhibiting their function which, when active, bind 
to nuclear receptors and activate genes specific for epidermal differentiation. The 
inhibition of these BMPs blocks epidermal differentiation and promotes neural 
differentiation; this process is termed the 'default model' of neurogenesis 68. Initially, as 
the neural plate forms, after signalling from the organiser, it forms cells which are 
associated with the forebrain only. It is only after the mesodermal transformation signal 
that this anterior neural tissue is converted into the more pqsteri,<?r cell types representing 
the midbrain, hindbrain and spinal chord respectively, which can be identified by the 
expression of specific groups of markers 57. It was hypothesised that at least one of the 
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transformational signals released from the paraxial mesoderm must be A TRA, which was 
known to induce neuronal phenotypes. 
Multiple experiments have been carried out verifying the presence of retinoids in the 
developing CNS of embryos. High-performance liquid chromatography (HPLC) was 
carried out on mouse embryo extracts at day 10.5 and day 13 and proved the presence of 
A TRA in the CNS. Endogenous ATRA was mainly found in the spinal cord, with much 
lower and decreasing amounts found in the hindbrain, midbrain and forebrain 
respectively 69. However, ATRA cannot be synthesised by the neural tube itself at these 
time points, as it contains no RALDH to catalyse its formation from retinal. RALDH 
activity is, however, found in the neighbouring paraxial mesoderm, and may enter the 
neural tube via passive diffusion. It is thought that ATRA may act in a paracrine fashion, 
patterning the CNS axis via pathways activated at specific positions along the ATRA 
concentration gradient 57. 
Throughout spinal chord development, A TRA expression becomes 'less uniform and 
localises where the limb buds form and where motor neurons are concentrated that 
service the limbs 70. It has been discovered that the general positional orientation of the 
spinal chord is instigated in a concentration dependent manner'by FGF and then ATRA 
refines the general patterning by inducing the expression of specific HOX genes 
associated with motor neurons, namely the HOXC genes 71. These HOXC genes form 
expression 'hotspots' which become the sites that go on to form the limbs. 
1.6 Retinoids and the Adult eNS: 
Much of the early research into retinoid modes of action focussed on the role of retinoids 
during embryonic neural development. This was due to the fact that A TRA is known to 
induce and regulate differentiation in many cell types, not a role which was thought to be 
required in the adult neural system. However, since the qiscovery that discrete areas of 
. -..-
proliferative cells are present in the adult brain, the study of retinoids has revealed an 
important regulatory role of these compounds within the adult CNS. The ability of retinol 
to cross the blood/brain barrier was demonstrated in studies which localised CRBP and 
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RBP binding sites in the blood capillary endothelium and in the epithelial cells of the 
choroid plexus respectively 72. The presence of several members of the RALDH enzyme 
family within the adult brain itself also indicated its ability to synthesis the active retinoid 
ATRA 73, 74. It was demonstrated that specific areas of the brain 'synthesised ATRA, 
namely the basal ganglia, olfactory bulbs, hippocampus and auditory afferents, all areas 
that are known to undergo active remodelling of neural connections throughout 
adulthood. In-situ hybridisation studies showed a close correlation betweell this apparent 
ability to synthesise ATRA and the presence ofCRBP-I, the compound that facilitates the 
conversion of retinol into active ATRA 75. Further studies used radio-labelled retinol 
administered to VAD rats. Ten hours post injection, brain areas were harvested and 
radioactivity detected. The highest amount of activity was found in the hippocampus-
cortex with the lowest being detected in the cerebellum. The radio-label tag was found to 
be connected to A TRA not retinol, again indicating the ability of cells in the adult CNS to 
convert retinol to ATRA 76. The high levels of ATRA and associated proteins in the 
hippocampus, specifically the dentate gyrus, strongly implied the involvement of these 
molecules in region-specific neurogenesis. It was revealed that A TRA contributed 
significantly to neuronal differentiation within the dentate gyrus, being involved at a very 
early stage throughout this process 77. Areas which care non-responsive, therefore 
sensitive to A TRA in the brain, have been shown to express specific enzymes, such as the 
cytochrome P450 enzymes P450RA-l and P450RA-2, which inactivate ATRA by 
metabolizing the compound to more polar metabolites, including 4-oxo-, 4-hydroxy-, (4-
OH-) and 18-hydroxy- (18-0H-) ATRA. These enzymes have been localised to the pons 
and the cerebellum, areas known to be unresponsive to ATRA stimulation 78, 79. These 
experiments all indicate that ATRA is an important reguhitory molecule within the adult 
CNS and interference of these pathways can result in neurological disorders. More 
evidence indicating the regulatory role of retinoids in the adult CNS is discussed below. 
1.7 Retinoids and the Hippocampus (Involvement in Lea~ning and Memory). 
As mentioned above, the hippocampus is an area of the adult brain with known neuronal 
plasticity. This remodelling of neural connections is the underlying process involved in 
episodic, declarative and spatial learning and memory establishment. Retinoic acid has 
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been found to play a regulatory role in the long term potentiation (L TP) and long term 
depression (LTD) processes involved in this neuronal plasticity within the hippocampus 
80. Investigations into V AD revealed a significant deficit in spatial learning and memory 
in rats deprived of vitamin A. As little as 12 weeks of dietary deficiency was enough to 
induce these deficits, which upon re-introduction of vitamin A into the diet were reversed 
81. Other studies have shown a more permanent reduction in the expression of RAR -~ and 
RAR~/y receptor subunits after 31 weeks deficiency 82. These studies all support the 
theory that retinoids are involved in the signalling pathways leading to higher cognitive 
functions. 
1.8 Retinoids in Neurological Disorders (Schizophrenia, Alzheimer's and Motor 
Neuron Disease). 
The retinoic pathway is becoming a key focus in many studies looking at neurological 
disorders. As with the embryonic regulation of the retinoid signalling pathway, any 
deviation from optimal levels appears to induce neurological dysfunctions. Recent papers 
have linked the addition of retinoic acid to the alleviation of oxidative stress-induced 
neuronal death in specific areas of the adult brain, namely those involved in cognition 
and conditions such as depression, Alzheimer's and Parkinson's disease 83-86. These data 
and those discussed below, indicate the importance of this particular pathway in optimal 
brain management, and hint at future therapeutic remedies in the control or treatment of 
this group of disorders. 
1.8.1 Schizophrenia. 
One such area where retinoic acid dysregulation appears to be involved in the diseased 
state is schizophrenia. The learning and memory pathways of the hippocampus are 
selectively impaired in schizophrenia, so it would stand to reason that retinoic acid 
pathway abnormalities could be involved in this disease. Many reports eluded to retinoid 
dysfunction as one of a number of causative factors for schizophrenia (for a review see 
Goodman, 1998 87). More recen,t experiments show concrete evidence of this effect. A 
decrease in RXR signalling is seen in some schizophrenia patients 88 and the 
administration of natural RXR agonists such as Docosahexaenoic acid (DHA) can 
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overcome some symptoms 89. Comparisons of normal and schizophrenia brain section 
expression of RARs indicated a two-fold increase of RAR-a in the dentate gyrus of the 
schizophrenia sections 90. Proteomic evaluation of body fluids from schizophrenia 
patients versus mentally healthy controls indicated a significant down-regulation of 
transthyretin (TTR) and apolipoprotein E (ApoE) in the cerebrospinal fluid. Both proteins 
are associated with the transport of retinol around the body and brain, therefore an 
important step leading to correct retinoid functioning 91. Potentially, data presented in 
these studies could signify that an insufficient amount of retinoids are being transported 
around the brain leading to the abnormal expression levels of retinoid signalling 
components. It was also noted that, after 2 months treatment with antipsychotic drugs, the 
plasma expression of TTR tetramer was significantly increased in those patients that were 
responding to the treatment, indicating that these aberrant expression levels could be 
rescued 91. It can be concluded that the synthesis of specific retinoid compounds/retinoid 
transporter molecules could be advantageous in the treatment of this disorder and this is 
discussed in more detail below. 
1.8.2 Alzheimer's Disease. 
Retinoids have also been implicated III Alzheimer's disease (AD), another disease 
associated with cognitive abnormalities. Although, to date, no specific genes have been 
linked to AD, genome scans have indicated strong gene linkages, and at these specific 
loci important genes related to the retinoid pathway ar~ always found 92. As in the 
schizophrenia research, some of these retinoid genes have been identified as playing a 
role in the transport of retinoids 92. Again, if these transporters are not functioning 
adequately, or are found in decreased levels, this has the potential to have serious 
implications for optimal retinoid functioning. Disruption of the retinoid signalling 
pathway also appears to increase the amount of amyloid ~·protein in the brain, one of the 
major components involved in amyloid plaque formation, a major characteristic of AD. 
In one year old rats that have been V AD since weaning, positive expression for amyloid 
~ protein is seen in the cerebral cortex, compared to negative result~ in corresponding 
control samples 93. In similar in vivo deficiency models, an increase in amyloid precursor 
protein is seen with a decrease in the expression of the retinoid r~ceptor RAR-~ 94, which 
can be rescued upon re-introduction of vitamin A into the diet. This is consistent with in 
vitro observations that a high level of retinoic acid is able to protect against the death of 
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hippocampal neurons mediated by amyloid ~, another characteristic of AD 95. All of 
these studies again indicate the therapeutic potential of retinoids in the control or possible 
treatment of this disease, however it must be noted that the effects witnessed after 
retinoid supplementation may not necessarily be mediated via receptor activation, and 
could be non-receptor mediated. 
1.8.3 Motor Neuron Disease. 
There are many other neurological disorders which the symptoms are associated with a 
dysregulation of the retinoid signalling pathway. Another example is motor neuron 
disease. In this disease, an accumulation of neurofilament and vacuo lations in motor 
neurons followed by motor neuron cell death is characteristic, alongside an increase in 
astrocytosis. In V AD rat models, these characteristics were noted in samples of motor . 
neurons from the spinal cord, along with a decrease in expression of RAR-a 96. This 
study also examined expression patterns in human patients of amyotrophic lateral 
sclerosis (ALS). They showed a decrease in the total number of RAR-a positive neurons 
and a decrease in RALDH-2 positive neurons compared to control samples, and in the 
motor neurons that were left, there was a decrease in expression of both of these 
transcripts. Other studies examined whether there was a difference in serum levels of 
retinol between ALS patients and age-matched healthy controls. Using HPLC, the 
authors concluded that there was no significant difference between the healthy and 
diseased groups 97. When combined, these studies lead to the conclusions that motor 
neuron disease is in part a consequence of retinoid signalling malfunctions and not in 
general due to a deficiency of vitamin A. Again, it appears that the transport of the 
retinoid is defective, leading to an aberrant expression of the receptors involved. It is yet 
to be established whether motor neuron cell death can -be rescued via some form of 
retinoid therapy. 
1.9 Novel Retinoid Compounds as a Therapy for Neurological Diseases and 
Cancer. 
As alluded to above, there is evidence that in some neurological disorders, at least in in 
vitro experiments, symptoms associated with retinoid dysfunction can be overcome with 
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retinoid therapy. The natural retinoids ATRA, (Fig. 1.Sa), 13-cis-retinoic acid (13-
cisRA), (Fig. 1.Sb) and 9-cisRA, (Fig. I.Se) are already used in some therapy regimes for 
some cancers and for some dermatological diseases such as acne. For example, ATRA is 
used with relative success in the treatment of acute promyelocytic leukaemia due to its 
ability to induce differentiation of the aberrant cell population 98. However, due to its 
rapid metabolism and catabolism by the cytochrome P450 enzymes within the body, and 
serious side-effects after long-term treatment, it is a far from ideal compound. Accutane 
(containing 13-cisRA) is used for the treatment of acne. 13-cisRA has been shown to 
remain in the circulation much longer than ATRA in human subjects, with an elimination 
half-life of 20hrs compared to just 0.9hrs for ATRA 99. This makes it a more attractive 
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therapeutic compound than ATRA, however, its use is the subject of serious controversy 
(summarised in Strahan and Raimer, 2006 100 and references therein). Some scientific 
groups have proposed a link between the chronic use of this compound and depression 
-, 
and suicidal tendencies, due to a decrease in hippocampal cell formation (see, for 
example, Crandall et ai. 2004 101). However, other groups disagree with these findings 
(see, for example, Jick et ai. 2000 102). 
Both of these compounds are pan-RAR activators, and therefQre, have the potential to 
effect numerous different biological processes which could explain the associated 
debilitating side effects. For example, activation of the RAR-y receptor sub-types is 
associated with retinoid skin toxicity side-effects 103. Much research has focussed on the 
synthesis of specific and selective RAR agonists and antagonists to use in the treatment 
of many neurological disorders. The rationale is that these more selective activators of 
retinoid pathways could overcome the side effects associated with the use of their natural 
pan-RAR activating counterparts. Whilst there is reference to the chemical production of 
many thousands of different synthetic retinoids in the literature, there are comparatively 
few data concerning an in-depth characterisation of their biological activity, let alone 
their effect on neural cells. One promising study which does show good evidence of 
biological activity was reported in 2005 104. Simoni ei ai. synthesised a number of 
terphenyl compounds, synthetic retro-retinoid analogues, to try to establish their 
apoptotic qualities. They discovered that these compounds actually protected 
promyelocytic HL-60 cells against apoptosis. As many neurological diseases are 
associated with apoptosis of neurons, i.e. AD, Parkinson's disease, Huntington's disease 
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and motor neuron disease to name a few, the group became interested in this quality. 
However, they found that the compounds only had modest protective apoptotic activity in 
neuronal cell lines, but concluded that further study into this group of compounds could 
be very worthwhile for treatment of neurological disorders. 
Another synthetic retinoid which has promising therapeutic potential for a number of 
different neurological disorders is Am80 (tamibarotene, (Fig. LSd) 105). This synthetic 
retinoid has been shown to rescue scopolamine induced memory-loss in rat model 
systems 106: the most effective result was observed when the retinoid was administered in 
tandem with the rexinoid HX630. In this model system no adverse side effects was seen. 
These data point to the use of these compounds to treat neurological disorders associated 
with learning deficits such as AD. Human clinical trials of Am80 have already been 
carried out in other fields, investigating Am80 as a possible treatment for APL. As 
mentioned above, A TRA is the main drug of choice for this disease; however, in patients 
who relapse from complete remission after ATRA therapy, a second course of this drug is 
. relatively ineffective. In one study, patients who had relapsed were treated with Am80 
and 58% achieved complete remission. As Am80 is an agonist for only RAR-a and RAR-
~, milder side effects were observed with this compound 107. Again, this established 
specificity can be seen as advantageous in the treatment of many neurological disorders. 
More specific agonists of the RARs have also been developed. Using their novel cell-
based assay R-SAT, Piu et al. identified a variety of selective RAR compounds 108, the 
most interesting being a potent RAR-~2 agonist, (Fig. loSe), that distinguishes between 
the different RAR-~ sub-types 109. This particular sub-type has been shown to be very 
important in the neurite out-growth of the embryonic spinal cord, and is absent in adult 
spinal cord sections. When it was transfected into neurons of the spinal cord from adult 
rats and mice, neurite outgrowth was observed in vitro 110._This receptor sub-type has also 
been associated with the dopamine signalling pathway III. Dysregulation of this pathway 
is seen in some neurological disorders, for example Parkinson's disease and 
schizophrenia; therefore, this agonist may have potential utility as a treatment for these 
types of neurological disorders. 
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The synthesis of molecules with higher cytotoxic activity on cancer cells and increased 
water solubility improves their ability to act as chemotherapeutic and chemopreventative 
agents. Novel synthesis approaches and biological evaluations of the products are 
producing compounds which appear to be exciting new anti-cancer drugs 112. 
Other areas of retinoid research have focussed on the development of compounds which 
will enhance the therapeutic potential of already available retinoid compounds. For 
example, in order to overcome the rapid breakdown and sensitizing of A TRA by the body 
after use as a therapeutic treatment, retinoic acid metabolism blocking agents (RAMBAs) 
have been developed. These compounds elicit a response by inhibiting the P450 enzymes, 
namely CYP enzymes, which catabolises ATRA (for a recent review see Njar et al. 2006 
113). The most studied RAMBA is Liarozole, (Fig. 1.Si), developed by the Janssen 
Research Foundation 114. In 2004, Liarozole was granted orphan drug designation by the 
U.S. Food and Drug Administration for the treatment of congenital ichthyosis (a severe 
dermatological disorder) and has also been granted orphan drug status by the European 
Commission. This is a good example of how manipulation of the retinoic acid signalling 
pathway can be key to the treatment of certain related diseases. 
~COOH 
a. All-trans retinoic 
acid 
b. 13-cis retinoic acid 
QcYP'~ V 
d. AmBO 
e. Potent RARP 
agonist 
c. 9-cis retinoic acid 
Q ~ 
CI 
_ f. Liarozole 
Figure 1.5: Chemical structures of retinoids (a-e) and a retinoic acid metabolism blocking agents 
(RAMBAs) compound (t) which are either already being used in therapy regimes for neurological 
disorders (a, b, c, d & t) or show promising potential as therapeutic agents (e). a, b, & c are naturally 
occurring retinoids and d, e, & f are synthetic compounds. Diagram taken from Christie et al 2008 123 • 
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1.10 Aim of Thesis: 
Instability of ATRA in vitro and the Need for Stable Alternatives 
As it has been outlined above, A TRA is a very important molecule in vivo, being 
involved in numerous regulatory processes throughout both embryonic and adult neural 
development. Due to its prominent involvement during these in vivo processes, ATRA 
has been used extensively to promote neurogenesis in vitro in many different cell model 
systems. It has been this in vitro use of ATRA which has lead to many of the findings 
discussed above. However, the in vitro use of ATRA is complicated by its structural 
instability, leading to a tendency to isomerise and degrade when exposed to light or heat 
115-118. The five conjugated double bonds which give ATRA its excellent chomophore 
properties, efficiently absorbing light in the region of 300-400 nm, are what also make 
this compound susceptible to photoisomerisation. This leads to degradation of A TRA into 
a mixture of several different retinoic acid isomers and degradation products. Previous 
studies have shown that during the preparation and maintenance of cell cultures with 
A TRA, the concentration levels have been shown to decrease markedly over time, and 
this appears to be both a consequence of its degradation and metabolism 119. Therefore, 
compound stability is an important feature when reagents are being routinely used for cell 
culture in in vitro applications, one which is often overlooked by cell-biologists. There is 
an unavoidable variation in actual A TRA concentration being applied throughout 
investigations, dependant on how often or how long ATRA has been thawed out and/or 
exposed to light when in use. As explained earlier, very defined concentrations of ATRA 
are· required to induce specific neuronal phenotypes, therefore any discrepancy in 
concentration accuracy can potentially elicit dramatically different biological results. It is 
also known that some of the degradation products of isomerised A TRA also elicit 
differing biological activities, adding to the problems associated with in vitro ATRA use. 
For example these different isomers effect the ability of embryonic stem cells to 
differentiate into defined neuronal products 119,120. These problems have prompted efforts 
to create more stable synthetic ATRA analogues which are able to elicit similar 
biological effects. In essence, retinoids contain three structurally important regions, a 
hydrophobic section, a variable linker, and an acidic function respectively. Extensive 
chemical modifications to these three separate regions are possible, some of which are 
able to instil extra chemical stability. For example, the incorporation of an aromatic ring 
20 
to replace part of the polyene chain increases stability, whilst the compound still retains 
the ability to induce differentiation of embryonal carcinoma cells.· This new group of 
retinoids is termed arotinoids 121. As with the creation of synthetic retinoids for 
therapeutic use, many retinoid libraries have been formed and published, with their 
specific receptor binding affinities calculated, however, very few of these retinoid 
analogues have undergone sufficient biological analysis and screening to be verified 
biologically (For example 122). These libraries of synthetic retinoids make a solid starting 
point in the hunt for a more stable A TRA altem~tive which would have the potential to 
replace A TRA in in vitro investigations. This approach is likely to yield successful 
candidates. Therefore, to try and address this issue, the aim of this thesis is to focus on 
the synthesis and subsequent biological analysis of two arotinoid compounds, termed 
ECl9 and EC23, which are hypothesised to have inferred stability compared to ATRA. 
1.11 Synthesis of retinoid analogues EC19 and EC23 
To address the stability issues outlined above with the in vitro use of ATRA, in 
collaboration with scientists from the Chemistry Department, Durham University, this 
thesis aims to investigate the biological activity of synthetic retinoids on a variety of cell 
model systems. Specifically looking at their ability to induce neurogenesis compared to 
the natural retinoid A TRA. As outlined above A TRA is a very important regulatory 
molecule during neurogenesis in both embryonic neural development and adult neural re-
modelling and development. Using available literature, and chemical modelling 
programmes, two isometric analogues of A TRA were· synthesised with the aim of 
improving retinoid stability when handled under standard laboratory conditions. One 
compound analysed was a known synthetic retinoid which has been shown to activate all 
of the retinoic acid receptors in previous binding studies 122. The other compound was 
novel, and its structure was based on that of the previous compound. These two synthetic 
retinoids were then put forward for biological analysis on a range of cell-based model 
systems to test their biological reactivity, and these were compared against the natural 
retinoid A TRA 123. Models of embryonic stem cells and embryonic and adult neural 
progenitor cells were used as A TRA is known to influence the differentiation of all of 
these different cell types in vitro. It was therefore important to asses the ability of the 
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synthetic retinoids to induce differentiation in all of these cell types too. Differentiation 
was assessed using a number of different cellular and molecular techniques including 
evaluation of cell viability, cell markers of differentiation and 'sternness', followed by 
proteomic and molecular analysis of markers of the retinoic acid receptor pathway. A 
model of a neural childhood tumour, which responds in part to ATRA treatment, was also 
evaluated as it was also important to address whether the synthetic compounds may have 
enhanced therapeutic potential. To evaluate these properties analysis of cell cycle 
markers and proliferation analysis was carried out. 
To create the new synthetic retinoids many modifications to the ATRA common retinoid 
structure were made. As mentioned above, to instil stability, an aromatic ring was 
incorporated, replacing some of the long polyene carbon chain. A triple carbon bond was 
also added to incorporate stability along the carbon linker region, and finally in place of 
the trimethylcyclohexenyl ring and part of the polyene chain a 1,1,4,4~tetramethyl-
1,2,3,4-tetrahydronapthalene unit was incorporated. It was anticipated that an acetylene 
moiety would induce the desired linear structure, and also act as a non-isomerisable 
linker unit. Due to this non-isomerisable quality, it was decided that two isomers of this 
compound would be synthesised and analysed, whereby the position of the carboxylic 
acid function was placed in either the para- or meta- position. The para- isomer was 
termed EC23, and the meta- isomer was termed EC19, and their structure and chemical 
alignment are shown in Figure 1.6. 
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Modelled alignment Chemical structure 
ATRA 
EC19 
EC23 
Figure 1.6: Structure and chemical alignment of ATRA and the synthetic retinoids EC 19 and 
EC23. It is noted that the chemical alignment of EC23 is most similar to the natural retinoid 
A TRA. Both EC 19 and EC23 have a triple carbon bond inserted into the polyene chain. This is 
hypothesised to instil stability to these synthetic analogues. 
To synthesise the retinoid analogues EC19 and EC23, III brief, 
tetrarnethyltetrahydronaphthalene units underwent Sonagashira cross-coupling with 
trimethylsilylacetylene (TMSA), this reaction was enhanced with the addition of an 
iodide group to the starting molecule (71 % yield), and allowed for lower levels of 
palladium to be used as the catalyst for the Sonagashira cross-coupling, i.e. with iodide 
the coupling with TMSA under Sonogashira conditions at room temperature, only 
required 1 % Pd catalyst, resulting in an 88% yield of the product. Subsequent 
deprotection of the linker region, was carried out with hydroxide, giving the terminal 
alkyrie product. The terminal alkyne was then subjected to a further Sonogashira coupling 
with both para- and meta-iodobenzoate methyl esters to provide smooth conversion to 
each of the isomeric esters respectively in 87% and 59% yield. Finally, saponification of 
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the methyl esters produced the carboxylic acids EC23 and EC 19 in 72 and 78% yields, 
for the para- and meta-isomers respectively (Scheme outlined in Fig. 1.7). 
HI04, AcOH, 
HP, 70°C 
~I 
XV 
71% 
Pd(PPh3)2CI2, 
CuI, Et3N 
= TMS 
a; para-C02H 72% 
b; meta-C02H 78% 
"" NaOH, MeOH, ~1PTMS I • h- Etp 
88% 
NaOH, THF, 
Pd(PPh3)2CI2, 
CuI, Et3N 
74% 
a; para-C02Me 87% 
b; meta-C02Me 59% 
Figure 1.7: Scheme of synthesis of synthetic retinoids EC19 and EC23. The starting material 
underwent a Sonagashira coupling with TMSA, followed by a deprotection step followed by a 
final Shonagashira coupling to obtain the terminal alkyne in both the para- and meta- isofonns. 
Subsequent saponification of the methyl esters resulted in the carboxylic acid isomers. Diagram 
adapted from Christie et al 2008 123 • 
24 
1.12 Conclusions 
Retinoids have been demonstrated to be powerful regulators of neural differentiation and 
regulation both within embryonic development and adult brain functioning. They elicit 
biological activity by binding to specific receptors located within the nuclear envelope. 
Activation of these receptors results in a mediation of specific· gene expression. A 
dysfunction in this pathway leads to many abnormalities in embryonic development and 
. is shown to be associated with numerous' neurological disorders within the adult. The 
natural retinoids are involved in the treatment programmes for many different disorders; 
however, their utility is limited due to the rapid breakdown of the compounds within the 
body and debilitating side effects associated with their long-term use. To overcome these 
problems, novel retinoid compounds have been synthesised which are much more 
receptor-specific. The limited biological activity data available suggests that these 
compounds are as potent as their natural counterparts, but it remains to be seen whether 
they over-come the side effects. 
It appears that the dysregulation of the retinoid pathway in the neurological disorders 
discussed above often results from a defect in the transport of retinol into the cells in 
question. It would be of interest to investigate synthesising more efficient novel retinoid 
transporter molecules, which could lead to an increase in retinoid availability. This 
approach could provide an improved method of treatment/management for these 
debilitating diseases. 
The natural retinoid ATRA is used extensively for in vitro work, for example as an agent 
to induce neurogenesis in many different cell-based model systems. However, due to its 
chemical structure A TRA is very unstable when exposed to light or heat, isomerising and 
degrading readily. This has obvious problematic implications associated with its in vitro 
use. One area of science which is trying to over-come these issues is the synthesis of 
retinoid analogues which elicit the same biological responses to A TRA. In collaboration 
with the Chemistry Department, Durham University, this thesis aims to evaluate the 
biological activity of two synthetic retinoids EC19 and EC23. Their ability to induce 
neuronal differentiation will be studied and compared to the natural retinoid A TRA. It 
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was hoped that these synthetic analogues would elicit s!milar effects to A TRA in the 
range of cell model systems tested, but that they would be able to withstand a much 
higher level of light and heat exposure, making them an attractive alternative for in vitro 
investigations into retinoid biology. 
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2 Chapter 2: Materials and Methods: 
2.1 Cell Culture: 
All cells were cultured in a humidified atmosphere of 5% C02 in air at 37°C in a Sanyo 
CO2 incubator. Cell cultures were handled using aseptic techniques in a class II bio-safety 
flowhood (BioMat). Cultures incubated with retinoid compounds were done so in 
reduced light conditions. All tissue culture plastic-ware was purchased from Nunc unless 
otherwise stated. Phase contrast images of growing cultures were obtained using a light 
microscope (Nikon Diaphot 300) and photomicrographs captured using digital 
photography (Nikon). Media reCIpes and specific culture techniques are found in 
individual Chapters. 
2.2 Retinoid Stocks: 
Stock solutions of synthetic retinoid compounds EC 19 and EC23 (Durham University 
Chemistry Department), ATRA and 13-cis-Retinoic acid (Sigma), were prepared in 
dimethylsuloxide (DMSO) (Sigma) to concentrations of 10mM. Aliquotted stock 
solutions were stored at -80°C in the dark. 
EC 19 and EC23 molecules obtained from the Chemistry department both had molecular 
weights of 332, therefore stock solutions were worked out as follows: 
1M = 332g/litre 
10mM = 3.32g/litre 
3.32mg/ml 
33.2mgllOml DMSO 
2.3 MTS Cell Viability Assay: 
The MTS cell viability assay worked via a colorimetric change that can be quantified on 
a spectrometer. MTS is a yellow tetrazolium-based dye that is reduced by live (and not 
dead) cells to a purple formazan compound. Cells were cultured on 24-well plates for 
MTS cytotoxicity assay analysis. 50,000 cells/well were- seeded and either cultured in 
proliferation media (control), or differentiation media containing one of the retinoids 
being investigated. Cells were cultured for up to 14 days and at 3, 7 and 14 day time 
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points the assay was carried out. 200lli of MTS reagent (CellTiter 96 AQueous One 
Solution Cell Proliferation Assay, Promega) was added to 1ml media/well. A control well 
containing no cells was also set up in the same way. The solutions were triturated then 
incubated for 4 hours at 37°C. The resulting colorimetric change was recorded as an 
absorbance, read at 490nm on a spectrometer (Thermospectronic, Fisher Scientific). All 
results were carried out in at least triplicate and were standardized against the no-cell 
control to account for background absorbance. 
2.4 Flow Cytometry: 
Flow cytometric analysis was carried out on either live cells using cell surface markers, 
or fixed cells using intra-cellular markers. A single suspension of cells or their 
differentiated derivatives was formed by the addition of 1 ml 0.25% trypsinJEDT A 
solution (Cambrex), and cell numbers were determined using a haemocytometer 
(500,000/antibody). For live staining cells were taken straight through the staining 
protocol outlined below. To fix cells they were incubated in 0.02% paraformaldehyde 
(PF A) solution (PF A in PBS (Sigma)), for 24hrs, then washed in PBS. Prior to staining, 
fixed cells were permeablised by incubation with 2% Triton-X-100 (in PBS, Sigma) at 
3rC for 30 minutes. 
Staining protocol: Suspended cells were pelleted and re-suspended in wash buffer (PBS 
containing 0.1 % bovine serum albumin (Sigma)). To an appropriate number of wells in a 
96 well plate o. 5x 106 cells were added in a 200llL volume. Plates were lightly centrifuged 
and the supernatant removed. Each cell pellet was re-suspended in 50111 of primary 
antibody solution followed by incubation for 1 hour at 4°C, after which the antibody was 
removed by 3 washes in wash buffer. Cells were then suspended in 50111 of FITC-
conjugated secondary antibody (Cappell, 1: 100) and incubated in the dark for 30 minutes, 
at 4 dc. Secondary antibody was removed by a further 3 washes in wash buffer. Finally, 
cell pellets were re-suspended in 500lli of wash buffer and samples were analysed in the 
flow cytometer (BD Biosystems F ACSFlow). Thresholds determining the number of 
positively expressing cells were set against the negative control antibody P3X (used neat, 
gift from Prof. P. Andrews, University of Sheffield). Cytometric, analysis was carried out 
on three individual cultures per treatment of cultured cells. 
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2.5. Cell cycle analysis: 
Cell cycle analysis was carried out using the CycleTESTTM PLUS DNA Reagent kit from 
Becton Dickinson. Protocols were carried out as directed in the instruction manual. In 
brief, a single cell suspension was gained after incubation with 0.25% trypsinlEDT A 
solution and washed 3X in the provided buffer solution. Cell number was then adjusted to 
500,000 cells/test in buffer solution. Samples were centrifuged at 400g for 5 minutes at 
room temperature (RT) and the supernatant is removed. 250)lL of solution A (trypsin 
solution to lyse cytoplasm) was added to samples and mixed by gentle tapping then left 
for 10 minutes at RT. 200)lL solution B (trypsin inhibitor plus RNase buffer) was added 
to each sample and incubated for a further 10 minutes. Finally, 200)lL of cold solution C 
(propidium iodide stain) was added, and resulting solution was mixed then incubated on 
ice in the dark for 10 minutes. Samples were then filtered through 50)lm nylon mesh and 
run using the appropriate settings on a flow cytometer--(BDBiosystems FACSFlow). 
Cytometric analysis was carried out on three separate experimental culture samples for 
reproducibility. 
2.6 Immunocytochemistry: 
Cells were cultured on 12-well or 24-well plates for .gnmunocytochemical analysis. 
Undifferentiated cultures were fixed PF A (Sigma) when confluent as outlined below, and 
differentiated cultures were fixed after the specified time point of growth in the presence 
of the respective retinoid compounds. Cell fixing was performed by incubation with ice-
cold 4% PFA in PBS (Sigma) for 30 minutes at RT, followed by 3 washes in PBS, and 
storage in the final wash solution at 4°C until required. Cell membranes were 
permeablised by treatment with 1 % Triton-X-I00 (Sigma) in PBS for 10 minutes at RT. 
Non-specific binding of antibodies was blocked using a solution of 1% goat serum 
(Sigma) in PBS containing 0.2% Tween-20 (Sigma). Fixed cells were incubated with the 
blocking solution on a bench-top shaker (Fisher Scientific) for 30 minutes at RT. Dilution 
of primary antibodies was carried out using blocking solution, and incubated with the 
cells for 1 hour at RT (see individual chapters for specific antibody information). Cells 
were then washed 3 times for 15 minutes in PBS followed by one hour's incubation in the 
dark at RT with appropriately diluted FITC or Cy3-conjugated secondary antibody 
(Alexafluor 488 1 :600 or JacksonLabs 1 :600). A further 2 washes of PBS was carried out 
in the dark, then cells were incubated with 1 )lg/ml Hoechst 33342 nuclear staining dye 
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(Molecular Probes, diluted in PBS). Cultures were then washed an extra 2 times in PBS, 
left in the final wash and imaged straight away. Fixed and immunostained cultures were 
, 
examined using a fluorescent microscope under restricted light conditions (Nikon 
Diaphot 300). DAPI, and the corresponding fluorescent photomicrographs were collated 
and stored using the appropriate filter sets and an adapted digital camera (Nikon). Imaged 
wells were then stored for further analysis with preservative mountant. Cultures were 
covered with a glass cover-slip (13 mm, VWR) ove('a small drop of Vectashield 
niountant, (Vector Labs) and stored at 4°C. Triplicate experiments were carried out for 
reproducibility. 
2.7 Phalloidin immunostaining: 
Cells were PF A fixed as outlined above, then permeablised and blocked also according to 
the methods outlined above, and then cultures were incubated with TRITC-phalloidin 
(Sigma) for 30 mins at RT in the dark. For a 12-well plate 2 units of active solution in 
200111 PBS was required (1 unit = Sill). Cells were washed 6X for 10 mins in PBS, then 
mounted ready for visualisation as above. 
2.8 Bromodeoxyuridine (BrdU) Immunostaining: 
Stock BrdU Solution: Stock solutions were made by dissolving 10mM BrdU (Sigma) in 
PBS. Solutions were sterilised by filtration (f/s) through a 0.2um filter and were store at -
20°C. 
BrdU labelling solution: BrdU stock solution was diluted 1/100 in culture medium to 
yield a IOOIlM solution (1 OX). The lOX solution was added to cultures to give a final 
concentration of 10 11M. 
DNA denaturing solutions: 
2N Hel: 83.33ml conc. HCl (pure HCl is 11.6M) 
Bring up to 500ml in dH20 
Borate buffer: Borax solution from Sigma is used to neutralise the acid solution. 
BrdU Pulsing: 24hrs before time point (i.e. on day 2 before 3 day time point), IOIlM 
BrdU solution was added to cells and left for 24hrs (i.e. 200uL of BrdU labelling solution 
is added to 2ml media). The BrdU WAS NOT added with fresh media as the renewal of 
FCS stimulates cell proliferation. 
30 
Immunocytochemistry: Cells were cultured on 12-well or 24-well plates for 
immunocytochemical analysis. Undifferentiated and differentiated cultures were fixed at 
3 and 7 day time points in 4% paraformaldehyde (PF A) (Sigma) which was found to be 
optimal for each of the antigens detected. Cells were incubated with ice-cold PF A (4% in 
PBS) for 30 mins at RT, then washed 3X in PBS and stored in the final wash solution at 
4°C until required. Cells were permeablised by the incubation of cultures with 1 % 
Triton-X-100 (Sigma) in PBS for 10 mins at RT. Cultures were then denatured to expose 
DNA for BrdU detection by incubation with 2N HCl for 30mins at RT. The acid was then 
neutralised with a wash of Borax solution (Sigma). 
Cultures were then stained us outlined in the above protocol. Primary antibody BrdU 
(Molecular Probes, 1 :30) was diluted in the blocking solution as appropriate and 
incubated with the cells for 1 hour at RT. 
2.9 Protein Extraction: 
Protein samples were prepared from undifferentiated cells and their 7 day retinoid-
induced derivatives in igepallysis buffer (1 % igepal (Sigma), 50mM Tris-HCl [pH 8.0], 
150mM NaCl, 1mM MgCb, and protease inhibitors (Roche Diagnostics)). After a 30 
minute incubation period the resulting protein solutions were clarified by centrifugation 
at 15000 rpm for 4 minutes, and the supernatant transferred to a fresh tube. Protein 
concentrations were determined using the standard Bradford based assay and 
concentrations were adjusted to contain 20llg protein . 
.2.10 Fractionation of Protein Lysates: 
Strong anion exchange fraction was carried out on EC celllysates using Vivapure Q Mini 
H strong anion exchange (SAX) spin columns (Sartorius). A single replicate sample 
aliquot for control untreated and each retinoid treatment containing 200 Ilg protein was 
. diluted to 50 III with cell lysis buffer, then diluted further to 400 III with 25 mM Tris-
HC1, pH 9.0. Columns were prepared by adding 400 III 25 mM Tris-HC1, pH 9.0 
followed by centrifugation for 5 minutes at 4,000 g. Sample solution was applied 
followed by centrifugation and the flow-through retained. Two successive washes of 200 
11125 mM Tris-HC1, pH 9.0 which were pooled and retained. Step elutions were 
performed using a series of 200 III volumes of increasing concentrations of NaCl 
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dissolved in 25 mM Tris-HCI, pH 9.0 (0.1, 0.25, 0.5, 0.75, 1.0 and 1,5 M NaCl). Each 
eluate was retained in a separate tube. 
2.11 SDS-Polyacrylamide Gels Electrophoresis: 
Total cell lysate protein samples were prepared for SDS-PAGE using sample loading 
buffer and reducing agent (NuPage, Invitrogen) and separated using NuPage Novex 4-12 
% Bis-Tris pre-cast gels (Invitrogen). Gels were run at 200V for 1hr in the XCell 
SureLock Mini-Cell tank system (Invitrogen). For total protein visualisation gels were 
incubated at room temperature in three successive solutions of Coomassie brilliant blue 
R-250: (i) 10% acetic acid, 25% isopropanol, 2% Coomassie R-250; (ii) 10% acetic acid, 
10% isopropanol, 0.25% Coomassie R-250; (iii) 10% acetic acid, 0.25% Coomassie R-
250. Preparation of SAX eluates for SDS-PAGE involved overnight precipitation of 
protein by overnight incubation with four volumes of acetone at room temperature. 
Precipitates were sedimented by centrifugation and resuspended in 1 x NuPage sample 
loading buffer and 10% reducing agent (Invitrogen). 
2.12 MALDI-TOF Analysis: 
Samples were prepared for protein profiling using Zip Tip fractionation (C-18, Millipore). 
For analysis of total lysates aliquots containing 20 Ilg protein were normalized to a 
volume of 10 III using lysis buffer and acidified with TFA (final concentration 1%). 
ZipTips were prepared with three 10 III passes of acetonitrile and three 10 III passes of 
0.1 % TF A. Sample was applied by pipetting up and down 10 times. The resin was 
washed by three 10 III passes of 0.1 % TF A before sample elution into. a clean tube by 
pipetting up and down five times with 7 III 50% acetonitrile, 0.1 % TF A. For analysis of 
SAX eluates, ZipTip desalting was performed directly as outlined. 
Mass profiling and biomarker analysis 
Aliquots of each Zip Tip eluate were mixed with 1 volume of 2% TF A and 1 volume of 
matrix solution (0.1 M 2,5-dihydroxyacetophenone (Bruker Daltonics) in 75% ethanol 
and 20 mM dibasic ammonium citrate. Of this mixture 1 III was spotted onto individual 
sample target spots on AnchorChip 600 MALDI target plates (Bruker Daltonics). Mass 
profiling was performed on a Bruker Daltonics Autoflex II MALDI TOF-TOF 
instrument, operated via Flex Control software. External mass calibration was performed 
using standard ubiquitin ([M+Hl+ = 8565.885 m/z) and myoglobin ([M+H+t = 
16,952.55 mlz; [M+2H+]2+ = 8476.775 m/z).· Linear mode mass spectra were acquired in 
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the detection range 4-50,000 m/z (510 shots per sample). Raw data were visualised 
following spectral smoothing and baseline subtraction in FlexAnalysis software (Bruker 
Daltonics). For biomarker analysis triplicate sample spectra were opened as individual 
groups in ClinProTools version 2.0 software (Bruker Daltonics). Analysis was 
performed in the mass range 4,000-20,000 m/z, at a resolution setting of 800. Spectral 
smoothing was performed using the Savitsky Golay function (width 10 m/z, 1 cycle). 
Recalibration settings allowed for a 0.2% maximal peak shift, 30% match to calibrant 
peaks, and exclusion of not recalibratable spectra. Null spectra exclusion was enabled. 
Peak area calculation was performed using end-point level area calculation, and a signal-
to-noise threshold of 5.0 was applied. 
2.13 Western Blot: 
Total lysates: Protein samples were prepared in sample loading buffer (NuPage, 
-. 
Invitrogen) and run using a NuPage Novex 4-12 % Bis-Tris pre-cast gel (Invitrogen). 
Samples were run at 200V for 1hr using the XCell SureLock Mini-Cell tank system 
(Invitrogen). Resolved proteins were immediately blotted (30V, 1hr) onto polyvinylidene 
difluoride (PVDF) membranes (Amersham Parmacia) using the XCell II Blot Module 
(Invotrogen). 
For immunoblotting, PVDF membranes were blocked in a solution of 5% dried milk 
powder and 0.2% Tween-20 in TBS (TBSM) for 1hr at RT. After blocking, membranes 
were incubated for 1hr with the primary antibody, cellular retinoic acid binding protein I 
(CRABP-I, 1 :600, AbCam) diluted in TBSM. Blots were subsequently washed 3 times in 
TBSM for 10 minutes each, followed by incubation with mouse horseradish peroxidise 
secondary antibody for a further 1hr (Amersham, 1:1000 ip. TBSM). A final 3 lO-minute 
washes was performed in TBS before protein-antibody interactions were visualised using 
chemiluminescence solutions "(Santa Cruz). Detection occurred using the Intelligent Dark 
Box II transilluminator (FujiFilm) and subsequent densitometric analysis of results was 
performed using FijiImage software (Fuji). 
Evidence of equal sample loading was obtained by probing for the ubiquitously expressed 
protein ~-actin (Sigma, 1: 1 000 in TBSM). In all cases triplicate experiments were carried 
out for reproducibility. 
Fractionated samples: Western analysis was also carried out on protein samples obtained 
after strong anion exchange fractionation of 50llg total lysate. Methods as described 
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above, apart from individual fractions were prepared for electrophoresis by acetone 
precipitation as described in fractionation of protein lysates section. 
2.14 Mass Spectrometry Protein Identification: 
Gel bands of interest were excised from SDS-PAGE gels, sliced into Imm cubes and 
washed with 50 mM NH4HC03 in 50% acetonitrile for 15 minutes. This solution was 
discarded and gel pieces were covered with a small volume of acetonitrile. Excess 
. . ~. , 
acetonitrile was removed and gel pieces were rehydrated by incubation 50 mM 
NH4HC03 for 15 minutes followed by addition of an equal volume of acetonitrile. The 
solution was allowed to stand for a further 15 minutes before being discarded. 
Acetonitrile was added to the gel pieces until they had shrunk and excess acetonitrile 
discarded. Gel was dried in a vacuum centrifuge followed by incubation in 10 mM DTT 
in 25 mM NH4HC03 for 45 minutes at 56°C. Samples were cooled and supernatant 
removed. Alkylation was performed in two 15 minute washes in 55 mM iodioacetamide 
in 15 mM NH4HC03. Supernatant was removed and gel pieces were dehydrated by 
washing in acetronitrile followed by vacuum centrifugation. For tryptic digestion 
samples were covered with trypsin solution (5 ng/1l1 in 25 mM N~HC03) and incubated 
for 30 minutes at 37°C. Sample coverage was maintained by additional 25 mM 
NH4HC03 if required, followed by.overnight incubation at 37°C. Samples were 
sonicated for 10 minutes and the supernatant was transferred to a clean tube. To the gel 
pieces an equal volume of 50% acetonitrile, 1 % TF A was added. Sonication was 
repeated followed by further addition 50% acetonitrile, 1 % TF A was added. 
Supernatants were pooled in the clean tube. Peptide samples were prepared for MALDI 
MS using ZipTips (C-18, Millipore). Samples were eluted in 50% acetonitrile. For 
MALDI analysis 1 III sample was mixed with 10 III matrix solution (0.3 mg/ml a-cyano-
4-hydroxycinnamic acid in 2: 1 ethanol :acetone), and 1 III spotted onto AnchorChip 600 
11m target plates (Bruker Daltonics). 
, 
Mass analysis was performed in a Bruker Daltonics Autoflex II MALDI -TOF/TOF 
instrument using default settings for peptide analysis in reflectron mode. External mass 
calibration was performed to within 10 ppm mass accuracy using the Bruker Daltonics 
Peptide Calibration Standard mixture. Sample spectra were acquired and submitted for 
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interrogation against human entries in the Swissprot database (100 ppm mass tolerance, 
variable modification: oxidation of methionine). 
Peptides selected for MS/MS fragmentation. were re-acquired in LIFT mode. Peptide 
fragment spectra were accumulated and submitted to the Swissprot database as described 
above. 
2.15 RNA extraction and Real Time PCR: 
RNA extraction using Qiagen RNeasy Mini kit: Before 151 time use of kit Buffer RPE 
must be diluted by adding 4 volumes of ethanol (96-100%). 
Prepare DNase 1 stock solution. Dissolve the lyophilized J?Nasel in 550 fll of RNase free 
water provided (to avoid loss of DNasel inject water into vial with RNase free needle 
and syringe). Mix gently by inverting the vial, DO NOT VORTEX. Aliquot and store at-
20, do not re-freeze thawed aliquots. Can be stored for 6-8weeks at 2-8°C. 
Cells grown in a monolayer (no more than 1 x 10/\7) are trypsinised (aspirate medium, 
add 0.25% trypsin solution, deactivate with trypsin inhibitor), solution is transferred to 
RNase free centrifuge tube and centrifuged at 300g for 5 mins. Supernatant is completely 
removed. 
Cells are disrupted by adding Buffer RL T: Loosen pellet by flicking tube, add 600fll 
of buffer RL T. Vortex or pipette to mix. Pipette thoroughly to homogenize the lysate (10-
20 times). Add 1 volume of 70% ethanol and mix well by pipetting (precipitates may be 
seen at this stage). Transfer up to 700fll to an RNeasy· spin column placed in a 2ml 
collection tube. Close lid gently and centrifuge for 15 s at 8000g. Discard the flow-
through 
On column DNase digestion: Add 350fll buffer RWI to column and centrifuge for 15 s 
at:> 8000g to wash, discard flow-through. Add IOfll DNasel stock to 70fll buffer RDD. 
Mix gently by inverting tube and centrifuge briefly to collect solution. Add DNasel 
incubation mix directly to the column membrane and incubate on bench top for 15mins. 
Add 350fll buffer RWI to column and centrifuge 15 sat >8000g. Discard flow-through. 
Wash steps: Add 500fll buffer RPE to column and centrifuge 15 s at >8000g to wash. 
Discard flow-through. Repeat step but centrifuge for 2 mins. 
Collection of RNA: Place the column in a new 1.5ml collection tube. Add 30-50fll 
RNase-free water directly to spin column membrane. Centrifuge for 1 min at > 8000g to 
elute RNA. Snap freeze and store at -80. 
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RNA purification using the Nanodrop: Add 2.1 ~l RNase free water to sample arm and 
close arm, click together then reopen and clean with tissue. In window change sample 
type to RNA 40, lamba to 260, rest leave the same. Add more water to the arm and press 
blank. Clean arm with tissue. Load 2~1 of sample onto arm and close. Click measure 
clean arm and repeat for remaining samples. Clean, with water and leave arm closed. 
Click Show report. Print data. 
Reverse Transcription of RNA with High capacity cDNA r-t kit (Applied 
Biosystems): 
Making the Master Mix: 
Allow the components to thaw on ice. 
Calculate the volume of components needed to prepare the required number of reactions. 
Prepare on ice (include additional reactions to account for loss that occurs during reagent 
transfers) 
Volume (uL)/Rea(!tion kit 
Component 
For 1 reaction 
lOX RT Buffer 2.0 
25X dNTP Mix (lOOmM) 0.8 
lOX RT Random Primers 2.0 
MultiScribe Reverse 1.0 
Transcriptase 
RNase Inhibitor 1.0 
Nuclease-free water 3.2 
Total per reaction 10.0 
Place the 2X RT master mix on ice and mix gently. 
Preparing the cDNA Reverse Transcription reactions: 
X4 (to get 40uL) and X21 
(for number of samples 
_plus 11 
168 
67.2 
- 168 
84 
84 
268.8 
40.0 
, 
Pipette 40uL of the 2X R T master mix into each individual tube. 
Pipette 40uL of RNA sample (correct amount of RNA to give 2ug then made up to 40uL 
with RNase free water) into each tube. Pipette up and down two times to mix. 
Briefly centrifuge tubes to spin down contents and eliminate any air bubbles. 
Place tubes on ice until ready to load onto thermal cycler. 
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Programme the thermal cycler using conditions below then run. 
Step 1 Step 2 Step 3 Step 4 
Temperature °C 25 37 85 4 
Time 10min 120min 5sec 00 
Store samples at -80 until required. 
Relative Quantitation using Comparative Ct Real time PCR: 
Setting up the Plate: 
Want to have between 10-100ng of cDNA per sample. After rt step have 2ug 
cDNN80uL, which is 25ng/uL. Will add 2uL of stock giving 50ng cDNNreaction. 
Prepare in eppendorfs a pre-mix for each individual TaqMan Gene Expression Assay 
(RAR-b, CYP26Al and GAPDH) containing sufficient reagents for all reactions plus 
extra for pipetting errors. 
Reagent lXuL 
TaqMan Gene Expression Assay 1 
TaqMan Fast Universal Mastermix 10 
Water .. 7 
Total 18 
Vortex each tube to create a homogenous solution and spin briefly. 
Add 18uL of reagent .cocktail and 2uL of template cDNA to a 96-well optical plate 
acq)rding to a plate map, also adding a no template control (NTC). Do each sample in 
triplicate for technical repeats. NB: place plate in cradle so bottom of well isn't 
contaminated. 
Load plate into PCR machine and run a relative quantitation plate assay from software. 
Run with default universal settings. 
Export data into relative quantitation study document to ,analyse data. Duplicate 
experiments were analysed for reproducibility. 
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2.16 Statistical Analysis of Data: 
Where appropriate statistical analysis of data was performed ~sing the one-tailed, paired 
student t-test. Statisitical significance of the finding was determined compared to the 
undifferentiated control sample unless otherwise stated. Levels of statistical significance 
are outlined in the individual figure legends. For comparisons between the four sample 
groups within the proteomics section, statistical significance was determined usmg 
ANOV A statistical analysis. 
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3 Chapter 3: Evaluation of the Biological Activity of Synthetic 
Retinoids EC19 and EC23 on Embryonic Stem Cell Model Systems. 
3.1 Introduction: 
This chapter is concerned with the ability of synthetic retinoid compounds EC 19 and 
EC23 to induce neural differentiation in pluripotent stem cell model systems. Their 
natural counterpart ATRA is a well known modulator of development and cell 
differentiation and is frequently used to induce neurogenesis in in-vitro stem cell model 
systems (as outlined in Chapter 1). Here we evaluated ATRA vs. synthetic retinoid stem 
cell neurogenesis ability. Two model systems were analysed, a human embryonal 
carcinoma (EC) cell line and a human embryonic stem (ES) cell Jine. The EC cell line is a 
more robust model to use to follow responses to synthetic retinoid culture and to dissect 
the retinoic acid receptor pathway. EC cells are a relevant model to establish embryonic 
cell responses as they have been shown to be the malignant counterpart to ES cells, as 
outlined below. Once suitable analysis had been obtained, synthetic retinoids which 
appeared to be suitable alternatives to A TRA were verified in ES cell cultures. 
3.1.1 Embryonal carcinoma cells 
EC cells are obtained from teratocarcinomas derived from germ cell tumours, most 
commonly from either dermoid cysts of the ovaries or tumo~rs of the testis. 
Teratocarcinomas contain both differentiated tissue and undifferentiated epithelial cells, 
which give rise to the malignant nature of these tumour types 124. It is these 
undifferentiated cells that are termed EC cells. The relationship between EC cells and 
cells found in the embryo was first analysed back in the seventies with the aid of cell 
surface markers 125. One ofthe first of these studies showed that antibodies raised against 
the F9 murine EC cells were not expressed by any differentiated cells types tested, but 
were also highly expressed by cells of the inner cell mass of the embryonic blastocyst. 
Further evidence of the close relationship between EC and ES cells came when studies 
outlined the ability of murine EC cells to be incorporated into developing murine 
embryos. Chimeric off-spring were produced containing the EC cells which had 
differentiated into many different tissue types 126. It was also shown that the EC 
component within these chimeric mice was capable of extending to the germ line, 
- . 
bringing the relationship ofEC cells to ES cells even closer 127. 
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One of the first and most well known human EC cell lines is the TERA2 cell line, 
isolated from a lung metastasis originating from a testicular germ cell tumour 128. Studies 
of human EC cells highlighted significant differences to their murine counterpart, 
namely, the expression of different cell surface markers such as TRA-I-60, stage specific 
embryonic antigen-3 and -4 (SSEA-3 & -4) but not SSEA-l 61. The expression of SSEA-
3 and -4 appeared to relate human EC cells not to the cells of the inner cell mass, but to 
cells from an earlier stage of embryonic development, found in cleavage stage embryos. 
These cleavage stage embryonic cells and human EC cells both retain the capacity for 
trophoblastic differentiation, something which murine EC cells rarely do. The original 
human TERA2 cell line was impure and frequently only contained around 1-2% EC cells, 
making study of these cells difficult. To overcome this problem numerous cloned lines 
were derived from the parent culture, all of which showed varying abilities to 
differentiate upon instruction. One of the most studied and robust cloned lines was 
created by Andrews et al in 1984 and termed NTERA2 129. This clonal line responded to 
culture with retinoic acid, forming neurons. Another more recent clone which was shown 
to have enhanced neuronal ability was created in 2001 by immunomagnetic isolation and 
subsequent single cell selection and culture. This cell line was termed Tera2.spl2 130, and 
is the cell line used in this study. Undifferentiated Tera2.spl2 cells retain the cell surface 
antigens TRA-I-60, SSEA-3 and -4 signifying their EC cell state. They also have been 
shown to differentiate in response to ATRA, down-regulating these stem cell markers and 
up-regulating cell surface antigens associated with neural differentiation, such as A2B5 
and VINIS-53 131, 132. After 21 days of culture in the presence of ATRA, TERA2.spI2 
cells differentiate into a heterogeneous population containing many mature functioning 
neurons 133, making them a useful model system for the in vitro study of neurogenesis. 
3.1.2 Embryonic stem cells 
It was the discovery of EC cells that led to the ground-breaking research of isolating 
murine ES cells 134, \35, then ultimately to the isolation of human ES cells 136 in 1998. This 
first human ES cell line was derived from a human blastocyst and shown to have a 
normal karyotype and express cell surface markers which characterised primate ES cells. 
The cell line was shown to remain in an undifferentiated, proliferative state in-vitro for 4 
to 5 months, after which the cells still maintained their full developmental potential by 
forming trophoblast cells and derivatives of all three of the embryonic germ layers. The 
cell line was termed H9, and is the cell line used throughout this investigation. As found 
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in EC cell studies, significant differences between murine and human ES cell cultures 
was .observed, namely the different expressiDn profiles .of the SSEA antigens alDngside 
IDW expressiDn .of LIFR in human cells cDmpared tD the mDuse 137. 
Unlike their EC cDunterparts, ES cells remain a challenge tD culture and there use is 
surrDunded by ethical cDntrDversy. FDr the purpDses .of this investigatiDn initial 
experiments were carried .out .on EC cells, and further analysis was cDmpleted .on ES 
cells. ES cells require a very clDsely defined culture medium, which up until recent 
advances required the CD-culture with mDuse embryDnic feeder layers (MEF) (as 
practiced in this investigatiDn). Feeder layers release sDluble factDrs and extra-cellular 
matrix cDmpDnents which remain unidentified, but are essential for ES cell proliferatiDn. 
MEFs therefDre have tD be seeded at a sufficient density SD that there are enD ugh factDrs 
tD SUPPDrt ES grDwth, but nDt tDD many cells SD they inhibit cDIDny .outgrowth. FDr the 
H9 line a density .of 20,000 cells/cm2 has been fDund tD b~ .optimal 138. As in the EC cell 
system, A TRA is used in many defined differentiatiDn prDtDcDls fDr the inductiDn .of 
neurDnal sub-types 139. In a recent investigatiDn .on H9 ES cells, it has been ShDwn that 
regiDnally specific neural precurSDrs can be .obtained in chemically defined media 
cDnditiDns. The additiDn .of ATRA intD the media acted as a caudalising agent, inducing 
mDtDr neurDns 140. 
3.1.3 ATRA - Instability. 
While A TRA remains a very impDrtant mDlecule assDciated with, amDng .other things, the 
CDrrect neurDgenesis and DrientatiDn .of the embryDnic central nervDus system, its use in 
in-vitro study is hampered by its inherent ability tD iSDmerise and degrade in respDnse tD 
light and heat 119, as .outlined in Chapter 1. Even under standard labDratDry cDnditiDns this 
instability is .observed. As part .of this multidisciplinary study .of retinDids and further tD 
earlier published studies, chemists at Durham University highlighted the ease at which 
A TRA degrades, .outlining the need fDr mDre stable alternatives fDr in-vitro 
investigatiDns. The susceptibility .of A TRA tD phDtDisDmerisatiDn and degradatiDn when 
expDsed tD light in the 300-400 nm range was first demDnstrated (Fig 3.1.IA). ProtDn 
NMR spectroscDPY shDwed that prDIDnged expDsure tD fluDrescent light led tD 
progressive degradatiDn .of ATRA. After 3 days .of expDsure apprDximately 37% .of 
A TRA was present in its .original state. A TRA was fDund tD be stable fDr at least 3 days 
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when kept in the dark, whereas exposure to fluorescent light for the same time period 
resulted in substantial isomerisationldegradation (Fig 3.1.1B). 
3.1.4 Stability of Synthetic Retinoids EC19 and EC23 
As outlined in Chapter 1, to address the issue of instability of ATRA, when used in-vitro, 
synthetic retinoid analogues were created as part of work contributing to this thesis 123 for 
synthesis methods refer to Chapter 1. It was hypothesised that these retinoids would 
possess greater physical and chemical stability during routine in-vitro use. To test this 
theory, initially two synthetic arotinoids were chosen for analysis and were termed EC19 
and EC23. Their photostability was tested. Synthetic retinoids were exposed to the same 
wavelength of fluorescent light for 3 days as in the ATRA analysis, 300-400 nm range, 
and NMR spectra were compared with control samples, which had been incubated in the 
dark for the same length oftime (Fig 3.1.1C & D). Both EC19 and EC23 were found to 
be completely unaltered by the light treatment. These results demonstrate that the 
introduction of an aromatic ring into the polyene chain, and the incorporation of a triple 
bond into the linker region results in greatly enhanced photostability under conditions 
which have dramatic effects on A TRA. Both of these synthetic retinoids were put 
forward for biological analysis. 
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Figure 3.1.1 : Proton NMR at 400 MHz of ATRA, EC23 and EC19 in DMSO-d6 (5.0-8.0 ppm 
region) A. NMR spectra of ATRA after exposure to white fluorescent light at 40 cm distance for 4 h 
(top), 16 h (middle) and 24 h (bottom) showing increased degradation with increased time. B. NMR 
spectra of A TRA after 3 days in absence of light (top), and 3 days exposure to white fluorescent 
light at 40 cm distance (bottom) showing degradation only with exposure to light. C. NMR spectra 
of EC23 after 3 days in absence of light (top), and 3 days exposure to white fluorescent light at 40 
cm distance (bottom), s~owing no degradation under exposure to light. D. NMR spectra of EC 19 
after 3 days in absence of light (top), and 3 days exposure to white fluorescent light at 40 cm 
distance (bottom), showing no degradation under exposure to light. 
3.1.5 Aim and Objectives 
Aim 
The aim of this Chapter was to evaluate the biological activity of the synthetic retinoid 
analogues EC 19 and EC23 on models of embryonic stem cells. ATRA is a well known 
and studied morphogen, inducing the correct dorsal/ventral and anterior/posterior axis of 
many different embryonic developmental processes. One such area where ATRA is 
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influential is the patterning of the CNS. It is already known that A TRA induces neural 
differentiation in stem cell model systems in-vitro and here we aim to study the ability of 
our more stable synthetic retinoids to do the same. 
Objectives 
• Analysis of the ability of synthetic retinoids EC 19 and EC23 to induce 
differentiation in the EC cell line TERA2.spI2. 
• Quantification of stem cell and neural differentiation markers. 
• Proteomic analysis of retinoid induced differentiation products. 
• Analysis of the ability of synthetic retinoids·· EC 19 and EC23 to induce 
differentiation in the ES cell line H9. 
• Quantification of neural differentiation markers. 
• The only chemical difference between EC 19 and EC23 is the position of the 
carboxyl group either in the para- (ECI9) or meta- (EC23) position. Whether this 
subtle change had any effect on the biological activ.ity visualised was analysed. 
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3.2 Methods: 
3.2.1 Tissue Culture 
3.2.1.1 Tera2.sp12 human embryonal carcinoma cells: 
Cells were cultured under standard laboratory conditions as described in Chapter 2. Cells 
were cultured in Dulbecco's modified eagles medium (DMEM) (Sigma) supplemented 
with 10% foetal calf serum (FCS) (Gibco), 2mM L-Glutamine and 100 active units each 
of penicillin and streptomycin (Gibco). Cultures were passaged using acid-washed glass 
beads (VWR) unless a single cell suspension was required for counting, in which case 
0.25% trypsin EDTA (Cambrex) solution was administered. For optimal cell culture, and 
to inhibit spontaneous differentiation, flasks were maintained at high confluency and split 
at a ratio of no more than 1 :3. Cultures intended for flow cytometric and proteomic 
analysis were set up in T25 flasks (Nunc) while 12-well and 24-well plates (Nunc) were 
used for MTS assays and immunocytochemical analysis. 
Differentiation protocol: 
Single cell suspensions were obtained using 0.25% trypsin EDTA and either 500,000 
cells/T25 flask or 1,200,000 cells/plate were seeded and left in proliferative media to 
settle for 24 hours. Cultures were then switched to differentiation media; standard 
proliferative media supplemented with either 111M or IOIlM retinoid as stated in results, 
and incubated as normal. Cultures were then left for the dedicated time period and 
underwent full media changes every three days. Subsequent analysis of obtained samples 
was carried out as described in protocols found in Chapter 2. 
3.2.1.2 H9 human embryonic stern cells: 
Cells were cultured under standard laboratory conditions as described in Chapter 2. Cells 
were co-cultured with mitotically inactivated mouse embryonic fibroblast feeder layers 
(MEF) in serum-free conditions. Proliferative media was knockout DMEM (Gibco) 
supplemented with 20% knockout serum (Gibco), 1% Glutamax (Gibco), 1% non-
essential-amino-acids (NEAA) (Gibco), 8ng/ml basic fibroblast growth factor (bFGF) 
(Gibco) and 1 % penicillin and streptomycin (Gibco). Cultures were maintained and 
expanded in 6-well plates (lwaki). After initial seeding, ES cells underwent a full media 
change after day 2 of culture. On day 3, cultures were 'cleaned-up', i.e. underwent 
removal of all spontaneously differentiated cells which usually occurred around the edge 
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of colonies. This was done by scratching cells off the plate using a 100)lL pipette tip 
, 
visualised down a dissection microscope. Media containing thy scratched off cells was 
removed and refreshed. On day 6 or 7 cultures were passaged. As MEFs only remain 
optimal for up to 7 days in culture, plates had to be passaged every week into fresh MEF-
coated plates. Cultures were split according to ES colony size ranging from a 1: 1 split up 
to 1:3 for confluent cultures. Routine passage of cultures was carried out by mechanically 
dissociating the ES cell colonies from the tissue culture plastic using pipette tips . 
.... .::.~, 
Colonies were cross-hatched with a 100)lL tip then lifted off using a 1000)lL tip and the 
resulting floating ES colonies were transferred to the fresh MEF plates. 
Differentiation protocols: 
Neuronal-specific differentiation protocol: Monolayer differentiation without MEFs was 
followed in this established protocol. First, 12-well plates (Iwaki) were co.ated overnight 
with 1 % gelatine solution (in PBS) then washed twice with PBS prior to use and not 
allowed to dry out. Confluent ES cell colonies .were cleaned of differentiated cells 
without disrupting the ES colony, then treated with collagenase solution (Img/ml in 
knockout DMEM media) (Sigma) for 15 minutes at 37°C. Detached colonies were 
transferred into the pre-coated 12-well plates (1: 1 plating ratio) and neuronal 
differentiation was induced by growth in differentiation media (DMEMlFI2 (PAA), 
supplemented with IX N2 supplement (P AA), IX B27 supplement (PAA), 1 % NEAA 
(Gibco), 1 % L-Glutamine (Sigma) and 1 % Penicillin and streptomycin (Sigma)). After 7 
days, medium was changed to a neuronal base medium (DMEM/F12:Neuronal base 
medium (PAA) 1: 1, supplemented with O.5X N2 supplement, O.5X B27 supplement, 1% 
NEAA, 1 % L-glutamine, 20ng/ml bFGF, 1 % penicillin .a~d streptomycin). Cultures at 
this stage were incubated with and without l)lM retinoids (without served as 
differentiation control). Cultures were maintained for a further 2 weeks with media 
changes every 3 days. Subsequent analysis of cultures was carried out as described in 
protocols found in Chapter 2. 
General embryoid body differentiation protocol: This method was a standard generic 
differentiation protocol incorporating embryoid body (EB) formation. Confluent ES cell 
colonies were cleaned of differentiated cells without disrupting the ES colony, then 
treated with collagenase solution (lmg/ml in knockout DMEM media) (Sigma) for 15 
minutes at 37°C. Detached colonies were transferred to bacteriological dishes (VWR) to 
undergo EB aggregate formation in suspension (4 plates: 1 dish seeding ratio). Media 
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used was knockout DMEM supplemented with 10% FCS (Hyclone), 1% NEAA, 1% L-
glutamine and 1 % penicillin and streptomycin. Dishes were cultured with and without 
I)lM addition of retinoids (without served as the differentiation control) . Media was 
changed every 3 days by allowing the EBs to settle on the bottom of a SOml tube and 
removing old media then refreshing with new. Cultures were also transferred to fresh 
bacteriological plates during this process. Cultures were maintained for 2 weeks, after 
which EBs were transferred a 24-well plate (8 wells/dish, i.e. 8 wells/condition studied, 
see diagram below) pre-coated with 10)lglml poly-I-ornothine (Sigma) overnight 
followed by S)lg/ml laminin (Sigma) coating also overnight with subsequent PBS 
washes, and cells maintained for a further week. Subsequent analysis of cultures was 
carried out as described in protocols found in Chapter 2. 
Con Oiff I IJlM ATRA I IJlM EC23 
I I 
00:00:00 
00:00:00 
I I 
00:00:00 
00100100 
3.2.2 Flow cytometry 
For complete methods refer to Chapter 2, section 2.4. 
Stem cell markers SSEA-3 and TRA-I-60 (used neat, generous gift from Prof. P. 
Andrews, University of Sheffield) and neural differentiation markers A2BS (I: 1 00, 
Abeam) and VINIS-S3 (used neat, generous gift from Prof. P. Andrews, University of 
Sheffield) were analysed. The expression of cell surface antigens has been used 
previously to indicate the status of cellular differentiation by human pluripotent 
TERA2.SP 12 stem cells. 
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3.2.3 Immunocytochemistry 
For complete methods refer to Chapter 2, section 2.6. 
Antibodies used: 
Antibody Company Dilution 
Nestin Chemic on 1:100 
Tun Covance 1:500 
NF-200 Sigma 1:200 
Cytokeratin-8 Sigma 1:200 
HB9 Abcam 1 :100 
3.2.4 Western blot 
For complete methods refer to Chapter 2, section 2.13. 
Antibody used: 
Antibody Company Dilution 
CRABP-l Abcam 1:200 
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Incubation Secondary 
. time 
Ihr Alexafluor 488 
Ihr Cy3 
Ihr Alexafluor 488 
Ihr Alexafluor 488 
Ihr Alexafluor 488 
Incubation Secondary 
time 
Ihr Horse-radish 
peroxidase 
3.3 Results: 
3.3.1 Morphological Effects of Natural and Synthetic Retinoids on Tera2.sp12 EC 
Cells 
To compare the effect of synthetic retinoid analogues EC19 and EC23 versus known 
natural retinoid responses on embryonal carcinoma cells, cultures of Tera2.sp12 EC cells 
were incubated with 1 f.lM and 10 f.lM concentrations of each retinoid compound tested. 
Control cultures consisted of untreated stem cells as well as cultures exposed only to the 
retinoid solvent DMSO, termed vehicle control. 
3. 3. 1.1 Cell viability assay 
Retinoid treated cultures were maintained for up to 21 days. At time points of 3 and 7 
days after retinoid addition, cell viability/number was an~lysed (MTS assay, Fig. 3.3.1). 
ATRA treatment at both concentrations resulted in reduced cell number compared with 
both control samples, and this effect was concentration dependent. Decreased cell 
number was also observed in cultures treated with both concentrations of EC23, although 
the. decrease was not as great as in ATRA cultures. There was no difference between cell 
numbers in control and 1 f.lM EC 19 treated cultures, indicating inability of this compound 
to arrest cell proliferation at this concentration. In particular, cells treated with 1 f.lM 
EC 19 continued to proliferate rapidly, to the point that, after 7 days the cultures had 
become over-confluent and all cells had died. lOf.lM EC 19 cultures did show an 
attenuation of cell number at the 7 day time point when compared with controls, 
however, this was to a much lesser extent than that seen with ATRA and EC23. 
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Figure 3.3.1: Cell number analysis using the MrS assay kit. Cultures exposed to either IJ-LM or 10J-LM 
ATRA, EC23 or EC19 were assayed at various time points and compared to control undifferentiated and 
vehicle exposed (DMSO) cultures. Cell number, expressed as an absorbance value, was attenuated in all 
ATRA and EC23 cultures compared to the controls, most predominantly in the lOJ-LM ATRA culture. 
However, IJ-LM EC19 cultures did not reduce cell number seen compar~d to control samples·, whereas at the 
10J-LM concentration by 7 days cell numbers were attenuated but not to the same extent as in ATRA and 
EC23 samples. Results are presented with ± standard deviation of the mean (SDM). n=3. * pSO.05, student's 
t-test compared to relevant undifferentiated control. 
3.3.1.2 Morphological analysis o/induced cell types 
Morphological analysis of retinoid treated cultures revealed dramatic effects of all three 
compounds (Fig 3.3.2). Cultures exposed to EC23 appeared to mimic their ATRA 
counterparts (Fig 3.3.2B & C), both displaying a high degree of heterogeneity and 
containing rosette-like areas typically seen in neural cell culture. On the other hand, 
treatment with 10 IlM EC 19 induced different cellular morphologies divided into two cell 
types. The first were highly proliferative cells which had become highly confluent and 
begun to layer upon one another. These cells were surrounded by a second large, flat cell 
type (Fig 3.3.2D). The 'plaques' formed by the large flat cells were distributed 
throughout the culture and were large enough to be seen with the naked eye. These 
plaques, also observed to a lesser extent in ATRA and especially EC23 cultures, were 
clearly visible upon immunocytochemical staining with cytokeratin-8, a marker 
epithelium (Fig 3.3.3). Cytokeratin-8 staining reinforced the apparent similarity between 
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A TRA and EC23 treatment (Fig 3.3.3A-D), and highlighted the high plaque content of 10 
11M EC 19 cultures (Fig 3.3.3E). 
Figure 3.3.2: Structural phenotype of Tera2.sp 12 cells treated with retinoids. Morphological analysis of 
differentiation of Tera2.sp 12 embryonal carcinoma stem cells. 21 days of culture with IOIlM concentrations of 
the natural retinoid all-trans-retinoic acid (ATRA) or synthetic retinoids EC23 or EC 19 induced significant 
morphological changes. Undifferentiated Tera2.sp I 2 cultures (A) retained a homogeneous ' cobblestone ' 
appearance throughout the culture. Cultures exposed to A TRA (8) exhibited highly heterogeneous 
morphology, including numerous neural-like rosettes (bordered area). Similarly cultures exposed to EC23 (C) 
exhibited heterogeneous morphology and rosettes (bordered area). Cultures exposed to EC I 9 (D) were distinct 
in morphology, characterised throughout by areas containing large flat cells (bordered area) surrounded by 
highly proliferative cells becoming layered on top of one another. Scale bar: IOOllm. 
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Figure 3.3.3: Cytokeratin-8 expression in cultures ofTera2.spI2 embryonal carcinoma stem cells incubated 
with (A) 111M or (8) 10l1M ATRA, (C) 111M or (0) 10l1M EC23, and (E) 10l1M ECI9. Low power (x 4 
magnification) images show the proportion of the culture area made up of cells with the large, flat 
morphology, seen predom inantly in the EC 19 culture (bordered areas). Micrograph (F) shows a high power 
(x 40 magnification) image of these large flat cells. Scale bars : A-E 250l1m, F 50Jlm. 
The number of plaques and the average area which they occupied in each culture was 
calculated, using Image] software, from 12 random images taken using the 4 X objective 
(Fig 3.3.4). In cultures treated with ATRA, plaque number and average area decreased 
slightly from 1 11M to 10 11M treatment. A similar, though slightly more pronounced 
trend was observed in EC23 cultures. Slightly fewer plaques were seen in 1 11M A TRA 
cultures, and slightly more in the 10 11M A TRA cultures, compared with the respective 
EC23 counterparts. The area of plaque coverage in 10 11M EC23 cultures is notably the 
lowest of all treatments. Treatment with 10 11M EC 19 resulted in approximately 4 times 
the number of plaques than in 10 11M ATRA cultures. More strikingly, plaques in the 
EC 19 culture occupied a dramatically greater area of the culture than in the A TRA 
counterpart. 
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Morphological analysis indicated that while both synthetic retinoids elicited 
differentiation of the Tera2.sp 12 cell line, EC23 appeared the more functionally related to 
A TRA at this stage of analysis. Although the different treatments were seen to give rise 
to similar cell types, the proportions of these derivatives were significantly different in 
EC 19 cultures compared with those of A TRA and EC23 treatments. 
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Figure 3.3.4: The number and average area covered by the non-neural , cytokeratin-8 positive large flat cell 
'plaques' increases in EC19 cultures. Tera2.spl2 EC cells were incubated with IflM or IOflM ATRA or 
EC23 or IOflM EC I 9 and cultured for 21 days. Cultures were immunocyto-stained for the cyto-skeletal 
marker cytokeratin-8. This marker was able to distinguish between plaque areas and the other cell types 
within the cultures. A random collection of 12 images/condition was collected. Using ImageJ the number of 
plaques/field of view (A) and area of plaques was analysed. The total area made up of plaques was 
compared to the total area studied and the average % plaque coverage was calculated for each condition 
(8). As the concentration of A TRA or EC23 increased the number of plaques visualised per field of view 
and subsequently the average area covered by plaques decreased, being almost totally inhibited in the 
IOflM EC23 culture. Compared to the control retinoid A TRA, EC 19 increased the number of plaques 
visualised and greatly increased the average area covered by the plaques, indicating thi s retinoid greatly 
enhances the differentiation of these EC cells into this particular cell type. Error bars on A: SDM n= 12. *** 
p:SO.0005, student ' s t-test compared to IOflM A TRA. 
3.3.2 Immunological Analysis of Tera2.sp12 EC Cells Exposed to Natural and 
Synthetic Retinoids 
3.3.2.1 Flow cytometry 
Flow cytometry was performed to demonstrate and characterise differentiation of 
Tera2.sp 12 cells in response to treatment with synthetic and natural retinoids. In line with 
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the known neural effect of A TRA in this cell line, a panel of markers was chosen to 
. specifically follow neural differentiation. 
Two stem cell markers were analysed, since a reduction in their expression would signify 
a departure from stem cell state. These markers were globoseries antigen stage specific 
embryonic antigen-3 (SSEA-3), and the keratin-sulphate-associated glycoprotein antigen 
surface marker TRA-I-60. Within 7 days of ATRA or EC23 addition t<? cultures, the 
levels of both SSEA-3 and TRA-I-60 had dropped dramatlcally~ indicating exit from the 
cell cycle and a commitment to differentiation (Fig. 3.3.5). Expression of both markers 
remained low through to the conclusion of the 21 day schedule, although it can be seen 
that the expression of these markers in 10 JlM EC23 is approximately 5% elevated over 
the 1 JlM EC23 and ATRA treatments. This perhaps reflects a proliferating 
subpopulation, in keeping with the slightly increased ceU· numbers deter~ined by MTS 
assay. SSEA-3 and TRA-I-60 expression levels remained comparatively high in EC19 
cultures up to 7 days after retinoid addition. Nonetheless, the decrease relative to control 
cultures was marked indicating that cellular differentiation had been triggered in a 
proportion of cells. After 7 days 1 JlM EC 19 cultures were discarded due to overgrowth. 
However, in 10 JlM EC19 cultures, SSEA-3 and TRA-I-69 continued to decline to levels 
comparable with A TRA and EC23 by the 14 day time point. Therefore it appears as 
though 10JlM EC19 induces the differentiation of Tera2.spI2, albeit at a slower rate than 
either ATRA or EC23. 
The differentiation markers VINIS-53 (an antibody reactive against neuronal cell 
adhesion molecule - NCAM), and A2B5 (a ganglioseries antigen marking early-stage 
neural cells), were analysed by flow cytometry (Fig. 3.3.5). All retinoid treatments 
resulted in elevated expression of these markers compared to the time zero control. It is 
important to note that the percent of cells expressing markers are relative to the threshold 
fluorescent settings, which was fixed throughout all analysis, including all biological 
repeats. 10 JlM A TRA causes the most rapid increase in VINIS-53 expression, peaking at 
approximately 25% cells expressing the marker at 7 days. 10 JlM EC23 expression 
increased at a slower rate and peaked at 14 days to a level of more than 30% positive 
cells (this number subsequently returned to approximately 25 % cells by day 21). Cells 
treated with 10JlM EC 19 displayed a marked delay in increase of VINIS-53 expression 
54 
compared with the other two retinoids. However, after 14 days the expression profile 
closely resembled that of the 1 /-lM EC23 culture, ultimately resulting in almost 20% 
positive cells. The expression profiles for A2B5 largely mirrored those for VINIS-53, 
although initial rates of expression increase were much closer between the A TRA and 
EC23 treatments. Once again, 10 /-lM EC23 caused the greatest increase occurring at 14 
days (- 40%) before returning to a lower level by day 21, and this was mimicked by 1 
/-lM A TRA. Of particular note is the exact correlation between the 1 /-lM EC23 and 10 
/-lM ATRA profiles of A2B5 expression. As with VINIS-53, cells treated with 10/-lM 
EC 19 showed delayed expression of A2B5 which ultimately reached numbers 
comparable with the other treatments. Taken together these findings support a close 
relationship between ATRA and EC23 . Furthermore, it appears as though both synthetic 
retinoids are able to induce the differentiation of Tera2.sp 12 cells towards derivatives 
which posses neural cell surface markers. 
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Figure 3.3.5: Flow cytometric analysis of markers for stem cells and neural differentiation. The percentage 
of Tera2.sp12 cells expressing the stem cell markers SSEA-3 (A) and TRA-1-60 (B) and neural 
differentiation markers VINIS-53 (C) and A2B5 (D) was measured at 7 day time-points following 
treatment with lOflM or 1 flM ATRA, EC23 or EC 19, alongside undifferentiated control cultures. Both 
concentrations of A TRA and EC23 resulted in a rapid decrease in expression of the stem cell markers and 
an increase in neural marker expression. Similarly IOflM EC19 induced differentiation as evidenced by 
complete absence of the stem cell markers after 14dys, although this down regulation occurred at a slower 
rate than that induced by EC23 and EC 19. On the other hand treatment with 1 flM EC 19 appeared not to 
induce neural differentiation with cells continuing to proliferate arid express stem cell markers whilst 
remaining negative for neural markers. Cultures treated with I flM EC 19 were maintained until 7 days 
whereupon cells became over confluent. Values represent ±SDM, n=3. 
3.3:2.2 Immunocytochemical staining 
Immunocytochemical staining was performed on 21-day-old retinoid-treated cultures, in 
order to further evaluate differentiation patterns. The neural progenitor marker nestin was 
first examined (Fig. 3.3.6). Nestin expression was evident in undifferentiated control 
cells (Fig. 3.3.6F), and became up-regulated in cells treated with both concentrations of 
ATRA and EC23 (Fig. 3.3.6 A-D). The neural-like rosettes, seen throughout ATRA and 
EC23 cultures under light microscopy, were positively reactive for nestin expression. In 
10 IlM EC 19 cultures, nestin expression was observed-in areas containing the small, 
highly proliferative cells. On the other hand, the large plaques consisting of large flat 
cells were all negative for nestin expression (Fig. 3.3.6E). In ATRA and EC23 cultures 
these plaques, which were fewer and smaller, also stained negative for nestin expression. 
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Figure 3.3.6: Induction of neural differentiation in cultures of Tera2 .sp 12 embryonal carcinoma stem cells 
incubated with (A) 1 jlM or (8) IOjlM ATRA, (C) I llM or (0) IOIlM EC23 , (E) IOIlM EC 19 or (F) 
undifferentiated controls. Undifferentiated and 21 day-differentiated cultures were immunocyto-stained for 
the neural progenitor marker nestin. Undifferentiated cells displayed relatively low expression levels of 
nestin (F). I jlM 21 day ATRA-treated cultures contained areas of high nestin expression (A) as did IOjlM 
cultures (8). Both concentrations of 21 day EC23 (C, 0) exhibited similar expression profiles to 10jlM 
ATRA. In 21 day EC 19 cultures (E) nestin expression was restricted to areas containing highly 
proliferative cells, and the large flat cells which dominate the EC 19 cultures were negative. Marked areas 
in micrographs A-O indicate the presence of neural rosettes. Micrograph E includes the nuclear counter-
stain Hoechst 33342 (Blue) image. Scale bar: 5011m. 
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Expression of neuronal specific proteins was examined using antibodies raised against 
the neuronal specific P-Ill-tubulin marker TUll (Fig. 3.3.7) and the late neuronal marker 
~.: 
neurofilament 200 (NF200, Fig. 3.3.8). Both markers were highly expressed in 1 flM and 
10 flM ATRA and EC23 cultures (Fig. 3.3.7A-D & 3.3.8A-D), with many neuronal 
processes visible in both. However, very few TUll or NF-200 positive cells were seen in 
lO . flM EC 19 cultures, and very few neuronal processes were evident (Fig. 3.3.7E & 
3.3.8E). Plaque regions were also negative in all cultures. As would be anticipated, 
undifferentiated cell cultures stained negative for both markers, indicating that induction 
of expression in ATRA and EC23 cultures occurred in response to the respective retinoid 
treatment. The number of NF200 positive cell bodies (perykarya) in each culture 
treatment was calculated as the mean from nine randomly selected immunostained 
images, with the aid of ImageJ software (Fig. 3.3.9). The highest number of NF200 
positive perykarya, and by inference mature neurons, was'seen in 10 flM EC23 cultures, 
decreasing as follows: lOflM EC23 >lOflM ATRA > IflM EC23 > IflM ATRA » 
1 OflM EC 19. Thus, at equal concentrations and under the conditions tested, EC23 appears 
to be a more potent inducer of neuronal differentiation than A TRA. The results also 
indicate a degree of neuronal differentiation in 10 flM EC19 cultures, however, this 
occurs at far lower frequency than observed following ATRA of,EC23 treatment. 
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Figure 3.3.7: Induction of neural differentiation in cultures of Tera2.sp 12 embryonal carcinoma stem cells 
incubated with (A) I JlM or (8) IOJlM ATRA, (C) I JlM or (D) IOJlM EC23 , (E) IOJlM EC 19 or (F) 
undifferentiated controls. Undifferentiated and 21 day-differentiated cultures were immunocyto-stained for 
the neuronal marker TUJ I. Undifferentiated cells displayed no expression ofTUJ I (F). Both concentrations 
of 21 day ATRA-treated cultures contained areas of high TUJ I expression (A, 8). Both concentrations of 
21 day EC23 (C, D) exhibited similar expression profiles to ATRA. In 21 day EC 19 cultures (E) TUJ I 
expression was restricted to areas containing highly proliferative cells, and the large flat cells which 
dominate the ECI9 cultures were negative. Micrograph E and F includes the nuclear counter-stain Hoechst 
33342 (Blue) image. Scale bar: 50Jlm. 
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Figure 3.3.8: Induction of neural differentiation in cultures of Tera2.sp 12 embryonal carcinoma stem cells 
incubated with (A) I J.lM or (B) IOJ.lM ATRA, (C) 111M or (D) IOJ.lM EC23, (E) IOIlM EC 19 or (F) 
undifferentiated controls. Undifferentiated and 21 day-differentiated cultures were immunocyto-stained for 
the late neuronal marker NF-200. Control undifferentiated cells displayed no NF-200 expression (F). 
However, Both concentrations of21 day ATRA-treated cultures highly expressed NF-200 (A, B), with long 
neuronal processes visible. Both concentrations of 21 day EC23 cultures (C, D) exhibited similar 
expression profiles to ATRA, also with many neuronal processes. In 21 day EC 19 cultures (E) very few 
NF-200 positive neurons were visible and only appeared in the areas of highly proliferative cells. The large 
flat cells which dominate the EC 19 cultures were negative for NF-200. Micrographs E & F include the 
nuclear counter-stain Hoechst 33342 (Blue) image. Scale bar: 50llm. 
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Figure 3.3.9: Induction of neural differentiation in cultures of Tera2.sp 12 embryonal carcinoma stem cells 
incubated with If.lM or IOf.lM ATRA, 1f.lM or 10f,lM EC23 or 10f,lM ECI9. 21 day-differentiated cultures 
were immunocyto-stained for the late neuronal marker NF-200. Using Image] software the number of NF-
200 positive cell bodies was counted on 9 random fields of view per condition. Results were averaged and 
represented graphically. Increasing the concentration of ATRA and EC23 increased the number of neurons 
seen, with the most neurons being visualised in the 10f,lM EC23 condition. Compared to the natural retinoid 
ATRA control EC 19 induced the differentiation of far fewer neurons. Error bars represent standard 
deviation of the mean n=9. * p:S0.05, *** p:S0.0005, student's t-test compared to 10f,lM ATRA. 
3.3.3 Proteomic Analysis of Tera2.sp12 EC Cells Exposed to Natural and Synthetic 
Retinoids. 
3.3.3.1 MALDI-TOF analysis 
All data collated up to this point has indicated a similarit), in the differentiation products 
induced by culture of Tera2.sp 12 Ee cells with either the natural retinoid A TRA or the 
synthetic retinoid Ee23. Differentiation products induced by the synthetic retinoid Ee 19 
were distinctly different. As a complimentary approach to further investigating the 
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similarity of natural/synthetic retinoid responses, we applied clinical biomarker analysis 
technology. Protein profiling has emerged as a potentially powerful tool for the 
measurement of diagnostic cohorts of biomarker proteins in the clinical arena. Here, we 
have investigated the applicability of biomarker profiling technology to characterise and 
compare the response of the EC stem cell model to natural and synthetic retinoids, an 
approach which this technology hasn't been used for before. It was hypothesised that this 
technology would allow the rapid and simultaneous detection of multiple proteinipeptides 
present in EC cells before and after retinoid treatment" and statistically analyse the 
similarities and differences between the sample groups. In principle this method should 
show the degree of similarity between the different cell treatments based on these protein 
signatures. 
Total protein lysates were obtained from undifferentiated Tera2.sp12 EC cells and their 7 
day retinoid differentiated counterparts. Only the 1 O~M retinoid concentration was used 
for these experiments. Total protein lysates underwent matrix assisted laser desorption 
ionisation time of flight (MALDI-TOF) analysis and resultant protein peak spectra were 
obtained and shown in triplicate (Fig. 3.3.10). Analysis of the raw spectra data shows 
obvious differences in protein profiles were visualised "between the different sample 
groups. Undifferentiated control samples were easily distinguished from the retinoid 
differentiated samples, and also differences were visualised between the EC19 protein 
profiles and those obtained from the other two retinoid conditions. Confirming above 
data, ATRA and EC23 protein profiles appeared very similar. Using the associated 
Clinprot biomarker analysis software a four-way analysis of the grouped triplicate sample 
profiles was performed. A list of discriminatory biomarkers which could significantly 
distinguish between at least two of the sample groups was compiled, and the top ten are 
shown in Table 3.3.1. Initially, the top 2 discriminatory biomarkers were analysed, and 
visualised on a 2D distribution plot (Fig. 3.3.11). All of the retinoid sample cultures were 
distinct from the undifferentiated control, again indicating a departure of these treated 
cells from the undifferentiated stem cell state. EC 19 was also distinct from ATRA and 
EC23, backing up previous data that EC 19 did induce differentiation, but the induced cell 
products were distinct from treatment with ATRA and EC23. 
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Figure 3.3.10: Triplicate MALDI protein spectra showing the similarities and differences between profiles 
obtained from control undifferentiated and retinoid differentiated EC celllysates. Total protein lysates were 
analysed from undifferentiated EC cells and EC cells cultured with lO/lM ATRA, EC 19 or EC23 for 7 
days. Obvious differences in protein profiles are visualised in the undifferentiated contro\' compared to the 
differentiated samples, also differences are seen between the EC 19 conditioii and the other two retinoids. 
A TRA and EC23 protein profiles appear very similar. n=3 
63 
Average peak area p-value 
Index No. Observed 
m/z 
Undiff ATRA EC19 EC23 
3 4944.19 9272 190.99 108.14 177.68 0.0137 
22 12000.43 13.2 30.97 40.57 38.49 0.0281 
5 5273.8 101.26 211.96 214.88 220.26 0.0438 
26 16802.57 lU88 38.99 21.81 46.92 0.0438 
4 4970.04 20.5 194.3 205.61 183.14 0.0536 
18 10858.03 56.27 143.61 214.2 125.46 0.0586 
14 8199.17 4457 150.28 36.96 91.55 0.0586 
21 11839.44 5U39 47.3 26.48 66.22 0.0586 
25 12779.6 1276 8.27 10.46 16.62 0.0586 
2 4286.22 90. <» 128.25 75.63 134.1 0..0.671 
Table 3.3.1: Table of the top ten discriminatory protein biomarkers as analysed by Clinprot biomarker 
analysis software. Marker proteins/peptides are statistically ranked (p-value of ANOYA test). Total protein 
Iysates were analysed from undifferentiated EC cells and EC cells cultured with 10IlM A TRA, EC 19 or 
EC23 for 7 days. Markers in bold type displayed average peak area changes of> 1.5-fold compared with 
control undiff samples. n=3 
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Figure 3.3.11: 2D distribution plot showing the top two biomarkers that were able to distinguish between 
the sample groups. Analysis was carried out using Clinprot biomarker analysis software. Retinoid protein 
samples were obtained from EC cells cultured with 10IlM retinoid for 7 days. All ofthe retinoid conditions 
distinct from the control undifferentiated control. EC 19 was also distinct from A TRA and EC23. The 
Clinprot biomarker software was unable to separate effectively ATRA and EC23 treated conditions, 
indicating the similarity in their protein profiles. n=3 
Even when considering the top two discriminatory biomarkers, the Clinprot biomarker 
software was unable to separate effectively A TRA and EC23 treated samples, thus 
further verifying the similarity in the differentiation response between these two 
treatments. It was noted that the 'spread' of the three biological repeats was a lot tighter 
- " 
in both EC 19 and EC23 samples compared with A TRA. This may be an indication that 
the induced-differentiation products visualised with the synthetic compounds are more 
tightly regulated and reproducible than in the ATRA counterparts. When considering the 
top ten discriminatory biomarkers in graphical form (Fig. 3.3.12) the similarity between 
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A TRA and EC23 treated cultures becomes even more apparent. In nine out of the ten 
biomarker profiles A TRA and EC23 elicit similar trends in protein expression levels 
(only Idx 25 is different). These top ten biomarkers also back up the differences seen with 
EC 19 culture. Seven out of the ten hits show a difference in expression levels between 
EC 19 profiles and the other retinoid samples (only Idx 5, 4, 25 are similar). Showing 
these data in a Venn diagram indicates a possible novel way to interpret the findings (Fig. 
3.3.13). The Venn diagram was constructed by focussing on markers of differentiation 
which are up- or down-regulated by one or more of the retinoid conditions greater than 
1,5 fold, with a statistical value of p<O.06. A total of nine peaks meet these criteria 
(indicated in bold in Table 3.3.1). Seven out of the nine peak profiles are shared between 
A TRA and EC23, indicating their effects are similar albeit not identical. Two of these 
markers are exclusive to ATRA and EC23. It is possible to hypothesise that these. are 
neuronal differentiation markers, however this would have to. be verified by further 
analysis. The five markers shared between each condition could be viewed as general 
differentiation markers as they are up-regulated in all conditions. The biomarker 
exclusive to EC 19 could potentially be a non-neural differentiation marker. This 
biomarker platform technology has proved to be a very efficient way for screening novel 
retinoid compounds against control natural samples as the resultant protein profiles can 
be compared for similarities and differences. This is also a significantly quicker method 
for detection as samples can be analysed after only 7 days of culture compared to 21 days 
for immuncytochemical staining methods outlined above. 
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Figure 3.3.12: Graphs showing the average peak distribution areas of the top ten discriminatory protein 
biomarker hits of undifferentiated EC cells and their differentiated derivatives. Retinoid protein samples 
were obtained from EC cells cultured with IOIlM retinoid for 7 days. In nine out of the ten profiles A TRA 
and EC23 elicit similar trends in protein expression levels (Idx 25 is different). Seven out of the ten hits 
show a difference in expression levels between EC 19 and the other retinoid samples (ldx 5, 4, 25 are 
similar). n=3 
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Figure 3.3.13: Venn diagram focussing on markers of differentiation which are up- or down-regulated by 
one or more of the retinoid conditions > 1.5 fold, p<O.06. A total of nine peaks meet these criteria. Seven 
out of the nine peak profiles are shared between ATRA and EC23 , indicating their effects are similar but 
not identical. Two of these are exclusive to ATRA and EC23 . A hypothesis could be that these are neuronal 
differentiation markers. The five markers shared between each condition could be general differentiation 
markers. The biomarker exclusive to EC 19 could potentially be a non-neural di fferentiation marker. 
Retinoid protein samples were obtained from EC cells cultured with I O~M retinoid for 7 days. n=3 
3.3.3.2 Analysis and identification o/proteins up-regulated after retinoid treatment. 
To try and simplify the protein profiles obtained from each sample group and to help aid 
the identification of some of these up-regulated proteins, fractionation of the total protein 
lysates was performed. Samples were fractionated using strong anion exchange columns 
and underwent a NaCI step elution process. The resultant protein fractions were run on 
SDS-Page gels together with the total protein Iysates (Fig. 3.3.14). Protein bands were 
visualised using Coomassie blue protein stain. A protein of interest of mass 15kD 
(marked with an arrow in the total lysate lane) was seen to be up-regulated in both ATRA 
and EC23 samples in the total lysate lane, however, it had not shown up on the protein 
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spectra obtained during the previous total lysate MALDI-TOF analysis. This protein band 
, 
was tracked to a fraction (marked with a star in O.lM NaCI lane), and this fraction was 
re-submitted for MALDI-TOF analysis. Another protein band at 17 kD which elutes in all 
retinoid conditions but not the undifferentiated control was noted, (marked with star in 
0.25M NaCI lane) and this fraction was also re-submitted for further MALDI-TOF 
analysis. The up-regulation of protein in the A TRA and EC23 conditions with a mass of 
15kDa was of particular interest, as it is known that the molecular weights of the cellular 
retinoic acid binding proteins are around the 15kDa mark. 
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Figure 3.3.14: SDS-Page gels run with total protein lysates and protein fractions obtained after strong 
anion exchange chromatography and NaCl step elution. A protein of interest of mass 15kD (marked with an 
arrow in total lysate lane) did not show up on total lysate MALDI analysis. This was tracked to a fraction 
(marked with a star in 0.1 M NaCl lane), and the fraction was re-submitted for MALDI analysis. Another 
protein band at 17 kD which elutes in all retinoid conditions but not the undifferentiated control was noted , 
(marked with star in 0.25M NaCllane) and this fraction was also re-submitted for further MALDI analys is. 
Retinoid protein samples were obtained from EC cells cultured with 10flM retinoid for 7 days. n=3 
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MALO 1-TOF re-analysis of total protein lysates alongside fractionated samples revealed 
that some proteins which were visualised readily on SOS-Page gels, were not being 
visualised in the total protein spectra obtained after MALDI-TOF analysis. However, 
these specific protein profiles were being visualised after fractionation (As shown in Fig. 
3.3.15A & C). This phenomena is explained by ion suppression within the total lysate 
samples, due to the abundance of proteins being analysed at one time. This was overcome 
when the protein content of the samples were 'thinned out' after fractionation. Pseudo gel 
images and those actually visualised on the SDS-Page gels from the fractionated samples 
showed identical patterns of expression (Fig. 3.3.158 & D). Further analysis of the 
proteins within these bands of interest was carried out using fractionated protein Iysates. 
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Figure 3.3.15: A & B: Comparison of MALDI spectra analysis from total cell lysate (red line) and specific 
fractionated cell lysate (green line) as chosen off gel analysis (A: 0. 1 M NaCI fraction, B: 0.25M NaCI 
fraction) (see figure 14). It appears that in the total cell lysate the protein peaks are not visualised due to ion 
suppression. C & 0: Corresponding pseudo gel bands of the triplicate fractionated MALDI data are 
identical to actual fractionated gel images from SDS-page analysis. Retinoid protein samples were obtained 
from EC cells cultured with 10llM retinoid for 7 days. n=3 
71 
3.3.3.3 Stathmin identification 
MALDI-TOF analysis of the 0.25M NaCI fraction showed two proteins were present 
within the 17kDa protein band visualised on the SDS-Page gels (Fig. 3.3.16). The fact 
that the two proteins were separated by only 80 Da meant they were not resolved 
separately on a standard SDS-Page gel. This is where the sensitivity of MALDI-TOF 
analysis becomes apparent. Overlaying all the corresponding fractionated sample spectra 
at this particular molecular weight indicated that both proteins were up-regulated in 
ATRA and EC23 cultures, just the 17,223 mlz peak was present in the EC 19 condition 
albeit at a lower intensity than in ATRA and EC23 samples, and none were 
present/expressed in the undifferentiated control. Corresponding gel bands were digested 
with trypsin and resultant peptides were analysed by MALDI-TOF MS and submitted for 
peptide mass fingerprint searches (Mascot). Six matching identifications were obtained 
from monoisotopic peptide masses (singly charged, [M+H+]+) and were listed in Table 
3.3.3 alongside the corresponding molecular weight search (MOWSE) scores and 
sequence coverage against the intact matching database sequence. Predicted molecular 
masses provided from the database searches for each matched database protein sequence, 
were compared alongside observed intact protein mlz values from our MALDI-TOF 
protein profiles. From all the searches and analysis it was deduced that the identity of the 
proteins we were studying in the 17 kDa band and MALDI-TOF traces were stathmin. 
The exact 80 Da shift in molecular size of the two proteins, and the fact that only one 
protein ID was obtained, strongly suggested that this was the same protein but with a 
single phosphorylation modification 141. Quantitative analysis of the expression profiles 
of these proteins in the different sample groups was shown in graphical form; the bars 
represent the mean peak area of the triplicate protein samples analysed via MALDI-TOF 
(Fig. 3.3.17 & Table 3.3.2). The patterns of protein expression were very similar 
between the A TRA and EC23 cultured cells, again indicating the similarity of the activity 
induced by these retinoids. Both conditions showed an up-regulation in stathmin 
expression compared to the undifferentiated control sample, and also a smaller but 
identical increase in phosphorylated stathmin was recorded. Protein collected from EC 19 
cultures only exhibited a minor increase in non-phosphorylated stathmin, which was not 
as pronounced as in A TRA or EC23 treated cultures. 
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Figure 3.3.16: MALOI protein peak spectra obtained from the O.25M NaCI SAX fraction from 
undifferentiated (red), IO/lM ATRA treated (green), IO/lM EC 19 treated (blue), and IO/lM EC23 treated 
cultures (yellow). The 17,223 kOa peak is identified as stathmin (Mass spec analysis- see table 3) and is 
up-regulated in all retinoid samples, but mainly ATRA and EC23. A smaller protein peak was identified in 
both the ATRA and EC23 conditions. As it has an exact 80kOa shift it can be tentatively assigned to 
phosphorylated stathmin, a protein known to be involved in tubulin remodelling during neuronal 
differentiation. Retinoid protein samples were obtained from EC cells cultured with IO)..lM retinoid for 7 
days. n=3 
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Figure 3.3.17: Quantification of the average peak area plot of stathmin (A) and phosphorylated stathmin 
(8) peak profiles obtained from MALDI-TOF spectra of fractionated protein Iysates. Stathmin is up-
regulated in all retinoid conditions, to similar levels in both ATRA and EC23, whereas phosporylated 
stathmin is only up-regulated in ATRA and EC23, also to a similar level. Retinoid protein samples were 
obtained from EC cells cultured with IO)..lM retinoid for 7 days. n=3 
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Average peak area p-value 
Assignment Observed 
m/z UnditT ATRA EC19 EC23 
, 
-15 kDa (0.1 M NaCI) 
CRABPI 15446.27 -0.02 6.26 0.78 33.57 0.0179 
CRABPII 15574.83 0.46 81.01 0.5 79.13 0.131 
CRBPI 15730.06 0.34 8.31 1.21 6.63 0.556 
Profilin-I 15860.54 0.11 13.79 3.2 22.9 0.365 
_. 
-17 kDa (0.25 MNaCI) 
Stathmin 17222.8 2.43 103.54 45.5 86.0 0.246 
Stathmin-P 17303.26 0.55 7.06 -0.3 6.51 0.298 
Table 3.3.2. Peak statistic data for enriched retinoid-induced proteins. Observed mass and average (n=3) 
MS peak area data for six retinoid-regulated proteins. Four proteins were enriched in 0.1 M NaCl eluates 
from SAX columns and two were enriched in 0.25M NaCl fractions. Statistical p-values (ANOY A) reflect 
the discriminatory power of each protein to separate the four samp~e groups (Undiff, ATRA, ECl9 and 
EC23). 
Protein Gd PMF l)Cptidc.!l I MOVille MSiM 10., ICak. MW Db, 
Accession numba (NCBI) band Obs(ncd [M+H+r score S lealc. MW- N- MW 
lSeq. [M+H to'mM 
T leal:. pi 
CRABPU A 949.3633: 1490.7919; 1108.5153; 1000.5060: 10165325; '81 115693 kDa 15574 
(Cdklbrretiloi: acid-binding H49.3147: 1100.4382; 1219.6325 244% 115561kDa niz 
Ilrutci12) )5--'2 
P29373 B 1490.7616: 11085171: 1016.5327: H49.2228; 1100.4887: '82 949.39 64 
1822.7433: 23H.9523 2(N% 85 53 
1108.5 
314 
CRABPI A 852.3503; 1181.5658; 1423.6121 .164 I I 5566 kDa 15H6 
(Cdubrrcti-lOi: acid-b"llling 221% 215-134kDa niz 
protein 1) 35.30 
P29762 B 920.3968: iI81.57J..l.; 960.4376; 1447.881·1: 1113.4973: 1107 1423.6 73 
852.3873; 1423.6608: 1551. 7852 251% 608 71 
1551.7 
852 
CRUPI A 1556.7 .. 115850kDa 15730 
(Cdu~lrretnol-b"llling ,Jrotan I) 180 58 ~ 15719kDa niz 
P09455 1572.7 14.99 
112 
970.4851; 1112.5020; 1556.6618; 1572.6701: 1434.1636; '59 
2650.0905: 1438.6100; 2015.8420 265% 
Profilil-l B 1643.8575; 1914.9667: 1470.7026; 1625.6672; '78 115054kDa 15860 
P077)7 1641.6741: 1870.7272: 1379.6589; 1234.5866 ~52% 38.44 ni, 
Stathmin C 1388.7062; 1541.7772; 1326.6163; 1074.4746; 1202.5873; '88 1388.7 97 117302kDa 17223 
P 16949 1165.4705 231% 062 35.76 ni, 
Table 3.3.3. Peptide data and database search results for proteins identified from SDS-PAGE gels. 
Proteins bands at approximately 15 kDa (O.lM NaCl SAX fraction) and 17 kDa (0.25M NaCl SAX 
fraction) were excised from gel profiles for A TRA and/or EC23 treated samples. Gel bands were digested 
with trypsin and resultant peptides were analysed by MALDI-TOF MS and submitted for peptide mass 
fingerprint searches (Mascot). Matching monoisotopic peptide masses (singly charged, [M+H+]+) are 
listed alongside corresponding MOWSE scores and sequence coverage against the intact matching database 
sequence. Peptides analysed using MSIMS fragmentations are detailed alongside corresponding ion scores. 
Calculated masses are provided in kilo Daltons (kDa) for each matched database protein sequence, 
alongside observed intact protein mlz values from MALDI protein profiles. In the case of CRABPII, 
CRABPI, and CRBPI, additional calculated masses are shown, which account for the post-translational 
removal of N-terminal methionine. Peptide mass fingerprint searches were performed under a mass 
tolerance of 100 ppm unless stated otherwise in the text (*). A ATRA, 0.1 M NaCl SAX fraction (15 kDa 
band); B EC23, 0.1 M NaCl SAX fraction (I5 kDa band); C ATRA, 0.25 M NaCl SAX fraction (17 kDa 
band). 
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3.3.3.4 Cellular retinoid binding proteins identification 
MALDI-TOF analysis of the 0.1 M NaCI fraction indicated that there were four separate 
proteins within the 15kOa protein band visualised on the SDS-Page gels (Fig. 3.3.18). 
Again, the fact that the four proteins were separated by only 414 Da meant they were not 
sufficiently resolved on a standard SOS-Page gel. This is where the sensitivity of 
MALDI-TOF analysis became apparent again. However, the 15 kDa band visualised in 
the SDS-Page gel was bigger than the previously analysed 17 kOa band, so was divided 
into two sections, the top half and the lower half, and underwent separate mass spec 
analysis. This was done in an attempt to correctly assign protein identification to the 
corresponding MALO I -TO F spectra. 
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Figure 3.3.18: MALDI-TOF protein peak spectra obtained from the 0.1 M NaCI SAX fraction from 
undifferentiated (red), 10l-lM ATRA treated (green), 10l-lM EC 19 treated (blue), and 10l-lM EC23 treated 
cultures (yellow). The 15,446 kDa peak is identified as cellular retinoic acid binding protein-I (CRABP I) 
and is up-regulated in both ATRA and EC23 conditions. The 15 ,574 kDa peak is identified as cellular 
retinoic acid binding protein-2 (CRABP II), and is strongly up-regulated in both A TRA and EC23 
conditions. This identity assignment is backed up by the 128kDa difference between the first 2 peaks, 
which is identical to the difference in their predicted masses in database searches. The third peak at 15 ,730 
kDa is identified as cellular retinol binding protein-I (CRBP I), which again has an identical increase in 
mass size (156kDa) from the previous peak compared to the predictive mass change. The final peak in the 
group at 15,860 kDa is identified as profilin-I, a protein involved in actin remodelling. (All protein 
identities are assigned after mass spec analysis and the associated predictive masses, see table 3). Retinoid 
protein samples were obtained from EC cells cultured with 10l-lM retinoid for 7 days. n=3 
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Analysis of the lower portion of the excised gel band identified three proteins. The gel 
band was digested with trypsin and resultant peptides were analysed by MALDI-TOF MS 
and submitted for peptide mass fingerprint searches (Mascot). Matching identifications 
were obtained from monoisotopic peptide masses (singly charged, [M+H+]+) and were 
listed in Table 3.3.3 alongside the corresponding MOWSE scores and sequence coverage 
against the intact matching database sequence. Predicted molecular masses provided 
from the database searches for each matched database protein sequence, were compared 
alongside observed intact protein mlz values from our MALDI-TOF protein profiles. 
The first protein to be identified was cellular retinoic acid binding protein II (CRABP-II). 
This ID had eight matching peptides from the A TRA gel. and 7 matching peptides from 
the EC23 gel with corresponding sequence coverage's scores of 44% and 64% 
respectively. The next protein identified was cellular retinoic acid binding protein I 
(CRABP-I). This ID had 3 matching peptides from the ATRA gel and 8 matching 
peptides from the EC23 gel with corresponding sequence coverage's of 21 % and 51 % 
respectively. The calculated masses of CRABP-I and CRABP-II are 15,566 and 15,693 
Da respectively, the difference between them being 127 Da. This mass difference 
corresponded very closely with the observed mlz difference between the first two 
MALDI-TOF spectra peaks (128m1z), thus enabling a tentative assignment to these two 
peaks as CRABP-I and II (Fig. 3.3.18). The third protein to be identified elicited eight 
matching peptides from the EC23 gel with sequence coverage of 65%. Initially no 
matching peptides were found from the ATRA gel, however, further MS/MS mass 
fingerprinting did elicit 2 peptides of similar mass. The protein ID for the third hit was 
identified as cellular retinol binding protein I (CRBP-I). The calculated mass for this 
protein was 15,730 Da, 156 Da more than the calculated mass of CRABP-II. This mass 
difference again, corresponded very closely with the observed mlz difference between the 
second and third peaks visualised on the MALDI-TOF protein spectra (156m1z), 
therefore the third peak was again tentatively assigned with this protein ID (Fig. 3.3.18). 
Quantitative analysis of the expression profiles of these proteins in the different sample 
groups was shown in graphical form; the bars represent the mean peak area of the 
triplicate protein samples analysed via MALDI-TOF (Fig. 3.3.19 & Table 3.3.2). All 
four proteins are up-regulated in both ATRA and EC23 samples compared to the 
undifferentiated controls, with EC23 showing a higher expression level of both CRABP-I 
and the as yet unidentified protein, compared to A TRA. EC 19-induced cultures displayed 
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very little protein expression of both CRABP-I or -II, and only a slight increase in 
expression levels of CRBP-1 and profilin-1 above the base control level. However, 
neither protein amount reached that of either A TRA or EC23 samples. The patterns of 
protein expression were again relatively similar between the A TRA and EC23 cultured 
cells, indicating the similarity of the activity induced by these retinoids. 
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Figure 3.3.19: Average peak area plots of CRABP I, CRABP II, CRBP I and profilin-I peak profiles 
obtained from MALDI-TOF spectra of fractionated protein Iysates. CRABP I is up-regulated in both 
ATRA and EC23 conditions, but most strongly in EC23. CRABP II is equally up-regulated in both ATRA 
and EC23 conditions, as is CRBP I, which is also slightly up-regulated in the EC 19 sample. Profilin-I is 
up-regulated in all retinoid samples compared to the undifferentiated control, with the strongest up-
regulation seen in EC23 followed by ATRA and EC 19 respectively. Retinoid protein samples were 
obtained from EC cells cultured with 1 OIJM retinoid for 7 days. n=3 
There was a consistent discrepancy between the observed and calculated masses of 
CRAB PI, CRABPII and CRBPI (119, 118, and 120 Da, respectively) . This was 
attributed to the post-translational removal of N-terminal methionine residues (131 Da). 
The N-terminal peptide for all three proteins was detected in their respective peptide 
mass fingerprints, and was found in each case to lack the starting methionine. Taking 
this into account the observed and calculated values differ by approximately 12 mass 
units only. Accordingly, we are confident that we have assigned these proteins to the 
correct peaks in the MALD I spectra. 
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3.3.3.5 Profilin-l identification 
To try and identify the final protein in the group of four yisualised on the MALO 1-TOF 
spectra the top half of the 15kDa band from the 0.1 M NaCI fraction underwent peptide 
mass fingerprinting. After initial database interrogation, 2 protein hits were returned; nine 
matching peptides were found for profilin-1 with sequence coverage of 52% and eight 
further peptides were found for CRBP-1 (Table 3.3.3). Unmatched peptides were 
resubmitted and returned a match with CRABP-II (eight peptides). Ther~fore the final 
protein in our MALDI-TOF spectra profile was assig~ed the identity of profilin-l. 
However, the calculated mass for profilin-1 is only 15,054kDa, significantly different 
from the assigned peak mlz of 15,860. We believe this assignment is correct as profilin-1 
was only identified in the top half of the gel band, which corresponds to the higher mlz 
proteins, therefore we attribute this extra mass to some kind of post-translational 
modification. It is well known. that profilin-l can undergo'phosphorylation, and also that 
this modification is likely to playa regulatory role 142. Phosphorylation of profilin would 
help account for its co-elution with proteins of different calculated isoelectric points (see 
Table 3.3.3). Thus, although non-phosphorylated profilin (calculated pI 8.44) would be 
anticipated to be only weakly anionic under the SAX fractionation conditions (PH 9.0), 
multiple post-translational phosphorylation could potentiaJly impart a significantly lower 
pI value. Profilin-l has been shown to influence the dynamics of the actin cytoskeleton 
during neuronal differentiation 143. Therefore we can tentatively suggest that the up-
regulation of profilin-l we see in the A TRA and EC23 samples could be attributed to 
actin re-modelling during neuronal differentiation (Fig. 3.3.19). 
3.3.3.6 Immunological verification of CRABP identifications 
To verify the identities of the CRABPs obtained via MALDI-MS, antibody detection was 
performed on western blot membranes. Blotted membranes were obtained from both the 
total cell lysate protein and the O.lM NaCI fractionated protein samples from all three 
retinoid conditions and compared against the undifferentiated control (Fig. 3.3.20A). The 
antibody used was a monoclonal human specific antibody for CRABP-I, however, when 
the company were queried over the specificity of the antibody it could not be verified, 
and therefore is considered to be recognised by at least both the CRABP-I and -II 
isoforms and possibly the CRBPs as well. Immuno-reactive signals were quantified for 
the fractionated sample data and shown in graphical form (F~g. 3.3.20B). The highest 
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level of expression for this antibody was seen in the EC23 sample followed by A TRA, 
EC 19 and undifferentiated cells respectively. This expression pattern is consistent with 
that seen in the MALOI data, however, in the MALOI data a greater difference was seen 
between the expression levels visualised in the A TRA and EC23 samples compared with 
EC 19. Also no detection was visualised in the undifferentiated samples. This could be 
due to the non-specificity of the antibody used, or more likely, due to the greater 
sensitivity of detection in the western blot and the higher detection threshold in the 
MALO I-TO F spectra. 
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Figure 3.3.20: Verification of protein identifications obtained after mass spec analysis was carried out via 
western blot analysis. A: 10 % acrylamide SDS-page gels were probed for an antibody raised against 
CRABP-1. Protein profiles were obtained from total protein lysates (T) and the fractionated protein samples 
(F). The visualised bands from the fractionated sample underwent densitometric analysis as shown in graph 
B. Retinoid protein samples were obtained from EC cells cultured with IOIlM retinoid for 7 days. n=3 . . ** 
p:SO.005, student's t-test compared to the undifferentiated control. 
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3.3.4 The Biological Analysis of Natural and Synthetic Retinoid Activity on H9 
Human Embryonic Stem Cells. 
The culture of both synthetic and natural retinoids with the robust stem cell model system 
Tera2.sp12 provided insight into both the natural and synthetic retinoids mode of actions. 
Results obtained so far indicated that the synthetic retinoid EC23 elicited similar 
biological responses to the natural retinoid ATRA, potentially via similar retinoic acid 
induced pathways. Both retinoids induced a significant amount of neuronal 
differentiation within the culture conditions tested. However, the important difference 
between the two molecules is that EC23 is more stable under standard laboratory 
conditions, making it a more favourable alternative for in-vitro work. To further observe 
the biological similarity of EC23 to A TRA, experiments were conducted where the 
retinoids were cultured with pluripotent human embryonic stem cells, to further assess 
the potential of the compounds to induce cell development. Markers of neural 
differentiation were analysed to see if the retinoids were able to direct neuronal 
differentiation in this model system. 
Two methods of inducing cell differentiation were carried out: a specific method for the 
induction of neuronal cell types; and a generic differentiation protocol involving the 
formation of embryoid bodies. These were chosen to see if the retinoids (both ATRA and 
EC23) had any effect on the differentiation products visualised in either circumstance. 
Control differentiation cultures were set up in each case and acted as the base level of 
differentiation induced with each protocol. One )lM concentrations of retinoids were used 
in all experiments. 
3.3. 4.1 Culture techniques required for optimal ES cell proliferation 
The culture of human H9 embryonic stem cells (ES cells) requires a defined culture 
condition, and deviation away from this may result in spontaneous differentiation. ES 
cells are cultured with the aid of a mouse embryonic fibroblast feeder layer (MEFs) 
which have been mitotically inhibited with exposure to mitomycin-C 24 hrs before use. 
Small colonies of ES cells expand in the proliferative media, 'pushing' the MEFs out of 
the way (Fig. 3.3.21). It is thought that the MEFs release important factors which are 
required for ES cell proliferation; however the exact properties of these factors are as yet 
80 
unknown. As the colonies expand areas of spontaneous differentiation occur and need to 
be scraped off to maintain a pure ES cell culture, this procedure is done every three days 
or as necessary. Cultures also needed to be plated onto freshly inactivated MEFs every 7 
days to limit this spontaneous differentiation. Cultures underwent total removal of 
differentiated material before use in the differentiation experiments. 
Figure 3.3.21: Undifferentiated human ES cells, cell line H9. The proliferation of the human ES cell line 
H9 was propagated with growth on an inactivated mouse fibroblast feeder layer. Colonies of ES cells are 
visualised surrounded by the feeder layer. Areas of spontaneous differentiation (outlined by the dotted line 
in C) were removed with a lOOIlL pipette tip using a dissection microscope. Scale bar represents 50llm. 
n=5 
3.3.4.2 Specific neuronal-inducing differentiation protocol 
Initially, cultures were induced to differentiate using a defined neuronal differentiation 
protocol, whereby cells were grown in monolayer on 1 % gelatine coated plates in defined 
neuro-basal media. After 7 days, the cultures were switched to neuro-basal media plus 
bFGF, to induce outgrowth of neuronal cells, with or without retinoids, and left for a 
further two weeks. At this time point many neurons were visualised in all conditions 
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except the control cultures, which had been plated but left in proliferative media (Fig. 
3.3.22). These cells had spontaneously differentiated but did not appear to be neural, they 
appeared to contain a high content of fat lipids; however this observation was not verified 
and analysis of these cultures was not taken any further. 
Figure 3.3.22: Differentiated human ES cells, cell line H9. The differentiation of the human ES cell line 
H9 was induced by plating on 1% gelatine coated tissue culture plastic (A). Neuronal differentiation was 
enhanced by incubation in defined neuronal medium (8), plus the addition of retinoids (8, C). Neuronal 
processes (arrows) are readily visualised in all three neuronal culture conditions. Scale bar represents 
50llm . n=3 
To try and quantify the extent of neuronal differentiation a panel of neural markers was 
used to immunocyto-stain the obtained cultures. Nestin, an early neural marker, clearly 
showed differential expression levels between the thre~ different culture conditions. 
Many of the long neural processes were stained with nestin in the control differentiation 
condition compared with both the ATRA- and EC23-supplemented cultures, suggesting 
the presence of immature neuronal phenotypes (Fig. 3.3.23) In the retinoid conditions, 
the levels of nestin expression was decreased throughout the whole culture compared to 
control differentiation conditions, and very few of the long neural processes visualised 
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under light microscopy were nestin positive. This again, could .indicate that the cultures 
obtained with retinoid supplementation are more mature than those seen in the control 
differentiation, without retinoid supplementation, alone. All cultures contained neuronal 
cells which were positive for the P-III-tubulin marker, Tun (Fig. 3.3.23). There did not 
appear to be any differential expression of this marker between the different culture 
conditions tested. Next, two more mature markers of neuronal differentiation were 
analysed, namely the late neuronal marker neurofilament-200 (NF-200), and the motor 
neuron specific marker HB9 (Fig. 3.3.24). Low power (X4 objective) images showed the 
length and extent ofNF-200 positive neuronal in all conditions tested, again showing no 
real distinction between the different conditions. However, the expression of the motor 
neuron marker HB9 did appear to be differentially expressed. HB9-positive cell nuclei 
were visualised in the control differentiation condition, but upon supplementation with 
either A TRA or Ee23 the number of positive cells increased. This result was quantified 
using ImageJ software to count the number of positive cell nuclei/field of view in 
randomly sdected images (Fig. 3.3.25). An increase in the number of HB9-positive cell 
nuclei upon A TRA or Ee23 supplementation was confirmed. Both retinoids induced a 
similar increase in expression. 
Following a defined neuronal-inducing culture protocol, it was shoWn that H9 human 
stem cells are able to differentiate down a neuronal lineage. Supplementation with either 
A TRA or Ee23 into the culture media appeared to induce an increase in number of cell 
phenotypes indicative of a more caudal eNS location, as would be expected after ATRA 
.~ .. 
introduction. The synthetic retinoid Ee23 has again been shown to mimic A TRA action. 
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Figure 3.3.23: Nestin and TUJ I immunostaining of differentiated H9 stem cells after 21 days of culture. 
ES cells were differentiated on I % gelatine coated 12-well plates. Cultures were maintained in either 
differentiation media alone (C, F), or differentiation media plus 111M ATRA (A, D) or 111M EC23 (B, E). 
Nestin positive cells were found throughout the culture of the control differentiation condition. Nestin 
expression was visualised in a few distinct patches in both A TRA and EC23 conditions, with most of the 
cultures being negative for this antibody. TUJ I positive neurons were found throughout the culture of all 
differentiation conditions. Images were captured after the 21 day culture period. Nestin : Scale bar 
represents I OOl1m. TUJ I : Scale bar represents 250l1m. n=3 
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Figure 3.3.24: NF-200 and HB9 immunostaining of differentiated H9 stem cells after 21 days of culture. 
ES cells were differentiated on I % gelatine coated 12-well plates. Cultures were maintained in either 
differentiation media alone (C, F), or differentiation media plus 111M ATRA (A, D) or 111M EC23 (B, E) . 
NF-200 positive neurons were found throughout the culture of all differentiation conditions. HB9 positive 
nuclei were visualised in all conditions, with increased amounts in A TRA and EC23 supplemented 
cultures. Images were captured after the 21 day culture period. Scale bar represents NF-200: 250l1m, HB9: 
50l1m. n=3 
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Figure 3.3.25: Quantitative analysis of HB9 positive cell nuclei in differentiated H9 stem cells. Cultures 
were maintained in either differentiation media alone (control differentiation), or differentiation media plus 
I JlM A TRA or I JlM Ee23 . Using ImageJ software the number of HB9 positive cell nuclei were counted on 
13 random fields of view per condition_ Results were averaged and represented graphically. An increase in 
the motor-neuron marker HB9 was visualised after cultures were supplemented with either ATRA or EC23. 
Error bars represent standard deviation of the mean n= I3. *** ps O.0005, student' s t-test compared to 
control differentiation _ 
3.3.4.3 Generic differentiation protocol 
This method was followed to observe the responses induced by the retinoids during a 
non-specific differentiation cue. Unlike in the Tera2.sp12 system, to obtain neurons from 
ES cells, very defined protocols are followed, i.e. the addition of just retinoids is not 
thought to be sufficient. As these cells retain the capacity to differentiate into all the cells 
of the body, this was another good test to ascertain how closely Ee23 would mimic 
ATRA. 
To initiate differentiation ES cell colonies were grown in generic differentiation media, 
with and without retinoids, in bacteriological dishes. As these dishes are low attachment, 
floating embryoid bodies (EB) were formed and maintained for two weeks. After the 
culture period EBs were transferred to poly-L-ornotine/laminin coated 24-weII plates and 
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maintained for a further week, after which cells were fixed and immuncyto-stained. It 
was noted that measurements of diameter of the EBs formed after the two week culture 
period in the presence of both ATRA or EC23 were significantly smaller than those 
formed in just the differentiation media alone (Fig. 3.3.26). After plating out, cells had 
migrated away from the central EB in all conditions, but no obvious neural cells were 
visible under light microscopy, unlike in the neuronal-defined experiment (Fig 3.3.27). 
A B 
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Figure 3.3.26: Human stem cells, H9, were induced to differentiate and form embryoid bodies. Cells were 
cultured in defined differentiation media in uncoated bacteriological dishes for 14 days. Cells were either 
cultured in differentiation media alone (C), or differentiation media plus 111M ATRA (A) or 111M EC23 
(8 ). Images were captured of embryoid bodies after the 14 day culture period. The embryoid bodies in both 
retinoid treated cultures were smaller than those observed in control differentiation cultures. Scale bar 
represents 50llm. n=2 Using ImageJ software the diameter of the embryoid bodies was calculated and 
visualised in graphical form (D). On average the embryoid bodies were larger in the control differentiation 
condition. n= at least 8. Error bars represents ± standard deviation of the mean. Images were taken at X5 
objective. *** pSO.0005, student's t-test compared to control differentiation. 
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Figure 3.3.27: Differentiated H9 stem cells after 21 days of culture. After 14 days culture as embryoid 
bodies, the differentiated stem cells were then cultured on poly-L-ornothine/ laminin coated 24-well plates 
for a further 7 days. Cultures were continued in either differentiation media alone (E, F), or differentiation 
media plus 111M ATRA (A, B) or 111M EC23 (C, D). Differentiated cells appeared to grow out from the 
aggregates in all conditions tested. Images were captured after the 7 day culture period. Scale bar represents 
50~m. n=2 
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Nestin staining revealed differing patterns of expression between cultures incubated with 
the retinoids and those incubated without. In both A TRA and Ee23 cultures small areas 
of nestin positive cells were visualised, normally associated around an EB, however 
nestin expression in the control differentiation condition was much more generic and 
ubiquitously expressed throughout the culture (Fig. 3.3.28). The neuronal specific marker 
TUn was next examined. In both A TRA and Ee23 cultures no visible neuronal 
differentiation had occurred, however the antibody was expressed in some large flat cells 
of unknown identity (Fig. 3.3.29).The expression of the glial marker GFAP was 
subsequently analysed to see if these cells were glia, possibly reactive astrocytes, 
however, no OF AP expression was seen in any of the conditions analysed. It is therefore 
possible that this antibody is not specific for neuronal cells and that A TRA and Ee23 
have induced some other form of differentiation within these ES cell cultures. Small areas 
of typical TUn neuronal expression was visualised in the control differentiation culture. 
The neurons appeared to be emanating from the EBs, suggesting that the neural 
differentiation had been initiated during the EB stage of the culture protocol. It is 
interesting to note that the large flat positive TU] 1 cells were also visualised within this 
culture condition, but at a much lower frequency. It appears as if the addition of both 
retinoids in this differentiation protocol inhibits neuronal differentiation within the EBs. 
It is important to note that yet again Ee23 is mimicking the effects of A TRA. As 
mentioned above A TRA is an important morphogen during many different embryonic 
developmental processes so it is unsurprising that when A TRA or Ee23 is given to ES 
cells in an undefined culture media, a variety of cell types form. 
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Figure 3.3.28: Nestin immunostaining of differentiated H9 stem cells after 21 days of culture. ES cells 
were differentiated for 14 days as embryoid bodies, then cultured for a further 7 days as mono layers on 
poly-L-omothine/laminin coated 24-well plates. Cultures were maintained in either differentiation media 
alone (E, F), or differentiation media plus 111M ATRA (A, 8) or 111M EC23 (C, D). Patches of nestin 
positive cells were visualised in both cultures exposed to retinoids, however the number of nestin positive 
cells were not equal to that found in the control samples. Images were captured after the 21 day culture 
period. Scale bar represents A, C, E: IOOl1m, 8, 0, F: 50l1m. n=2 
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Figure 3.3.29: Neuronal specific ~-III-tubulin (TUJ I) immunostaining of differentiated H9 stem cells after 
21 days of culture. ES cells were differentiated for 14 days as embryoid bodies, then cultured for a further 7 
days as mono layers on poly-L-ornothine/ laminin coated 24-well plates. Cultures were maintai ned in either 
differentiation media alone (E, F), or differentiation media plus I)lM ATRA (A, B) or I)lM EC23 (C, D). 
TUJI positive cells were visualised in all conditions, however the morphology of positive cells was vastly 
different in ATRA and EC23 cultures compared to the control. Control cultures contained many neuronal 
cells. Images were captured after the 21 day culture period. Scale bar represents A, C, E: IOO)lm , B, D, F: 
50llm. n=2 
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It was also noted that when cultures were stained with the late neuronal marker NF-200, 
very few positive cells were visualised in any of the conditions tested (Fig. 3.3.30). So 
although some neural differentiation was recorded in the control condition, this appeared 
to be representative of more immature cells than those visualised after defined neuronal 
medium was used. 
Figure 3.3.30: Neurofilament 200 (NF-200) immunostaining of differentiated H9 stem cells after 21 days 
of culture. ES cells were differentiated for 14 days as embryoid bodies, then cultured for a further 7 days as 
mono layers on poly-L-ornothine/laminin coated 24-well plates. Cultures were maintained in either 
differentiation media alone (C), or differentiation media plus I ~M ATRA (A) or I ~M EC23 (8). Very few 
NF-200 positive cells were visualised in the retinoid conditions. Slightly increased staining was visualised 
in the control differentiation condition. Images were captured after the 21 day culture period. Scale bar 
represents 100~m. n=2 
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3.4 Discussion and Conclusions: 
The aim of this chapter was to test the biological activity of stable synthetic retinoids on 
model human pluripotent stem cells, and to compare the results with the known effects of 
the natural counterpart A TRA. We have demonstrated the design, synthesis and 
purification of two novel arotinoids, EC 19 and EC23. Furthermore we have shown that 
these compounds are resistant to light conditions which cause isomerisationldegradation 
of ATRA. We therefore present them as potential alternatives to ATRA for in vitro use 
(Literature review, Chapter introduction and 123). Arotinoids are not new compounds, 
they have been developed and synthesised since 1983 14\ when their ability to induce 
differentiation ofEC cells was reported. However, the emphasis has always been on their 
use as chemotherapeutic agents (for example, see 145), and not as a replacement for the in 
vitro use of ATRA. Consequently publications outlining their biological effects on stem 
cell models are limited. This quality was therefore investigated here, specifically their 
ability to induce neural differentiation in stem cell model systems. The ability of A TRA 
to induce neural differentiation in models of stem cells has been well documented (see 
literature review), and the specific neuronal-inducing qualities of ATRA has also been 
documented in the EC cell model system used here, Tera2.sp12 131,132. This background 
formed the basis for experiments carried out into the synthetic retinoid modes of action. 
Two effective concentrations of the synthetic retinoids EC 19 and EC23 were chosen for 
initial treatment of Tera2.sp12 EC cell cultures. At the lower concentration (lIlM), EC19 
did not induce significant alteration in cell phenotype. On the other hand, 10IlM EC 19 
did induce differentiation, albeit at slower rates and in a different manner to that observed 
for ATRA and EC23. In terms of cell proliferation, morphology, and marker phenotype, 
EC19 is quite distinct from ATRA and EC23 in its mode of action. For example EC19 
treatment of this cell line gives rise to a dominance of 'plaque-forming' epithelial-like 
cells at the apparent expense of neural derivatives. The second synthetic retinoid, EC23, 
was an effective inducer of differentiation at both concentrations as shown by decreased 
cell proliferation and the concomitant increased expression Qf neural markers. EC23 . 
expressIOn patterns revealed similar responses to those of ATRA. Nonetheless 
differences were apparent between EC23 and the natural counterpart, for example, 
delayed shut-down of stem cell marker expression in the 10IlM treatment, as well as 
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lower incidence of non-neural cell plaques. Perhaps the most significant difference 
however, was the increased number of mature neuronal cell~ compared with A TRA 
treatments at equivalent concentrations. Data presented here indicating the ability of the 
synthetic arotinoids EC 19 and EC23 to induce differentiation in EC cells backs up 
previous studies on arotinoid-induced differentiation of EC cells and teratogenicity in 
whole embryo culture 144, 146. Bechter et. at. published data indicating the ability of 
synthetic arotinoids to effect the differentiation of limb buds in the geveloping rat 
embryo, and also showed that some of the dysmorph~genesis visualised by A TRA 
teratogenicity was recapitulated in vitro by the synthetic arotinoids. As these 
abnormalities anse from incorrect CNS development it can be concluded that the 
arotinoids tested in those experiments were affecting neural cell development, as was 
observed in this investigation. Neuronal differentiation has also been induced by the 
synthetic retinoid TTNBP in P19 EC cells 147. They presented that' the neuronal 
differentiation induc.ed occurred via activation of the RARs, and not the RXR receptors, 
i.e. those which are activated by ATRA. It is already known that EC23 is able to activate 
all of the RAR subtypes, similar to ATRA 122. Therefore it is possible to hypothesise that 
the increased levels of neuronal differentiation visualised with EC23 compared to ATRA 
could be a consequence of the compounds' enhanced .stability (i.e. following media 
."~' . 
supplementation, EC23 has a longer active half-life than ATRA, resulting in an increased 
level of RAR activation). 
MALDI protein profiling and subsequent biomarker analyses described herein support 
the above findings into the response of EC cells to A TRA and the synthetic retinoids 
EC 19 and EC23: Immunological detection of a limited number of marker proteins 
showed similar differentiation patterns in response to A TRA and EC23 treatment, while 
EC 19 was found to elicit distinctly different phenotypes. The MALDI data revealed 
common markers of differentiation which were elevated following treatment with all 
three compounds when compared with the untreated stem cell control. These experiments 
also showed a close functional relationship between ATRA and EC23. However, the 
simultaneous detection of multiple protein constituents also revealed differences between 
ATRA and EC23 which might otherwise be overlooked using conventional methods. The 
discriminatory power of biomarker profiling has the potential to provide novel subtle 
insights into different modes of retinoid action. Surface enhanced laser desorption 
ionisation time of flight (SELDI-TOF) mass profiling has. previously been' carried out on 
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this particular cell line, enabling successful discrimination between stem ceil samples and 
their differentiated derivatives 148, SELDI-TOF data also discriminated between different 
pathway sets of differentiation 149. Therefore the MALDI data presented here not only 
verifies the use of these technologies for this type of investigative experimentation, but 
also presents the method used as a novel tool for discerning similarities and differences 
between stem cell samples and their retinoid-induced differentiated counterparts which 
would otherwise be overlooked. For example, 2D distribution plots of collated protein 
expression data has indicated enhanced experimental reproducibility obtained with the 
synthetic compounds compared to A TRA. On these plots, tighter protein expression 
levels were witnessed between biological repeat samples of the synthetic retinoid repeats 
than with the A TRA repeats. This could again be the result of greater stability of these 
compounds, leading to more consistent concentration levels throughout the culture 
period. This observation could easily have been over-looked if analysis had been 
restricted to traditional methods. MALDI profiling is more commonly associated with 
investigations into biomarker discovery for disease states, or for the hunt for biomarkers 
of specific cell types (for example, see recent review of MS proteomic technology in the 
search for biomarkers of neurodegenerative diseases 15~). However, here it has been 
shown to be applicable for the screening of retinoid-mediated protein profile changes in 
cell lysates. This technology will provide an effective tool for the quick and efficient 
screening and analysis of future synthetic retinoid compounds. It is hypothesised that 
once a comprehensive cohort of samples are analysed and the results collated and 
grouped, it may be possible to classify new retinoids on this basis alone. 
Subsequently, work in this investigation, focused our analysis on two protein bands 
which displayed strong up-regulation in response to retinoids as viewed on SDS-PAGE 
profiles of subfractionated cell lysates. Using MALDI-TOF MS methods we have 
identified from these bands two groups of proteins. The first group comprised of four 
proteins - CRAB PI, CRABPII, CRBPI and profilin-l, and the second group consisted of 
phosphorylation isoforms of stathrnin. 
These findings provided the first strong evidence that EC23 exerted its biological effects 
in a similar manner to ATRA, i.e. signalling via cellular retinoid response proteins 
downstream of the RAR receptor. Previously published data provides evidence for the 
up-regulation of these binding proteins upon A TRA stimulation and activation of the 
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retinoic acid receptor pathway in nerve regeneration 151. ATRA-mediated up-regulation 
ofCRABP-II has also been previously demonstrated in the Pl9 EC cell system 152, where 
proteomic techniques were used to evaluate up-regulated proteins after the induction of 
neural differentiation. As reported herein, CRAB PI and II, and CRBPI play central roles 
in the metabolism and gene regulatory effects of A TRA and retinol (Fig. 3.4.1). Although 
the exact functions of the CRABPs are not fully understood, it is widely held that they 
facilitate the metabolism and gene regulatory effects of A TRA in the cell, while also 
playing an important role in maintaining the cellular concentration of free A TRA within a 
suitable physiological range (as outlined in the literature review, Chapter 1). Briefly, it is 
thought that the predominant role for CRABP-I is to facilitate the metabolism of ATRA 
to more polar metabolites which can be excreted by the cell 23, while CRABP-II primarily 
functions to facilitate the transfer of A TRA to the nuclear envelope where it can interact 
with its specific receptors 25. From the results obtained so far it can be tentatively 
concluded that EC23 appears to act on cells via a similar mode of action to ATRA as it 
up-regulates the associated binding proteins which facilitate this process. EC19 does not 
appear to function in the same way as A TRA and may be inducing cellular responses by 
an alternative mode of action, for example via the retinol binding proteins or by other 
pathways altogether. These proposed roles for the CRABPs may explain the different 
inductive effects of ATRA and EC23 on CRABP-I expression. By definition we know 
that EC23 is more stable than A TRA therefore it is feasible that it could be non-
metabolisable by the cell, and therefore the cell increases tlle level of CRABP-I to try and 
compensate. Alternatively, EC23 may simply be more potent than ATRA, in which case 
the cell may similarly synthesise more CRABP-I to lower the effective free [RAJ. 
That EC 19 did not appear to effect the expression levels of the CRABPs compared to the 
undifferentiated controls supports the conclusion that the position of the carboxyl group 
is critical to the activity ofthese retinoids. The para- configuration seen in EC19 does not 
appear to be effective at activating this particular retinoid signalling pathway. However, 
since we do see morphological changes to cells cultured with this retinoid it can be 
concluded that EC 19 must elicit its effect via an alternative route to either ATRA or 
EC23. It is known that other arotinoids are able to elicit biological effects through 
pathways which do not involve the retinoid nuclear receptors 153, and this -would have to 
be evaluated in the case of EC19. The fact that all three retinoids induce an increase in 
expression of CRBP-l implies a feedback mechanism may be initiated to inhibit further 
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formation of ATRA from retinol, and EC19 must still, in part, activate certain retinoid 
mediated responses. CRBP-l is thought to facilitate the storage of retinol into retinal 
esters rather than its oxidation to ATRA (Fig. 3.4.1). 
Stathmin and profilin are involved in the dynamics of actin filament and microtubule 
assembly, and as such they play important roles in cytoskeletal reorganisation during 
neurogenesis. Our results show ATRA and EC23-mediated regulation of profilin-l and 
stathmin expression in vitro, and this may reflect direct regulation of these proteins by 
ATRA in vivo. Indeed there is close correlation between areas of natural high expression 
of these proteins and of A TRA localisation in the brain. Further investigations would 
need to be performed in in-vivo experiments to establish this hypothesis. 
Stathmin and its phosphorylated isoforms are involved in a number of different pathways 
related to cell proliferation and differentiation. It is a small regulatory protein which acts 
as a relay, integrating diverse intracellular signalling pathways 154,155. Stathmin's specific 
role is understood to be involved in the regulation of tubulin polymerisation. 
Unphosphorylated stathmin binds to two free tubulin a~-heterodimers in a T2S formation 
thus sequestering the tubulin monomers and inhibiting polymerisation. Once stathmin 
becomes phosphorylated a conformational change means it is unable to bind to free 
tubulin monomers thus allowing the elongation of tubulin polymers. Stathmin is 
ubiquitously expressed throughout the body but there are specific areas where high levels 
of expression are visualised. For example in the embryonic and juvenile brain where 
there is a creation and turnover of neural networks for learning and memory, i.e. areas 
that are associated with a high level of tubulin assembly and disassembly 156. Stathmin 
has also been identified via proteomic screening in 11.5 day cultured rat embryos, where 
high levels of cytoskeletal rearrangements occur during development I57. In agreement 
therefore, an up-regulation of phosphorylated stathmin in ATRA and EC23 treated 
samples is predictable in these cultures due to the high level of neuronal differentiation 
and neurite outgrowth, which in tum would require a high level of tubulin assembly for 
neurogenesis. As far as we are aware, this is the first time that stathmin and 
phosphorylated stathmin have been directly linked to retirioic acid mediated induction of 
differentiation. The novel link between the two pathways is visualised in Figure 3.4.1. 
97 
Profilin-1 is involved in the regulation of actin polymerisation. It appears to work in a 
number of different ways to modulate actin modelling which depends upon a complex 
combination of tissue specific signalling pathways found in all cells 142. Profilin-l can 
bind to g-actin monomers in a 1: 1 ratio, inhibiting/slowing down actin polymerisation, or 
it can promote filament elongation at the free end by dissociating the inhibiting capping 
proteins capG and capZ, or finally, it can play an important role in accelerating the ADP-
ATP exchange on g-actin there-by also increasing the elongation of filaments 142. 
Profilin-1 has been shown to influence the dynamics of the actin cytoskeleton during 
neuronal differentiation 143. Therefore we can tentatively suggest that the up-regulation of 
profilin-1 recorded in the A TRA and EC23 treated samples could be attributed to actin 
re-modelling during neuronal differentiation. Proteomic techniques used to evaluate 
protein expression in P 19 EC cell samples induced to differentiate down a neural lineage 
in response to A TRA, also indicated up-regulation o( prot~ins related to actin re-
modelling 152. The actin-regulating protein cofilin 1 was up-regulated after ATRA-
induced differentiation, which has a similar role as profilin-l during the cytoskeletal re-
modelling during neurite outgrowth. Indeed, in another earlier proteomic study, the up-
regulation of profilin-l was recorded in cancer cells, treated with A TRA, suggesting a 
major role in the inhibition of cell proliferation and migration and induction of 
differentiation 158. Taken together, these data suggest th~t profilin-1 is up-regulated in 
response to either ATRA or EC23-induced differentiation of EC cells and appears to be 
involved in the actin re-assembly of the cytoskeleton during neurite outgrowth. 
Of particular interest was the observed differential effect between A TRA and EC23 on 
". both CRABPI and profilin-l. Both proteins were expressed ata higher level in cultures 
exposed to EC23 compared to ATRA-treated cultures. As noted above, this suggests that 
resistance to cellular metabolism may be a contributing factor to the observed enhanced 
potency of EC23, which has a knock-on effect in stimulating enhanced neural 
differentiation within these cultures. While Western blot analysis was able to verify 
immunologically the presence of the CRABPs, this teclulique alone was insufficient to 
draw the above conclusions since cross reactivity of the antibody with the different 
isoforms is likely, and this would mask the differential effect of these two compounds 
specifically on CRABPI. 
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Protein profiling analysis is a useful tool to discriminate the different responses of stem 
cells to related retinoid compounds. Nonetheless, analysis of total celllysates is liable to 
reveal a relatively minor proportion of the total available information, and this work has 
demonstrated that additional strong markers become accessible following only 
rudimentary sample prefractionation. It is anticipated that more sophisticated means of 
fractionation and characterisation, such as LC-MALDI and top-down MS techniques, 
may provide even more in-depth analysis of these sets of samples. In the meantime, 
protein profiling can serve as a useful approach enabling simple quality control and 
classification of new retinoid compounds. 
Further verification of retinoid EC23 to mimic the biological activity of A TRA was 
carried out using the human ES cell line H9. ATRA is known to enhance the yield of 
neural cell types when incorporated into differentiation protocols of stem cells 159, 160, 
increasing the percentage of neurons recovered from just a few percent without A TRA 
conditioning to nearly 40% with A TRA conditioning. In this investigation, similar 
biological results were seen in the human ES cell cultures when incubated with either 
ATRA or EC23. Under defined neuronal-inducing differentiation cues, both retinoids 
were able to stimulate neuronal differentiation. Moreover, the number of cells expressing 
the motor-neuron marker, HB9, increased when samples were cultured with either ATRA 
or EC23, compared to control differentiation samples. The ability of stem cells to 
differentiate into motor-neurons has also recently been demonstrated by two independent 
laboratories 140, 161. Both studies showed that unless the.caudalising agent ATRA was 
present in the culture media, cells of a posterior location within the neural tube, i.e. 
motor-neurons, were not induced to differentiate. In another study, motor-neurons 
generated from human stem cells were transplanted into rat spinal cord and were shown 
to integrate with host tissue, extending choline acetyltransferase positive fibres 162. This 
incorporation of transplanted, functional neurons is paramount for the d~velopment of 
~ 
stem cell-based therapies of neurodegenerative diseases. Therefore our results 
corroborate with these findings, and also indicate the close correlation of biological 
activities of the natural retinoid ATRA and the synthetic arotinoid EC23. These data 
further exemplify the more stable synthetic retinoid as an attractive alternative to ATRA. 
We propose that the more stable EC23 analogue could be incorporated into a 
commercially viable neural supplement, replacing ATRA,-which may to added to culture 
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media to induce motor-neuron formation. This use of Ee23 would be advantageous over 
A TRA, as Ee23 is more stable. 
Under generic d ifferentiation cues both A TRA and Ee23 appeared to block neuronal 
differentiation in favour of another as yet unidentified cell phenotype. These initial 
experiments again indicate the ability of A TRA and Ee23 to direct differentiation in a 
human ES cell line which is capable of generating all cells of the three embryonic germ 
layers, and to do so in similar ways. 
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Figure 3.4.1: Proposed modified retinoic acid receptor pathway including new link between retinoid 
activation of the actin re-modelling protein profilin-I and the tubulin re-modelling protein stathmin. 
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3.4.1 Conclusions 
We have shown that a subtle structural difference between EC19 and EC23 (namely, the 
isomeric placement of the carboxylate function) has a major effect on the biological 
function of two closely related compounds. It is possible that this structural difference 
may change the chemical alignment/structure of the molecule sufficiently that it either 
does not bind to the same panel of RARs as ATRA or EC23, or does so with altered 
affinity/potency. It may be that EC19 activates different RARs or even RXRs and further 
research is required to investigate this. 
The observed similarity of biological-induced activity of EC23 to A TRA highlights this 
molecule as an exciting new retinoid, the potential of which must now receive further 
attention in alternative cell systems to further verify these interesting findings. 
The synthetic A TRA analogues reported herein may fofII!. the basis for th~ development 
of a range of novel compounds for use as alternatives to ATRA in stem cell research. Key 
to the benefits of these photostable compounds is the opportunity to exactly define their 
concentration in solution, a problem which poses a major hindrance when using ATRA. 
For instance, physiological concentrations of ATRA across the neural tube are critical for 
correct embryonic neural development (a~ outlined in Chapter 1), and work attempting to 
-
replicate physiological gradients in vitro would require that the exact working 
concentration of ATRA is known. It is anticipated that the availability of more stable 
alternatives to A TRA will contribute significantly to our ability to control retinoid-
induced neurogenesis in vitro, and may play an important role in identifying further 
downstream molecules involved in retinoid-mediated biological activities. 
h . i ; , ,,# . A· . 1,.,.._ 
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4 Chapter 4: The Role of Natural and Synthetic Retinoids in Neural 
Progenitor Cell Differentia.tion: 
4.1 Introduction: 
The ability of the synthetic retinoids EC 19 and EC23 to induce neural differentiation in 
pluripotent embryonic stem cell models was considered in the previous 'Chapter. This 
Chapter will address their ability to direct differentiation in cells which are already 
committed to specific neural cell lineages. Two models of neural progenitor cells will be 
analysed: an adult neural progenitor line and a neural progenitor line derived from 
embryonic neural tissue. 
4.1.1 Adult neural progenitor cells 
The importance of retinoid activity in the adult CNS is slowly being realised (refer to 
Chapter 1 and 163). As mentioned, the hippocampus is one of a few areas in the adult 
brain where the active remodelling of neuronal pathways occurs throughout life into 
adulthood. As in embryonic systems, the retinoic acid signalling pathway has been shown 
to be involved, with ATRA playing a vital role in this very tightly regulated process 80. 
Once this adult neurogenesis was discovered and verified, there was interest into how to 
exploit this novel area for the benefit of therapeutic applications. As a result many animal 
models of adult neural progenitor cells were established to try and increase the 
knowledge base in this relatively new area of neuroscience. Most model systems are 
derived from animal models and not human tissues dtle to the obvious inability of 
ethically obtaining living adult 'normal' brain material. There has recently been a paper 
indicating the ability to derive neural progenitor cells from human adult brains after death 
164, and this could potentially establish an attractive cell culture based system for 
investigating adult neurogenesis in humans. However, it can be assumed that evidence 
obtained in animal models will relate to human systems, as has been seen in embryonic 
.~ - . 
stem cell studies. However, it must also be noted that differences may also occur and will 
have to be taken into consideration. For example, differences are seen between mouse 
and rat progenitor cell lines derived from whole brain samples 165. It was found that 
A TRA incubation induced both neurons and glia in rat cultures but mainly induced 
astrocytes in mouse cultures. 
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One such animal model cell line was created in 1995 from the rat hippocampus by Fred 
Gage's laboratory at the Salk Institute 166, and further characterised a few years later 167. 
This cell line was transfected with the fluorescent protein GFP and termed HCN-nitGFP. 
This adult cell line was shown to proliferate in-vitro in response to bFGF media 
supplementation and was also shown to respond to ATRA by differentiating down a 
neural lineage 168. This cell line is used' throughout this investigation and termed adult 
hippocampal progenitor cells (AHPC). Most in-vitro studies have relied on synthesised 
A TRA to investigate retinoid action in adult CNS differentiation and neural cell 
homeostasis. However, as stated throughout this investigation, ATRA is extremely heat 
and photo-sensitive, degrading into multiple isomers which could possibly elicit different 
results from intact ATRA, due to ATRA's morphogenic nature. 
4. J. 2 Embryonic neural progenitor cells 
Human embryonic neural progenitor cells derived from aborted foetuses have been 
transplanted into animal models of neurodegenerative disorders with great success 169,170. 
Therefore these cell lines hold great therapeutic potential for the treatment of numerous 
brain disorders. However, as many such cell lines are derived from whole brain samples, 
and as it is already known that cells from specific locations respond to stimuli differently, 
a need for more brain-region specific cell lines is required. Cell lines derived from 
specific brain areas have been transplanted into brain models and have been shown to 
respond differently. For example in models of stroke, transplanted cells derived from 
striatal and cortex both integrated with the host tissue but differentiated into differing 
proportions of neural subtypes 171. Therefore to realise the full therapeutic potential of 
cell lines derived from specific brain areas, more basic investigation is required to 
understand their differentiation capabilities under specific differentiation induction cues. 
As outlined in Chapter 3, ATRA is known to have a caudalising effect on neuronal 
differentiation of embryonic stem cells; therefore the ability of cells to respond to this 
signal could be important. It was analysed here whether the addition of retinoids would 
have any effect on embryonic neural progenitor cells which are associated with a specific 
area of brain formation. The cell line used for this part of the investigation was a 
commercially available cell line derived from the ventral mesencephalon of a human 
foetus. The cell line was created by ReNeuron Group pic and was termed ReNcell VM 
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172. ReNcell VM is an immortalized human neural progenitor cell line with the ability to 
readily differentiate into neurons and glial cells with removal of growth factors from the 
culture medium. The cell line was immortalised by retroviral transduction with the v-myc 
oncogene, and retains normal karyotype even after continued proliferation. Cells have 
been maintained in an undifferentiated state in culture when grown on laminin for >45 
passages. In experiments carried out by ReNeuron Group pIc, ReNcell VM were shown 
to differentiate in vitro into dopaminergic neurons. These neurons have furthermore been 
shown to be electophysiologically active. It was not known what effect, if any, the 
addition of retinoids would have on this particular cell type. 
4.1.3 Aim and Objectives 
Aim 
The aim of this chapter was to study the effect of stable analogues of A TRA on an adult 
hippocampal neural progenitor cell line and an embryonic neural progenitor cell line 
derived from the ventral mesencephalon .. Synthetic retinoids were designed and 
synthesised in the Department of Chemistry, Durham University with emphasis on 
stability and a RAR mediated mode of action 122. The ratio~ale was to create an ATRA 
alternative which elicited the same biological effects but which was much more stable 
making it a promising alternative to A TRA in in vitro investigations. 
Objectives 
• The initial objective was to establish a valid adult neural progenitor cell model 
system. This would involve the use of natural retinoids (A TRA and 13-cisRA) to 
induce differentiation along a neural lineage and to demonstrate a concommital 
change in morphology and expression profiles. 13-cisRA was incorporated into 
the experimental plan as it is known to have a deferential effect on adult cells 
compared to ATRA in vivo. 
• Subsequently this model would be used to test the action of synthetic retinoids 
EC 19 and EC23. It was proposed that these molecules may enhance the 
knowledge of adult neurogenesis by inducing differentiation in a more controlled 
manner than the natural counterpart A TRA. 
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• It was hypothesised that EC23 would induce differentiation in a similar manner to 
A TRA, but given EC 19s differing activity in the EC cell system it was 
hypothesised that it may induce differing sub-types in adult progenitor cells too. 
• The next objective was to analyse the effect of both the natural and synthetic 
retinoid compounds on embryonic neural progenitor cells derived from the ventral 
mesencephalon. While there is a large body of work demonstrating the 
importance of A TRA in embryonic CNS development, to the best of our 
knowledge retinoids have not been tested in this particular cell line. 
• It was hypothesised that A TRA may induce a specific type of neural 
differentiation due to its caudal ising nature, and it was tested whether Ee23 
would again be able to mimic ATRA. 
• The activity of the arotinoid ECI9 was again hypothesised to be different. 
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4.2 Methods 
4.2.1 Tissue Culture 
4.2.1.1 HCN-nitGFP cells 
Cells were cultured under standard laboratory conditions as described in Chapter 2. 
Before use, all plasticware was coated with lOllg/ml poly-L-ornothine (Sigma, diluted in 
H20) for 24rs at room temperature (RT), followed by 51lg/mllaminin (Sigma, diluted in 
PBS (Sigma)) for another 24hrs at 37°C. Plates were then washed thoroughly with PBS 
before use. 
Cells were cultured under serum-free conditions at all times as outlined in protocols from 
the Salk Institute. To expand the cell cultures proliferation media used, consisting of 
DMEM/F12 (high glucose) (Irvine scientific), supplemented with IX N2 supplement 
(Gibco), 2mM L-glutamine (~igma), 20ng/ml bFGF (Sigma, added just before use) and 
100 active units of penicillin/streptomycin (Gibco). To maintain optimum cultures, media 
was changed every 3 days, and cultures were passaged at ~90% confluence. To passage 
cells, the media was aspirated, 1ml trypsin-versene solution (Cambrex) added and rocked 
over cells and the excess was immediately removed. Cells 'Yere dislodged from the 
plasticware by gentle tapping, and resuspended in 10mls DMEMIF12. The suspension 
was pelleted by centrifugation at 12000rpm for 3 mins. The supernatant was removed and 
the pellet resuspended in 1ml proliferation media and triturated to gain a single cell 
suspension. Cells then underwent a 1:5 to I: 10 split depending on cell numbers and were 
transferred to new poly-L-ornothine/laminin coated plasticware. 
Differentiation protocol 
HCN-nitGFP cell cultures were induced to differentiate with the introduction of 11lM 
ATRA (Sigma, diluted in DMSO (Sigma)) or 11lM 13-cisRA (Sigma, diluted in DMSO) 
into the media, and the reduction of bFGF concentration down to 1ng/ml. In preparation 
for differentiation, cultures which had reached ~90% confluence were treated with 
trypsin-versene solution to obtain a single cell suspension 'as outlined above. Cell number 
was subsequently determined using a haemocytometer under a light microscope. Unless 
otherwise stated, cells were seeded at 100,000 cells/well in a 4-well plate. Cultures were 
maintained for up to 14 days with media being refreshed every 3 days. 
EC19123-induced differentiation 
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The synthetic retinoids EC19 and EC23, produced by the Chemistry Department was also 
assessed for their ability to induce differentiation. Alongside corresponding control 
experiments using the natural retinoids, a range of retinoid concentrations was added into 
the differentiation media, O.Ol~M, O.1~M, and I~M. Cells were seeded at 100,000 
cells/well of a 4-well plate and maintained for up to 14 days with media being refreshed 
every 3 days. In a separate experiment cells were seeded at varying densities and cultured 
with differentiation media containing O.S~M EC23. Cell densities used were 20,000, 
60,000, 120,000, and 200,000 and a confluent T2S (~2-S,000,000 cells). The cultures 
were subsequently maintained as outlined above. 
4.2.1.2 ReNcel! VM 
Cells were cultured under standard laboratory conditions as described in Chapter 2. 
Before use plastic-wear was coated with laminin solution: Iml laminin (Sigma) was 
diluted in 49ml unsupplemented DMEM:FI2 media. 4ml was used to coat a T7S. 
Laminin solution was incubated in the flask at 37°C for at least 6 hrs. Flasks were then 
washed twice with media prior to use. 
ReNcell VM progenitor cells were cultured in serum free conditions using methods 
previously described. Briefly, DMEM:FI2 (1:1, Gibco) was supplemented with IOmls 
B27 (Invitrogen), 2mM L-Glutamine (Sigma), O.Sml Gentamycin (Gibco), and 1ml 
SOmg/ml Heparin solution (Sigma). For proliferation, growth factors were added from 
stock solution (for 10ml media; 1 O~L FGF and 20~L EGF). Cultures were passaged 
using 0.2S% trypsin EDT A solution and trypsin action was inhibited by incubation with 
trypsin inhibitor (Smg trypsin inhibitor dissolved in 1ml supplemented media then made 
up to 20ml with non-supplemented media. Solutions were then f/s through a 0.2~m 
filter.). Cultures were passaged 1:3 up to 1:6 as appropriate. 
Differentiation protocol 
Cultures were incubated with trypsin to obtain a single cell suspension as outlined above, 
then 100,000 cells/well were seeded into 12 well plates. Plates were allowed to get 7S% 
confluent then were switched to differentiation media with or without retinoid 
supplementation as indicated below. 
• 2 lanes were resuspended in proliferative media (+ growth factors) 
• 2 lanes were cultured in media minus growth factors (control diff) 
• 2 lanes were cultured minus growth factors + 1 ~M A TRA 
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• 2 lanes were cultured minus growth factors + IIlM EC23 
• 2 lanes were cultured minus growth factors + IIlM EC 19 
Cultures were incubated for 7 days then MTS analysis and immunocytochemical staining 
was performed as outlined in the Methods Chapter. 
4.2.2 Flow cytometry 
For complete methods refer to Intracellular staining, Chapter 2, Section 2.4 
Antibodies used: 
I Antibody I Company c:J 
I 
GFAP 
I 
Sigma 
I 
1:200 
I 
4.2.3 Immunocytochemistry 
For complete methods refer to Chapter 2, Section 2.6 
Antibodies used: 
Antibody Company Dilution 
Nestin Chemicon 1 :100 
TUn Covance 1:500 
NF-200 Sigma 1:200 
GFAP Sigma 1:200 
Phalloidin Sigma 2 Units 
4.2.4 Real-time peR 
For complete methods refer to Chapter 2, Section 2.15 
Primers used: CYP26Al, RAR-B 
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Incubation I Secondary I 
time 
Ihr Alexafluor 488 
Incubation Secondary 
time 
lhr Alexafluor 488 
-
lhr Cy3 
Ihr Alexafluor 488 
Ihr Alexafluor 488 
Ihr -
-
4.3 Results: 
4.3.1 Analysis of Natural and Synthetic Retinoid Induced Neural Differentiation of 
AHPCs: 
4.3.1.1 Cytological analysis of natural ~etinoid-induced differentiation 
Initial experiments were carried out to monitor the cellular response to the natural 
retinoids ATRA and 13-cis retinoic acid (13-cisRA). ~longside these experiments a 
preliminary run of the synthetic retinoid EC23 was carried out. Cells were exposed to 
either I/-LM ATRA, I/-LM 13-cisRA or 0.5/-LM EC23. It was decided to start with a lower 
dose of EC23 compared to that of the natural retinoids due to results obtained in previous 
experiments with EC cells, where EC23 appeared to be more potent/toxic (Chapter 3). 
Cultures were maintained for up to 14 days. At specified time points the cell viability 
assay MTS was carried out to determine what effect the retinoids were having on cell 
number over the time course. The MTS assay works via a colorimetric change that can be 
quantified on a spectrometer. MTS is a yellow tetrazolium dye that is reduced by live 
(and not dead) cells to a purple formazam compound. Surviving cultures also underwent 
immunocytochemical analysis with neural markers to monitor differentiation. After 14 
days exposure to A TRA, cell numbers remained constant, an indication that the culture 
may have stopped proliferating, (Fig. 4.3.1B) and had been induced to differentiate. 
Expression of the neuronal specific P-III tubulin marker, TUn, was evident throughout 
the culture (Fig 4.3.1A) with the majority of cells expressing this protein. A few cells 
were positive for the glial marker, glial fibrillary acidic protein (GF AP), and were 
distributed sporadically throughout the culture. After 14-days,exposure to 13-cisRA it 
was noted that reproducibly more TUn positive cells were seen compared with A TRA 
cultures (n=3) (Fig 4.3.1A). However the number of GF AP positive cells appeared to 
remain roughly the same (Fig 4.3.1A). As noted above, cell numbers did not increase in 
A TRA treated cultures over the time course, possibly an indication that the cells had 
dropped out of the cell cycle and had been induced to differentiate. However, when cells 
were exposed to l3-cisRA, although immunocytochemical data suggested that the cells 
had differentiated down a neural lineage, the MTS assay indicated that the number of 
viable cells was still increasing with time. This could possibly indicate that 13-cisRA is 
not as potent as ATRA or could be eliciting its effect via a different mechanism. 
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Figure 4.3.1: A: Adult hippocampal progenitor cells differentiate down a neural lineage in response to the 
natural retinoid compounds all-trans retinoic acid (ATRA) and 13-cis-retinoic acid (13cisRA). Cells were 
cultured with I ~M retinoid for 14 days, and subsequently underwent immuno-cytochemical analysis for the 
neuronal marker TUJ I and the glial marker GFAP. Extensive neural differentiation is observed in both 
cultures. Reproducibly, more cells in total and more neuronal cells are present in cultures exposed to 
13cisRA. All micrographs are counterstained with Hoechst. n=3 
B: Cell viability of AHPCs after exposure to natural and synthetic retinoid compounds. MTS cell viability 
test was carried out on AHPCs after exposure to either I ~M ATRA, I ~M 13-cisRA or O . 5~M EC23. Cells 
were seeded at 20,OOO/well in a 4-well plate. At this cell density EC23 was toxic to cell cultures. n=3 
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4.3.1.2 Seeding cell density effects EC23 biological activity in AHPCs 
The synthetic retinoid EC23 was initially supplemented into AHPC cultures at half the 
concentration of the natural retinoids to see if any morphological changes indicating 
differentiation were seen. Cultures were exposed to O.5)lM EC23, and run alongside the 
above experiments for up to 14 days. At this concentration very few viable cells were 
seen in the EC23 cultures compared to the natural retinoid cultures (Fig. 4.3.1B), and 
therefore no immunocytochemical analysis could be performed. However, in 
simultaneous experiments, O.5)lM EC23 or l)lM ATRA was simply added to confluent 
cultures of the AHPCs in flasks, for a period of 7 days, followed by morphological 
analysis (Fig. 4.3.2) Phase photomicrographs indicated. that in the confluent culture, 
significantly fewer cells were visible in Ee23 cultures compared to the undifferentiated 
control. Cell morphology had also changed significantly, resembling cultures exposed to 
ATRA. The neuronal specific marker TUn was analysed and was found to be expressed 
by these cells, also similar to A TRA cultures. 
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Figure 4.3.2: Neuronal differentiation was induced with the synthetic retinoid EC23. When AHPCs are 
seeded at a high enough density and cultured with O.S 11M synthetic retinoid EC23 for 7 days neuronal 
differentiation is visualised. Immunocytochemical staining with the neuronal-specific marker TUJ I 
revealed positive neuronal expression within the cultures tested. n=3, scale bar represents SOllm . 
On the basis of this morphological and immunological evidence it appeared that AHPC 
cells could be sufficiently induced to differentiate by EC23 exposure, but only if they 
were seeded at a high starting density. The issue of cell density was studied further in 
order to optimise culture conditions. O.SIlM EC23 was added to cultures of AHPCs 
seeded at varying densities in 4-well plates (20,000, 60,000, 120,000 and 200,000 
cells/well) and samples were subsequently analysed after 7 days in culture. Both Figures 
3 and 4 provide evidence suggesting that the biological effect of EC23 indeed appeared to 
be dependent on cell density. Cells seeded at 20,000 and 60,000 cells/well did not 
resemble normal healthy undifferentiated or differentiated culture morphologies. In phase 
photomicrographs (Fig. 4.3.3), and after immunostaining for phalloidin, a cytoskeletal 
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marker, cells appeared as round ball shaped cells with no visible cellular processes (Fig. 
4.3.4). However, when the cells were seeded at 120,000 or 200,000 cells/well their 
morphological appearance resembled cells which had started to differentiate i.e. they 
possessed long, extended processes and appeared significantly different from 
undifferentiated cultures (Fig. 4.3.3). Phalloidin immunostaining, also indicated the 
presence of long processes (Fig. 4.3.4). Therefore it can be inferred that given the 
appropriate culture conditions, AHPCs can be induced to differentiate down an 
apparently neural lineage by EC23 supplementation, similar to the effects seen when the 
AHPCs were cultured with the natural retinoids A TRA and 13cisRA. To study this 
apparent similarity in differentiation responses, experiments were next carried out 
directly comparing cultures induced to differentiate with both the natural retinoid A TRA 
and the synthetic retinoid EC23. 
A 
/ , 
\ -
Figure 4.3.3: EC23 biological effects on AHPCs appears to be cell density dependent. AHPCs were seeded 
at varying densities and exposed to O.SIlM EC23 for 48hrs. At low densities few cells survived and those 
present appeared to stay rounded (arrow heads) . At higher cell densities cells appeared to be more viable 
and put out processes which resemble neurites (arrows) . Cells were seeded at A:20,000, 8 :60,000, 
C: 120,000, D:200,000/well in a 4 well plate. Scale bars: SOllm. n=3 
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Figure 4.3.4: Cytoskeletal analysis of cultures exposed to EC23 . Immnocytochemical staining of AHPC 
cultures which have been seeded at increasing cell densities and exposed to O.SIlM EC23 for 7 days. The 
cytoskeletal marker phalliodin has been used to indicate cell area. It can be seen that with increasing cell 
density more cells appear to have started to extend long processes (arrows). Cell densities are A: 20,000 B: 
60,000 C: 120,000 D: 200,000. All cultures were seeded in 4-well plates. Scale bars: SOllm. n=3 
4.3.1.3 Concentration study of EC2 3 
Earlier data established that EC23 could induce differentiation in AHPCs. A 
concentration study was carried out on cultures seeded at constant cell densities to try and 
determine whether EC23 had an enhanced effect compared to the natural counterpart 
ATRA, as seen in embryonic stem cell cultures (Chapter 3). It was decided that 100,000 
cells/well would be used, as this appeared to be the lowest level at which the cells could 
be seeded whilst still eliciting the desired effect. 
Cultures were incubated with either 0.0 I ~M, 0.1 ~M or I ~M EC23 or A TRA for 7 days. 
After this time period cells underwent MTS analysis (Fig. 4.3.5). As in previous 
investigations, the vehicle control showed no attenuation of number of viable cells 
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compared to the undifferentiated sample. Ihe control natural retinoid, A IRA, induced a 
decrease in the number of viable cells compared to undifferentiated samples, and this 
effect was enhanced as the concentration of the retinoid increased. Cells in all A IRA 
conditions tested appeared healthy, looked like they had dropped out of the cell cycle, 
and appeared to have been induced to differentiate. EC23 samples showed similar 
attenuation of number of viable cells, with numbers decreasing with increasing retinoid 
concentration. The level of attenuation was greater in the 1 ~M EC23 samples compared 
with 1 ~M A TRA counterparts, and morphological analysis of these EC23 cultures 
revealed cells which appeared sub-optimal and were beginning to die. Ihese data further 
indicate that the synthetic retinoid EC23 has an enhanced effect compared to the natural 
retinoid A IRA, on which it is modelled. It appears that the toxic threshold of this cell 
type for EC23 is lower than that of A IRA. 
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Figure 4.3.5: Number of viable cells determined on AHPCs cultured with a range of retinoid 
concentrations for 7 days. 100,000 cells/well were cultured with either 0.01 , 0.1 or 1 ~M ATRA or EC23 
and subjected to the MTS cell viability assay. EC23 appeared to be more potent than A TRA with fewer 
cells surviving at the highest concentration studied. n=3, error bars represent ± standard deviation from the 
mean. *** pSO.0005, student' s t-test compared to the undifferentiated control. 
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Immunocytochemical analysis of a panel of neural markers was performed to investigate 
levels of specific neural differentiation visualised. Since l)lM EC23 cultures were not 
viable or healthy, the l)lM EC23 and ATRA treatments were not analysed further. The 
antibodies investigated were the neural progenitor marker nestin, the neuron specific 
marker ~-III tubulin (TUn) and the glial marker GF AP (Fig. 4.3.6). Undifferentiated 
cultures exhibited low level expression of both TUn and GFAP and highly expressed the 
progenitor marker nestin. Morphologically, cells appeared rounded with very small 
projections protruding out from the main cell body. After ATRA and EC23 treatment this 
rounded appearance was lost and long neural processes appeared. At both concentrations 
tested the cells with long pro_cesses were TUn positive, and therefore neuronal in 
phenotype. It is concluded that under suitable culture conditions EC23 is able to mimic 
A TRA-induced neuronal differentiation within this adult neural progenitor cell model 
system. 
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Figure 4.3 .6: Immunocytochemjcal staining of AHPCs exposed to varying concentration of A TRA or EC23 for 7 
days. Similar marker expression is seen with both natural and synthetic retinoid. Markers studied were nestin, a neural 
progenitor marker, TUJl , a neuronal marker and GF AP, a glial marker. Scale bars 50llm. n=3 
4.3.1.4 Concentration study ofEC19 
Analysis of the synthetic retinoid EC 19s activity was also assessed at similar 
concentrations. In previous experiments (Chapter 3), EC19 was shown to induce 
differentiation in stem cell model systems, however, the cellular sub-types induced were 
distinct from the control natural retinoid A TRA and the'synthetic analogue EC23. The 
effect of this retinoid on adult neural progenitor cells is described here. Initially a range 
of concentrations was administered to cultures, and after a 7 day time period, samples 
underwent both MTS and immunocytological analysis. Concentrations studied were 
0.01 IlM, 0.1 IlM and 1 IlM, and all cell cultures were seeded at 100,000 cells/well, in a 4-
well plate. MTS analysis revealed, as found above, that the vehicle control showed no 
attenuation of number of viable cells, compared to the undifferentiated sample (Fig. 
4.3.7). As previously, the control natural retinoid ATRA, induced a decrease in cell 
number compared to undifferentiated samples, and this effect became enhanced as the 
concentration of the retinoid increased. Again, morphological analysis of cells in all 
ATRA conditions tested looked healthy and appeared to have dropped out of the cell 
cycle and begun to differentiate. EC 19 cultures responded differently to the A TRA 
control. At the lowest concentration tested, O.OIIlM, EC19 induced a relatively small 
decrease in cell number compared with the ATRA counterpart. However, at the highest 
concentration tested, 1 IlM, very few cells remained viable after the 7 day period 
suggesting that the retinoid was toxic at this level. Complementing previous findings, it 
appeared that EC 19 exerted its biological effects in a narrow range of concentration, but 
was nonetheless able to induce differentiation in this adult neural progenitor model. 
Morphological analysis of the cultures indicated that at the 0.1 IlM concentration it did 
appear as though cells exposed to EC 19 had been induced to differentiate, they had lost 
their typical small round appearance and had developed long processes. 
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Figure 4.3.7: Number of viable cells determined on AHPCs cultured with a range of retinoid 
concentrations for 7 days. 100,000 cells/well were cultured with either 0.01, 0.1 or 1 flM ATRA or synthetic 
retinoid ECI9 and subjected to the MTS cell viability assay. EC19 appeared to be more potent than ATRA 
with fewer cells surviving at the highest concentration studied, however, at the lowest concentration studied 
cells continued to proliferate, subsequently increasing the final cell number in the EC 19 condition. At this 
concentration it appeared that EC 19 was less potent than ATRA. n=3, error bars represent ± standard 
deviation from the mean. *** p:S0.0005, student's t-test compared to the undifferentiated controL 
Expression of a panel of neural markers was next analysed to deduce the levels of 
specific neural differentiation visualised. As above, the markers analysed were the nestin, 
~-III tubulin (TUJl), and GF AP (Fig. 4.3.8). At the lowest concentration studied, 
O.OI/-lM, cell morphology in EC19 cultures remained small with no obvious neurite 
outgrowth, typical of cells in the undifferentiated state. The marker expression visualised 
at this level of concentration was also similar to that seen in undifferentiated cultures. 
Low level of expression of both TUn and GF AP was observed alongside a slightly 
elevated expression of nestin. This indicated that at this concentration no differentiation 
was induced by EC 19. At the same concentration, A TRA cultures showed limited neural 
differentiation with a small proportion of cells possessing extended processes, and these 
cultures exhibited up-regulated expression of Tun and GF AP compared to controls. 
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These data infers that EC 19 is either un-reactive at this concentration, or less potent than 
the natural retinoid A TRA. At the highest concentration tested, 1 )J.M, there were no 
viable cells in EC 19 cultures to stain, again an indication that at this concentration, EC 19 
is toxic to AHPC cells. The A TRA counterpart culture showed an elevated level of 
expression of TUn, with lots of cells expressing this neuronal marker, and extending 
long neuronal processes. Some glial differentiation was also witnessed. In the O.l)J.M 
condition, where MTS analysis indicated that EC19 doe.s aPP7ar to elicit a response, 
extensive neural differentiation was witnessed with this compound. Compared to the 
ATRA counterpart EC 19-induced differentiation appeared to be more glial in nature, with 
less cells expressing the neuronal Tun marker, and more expressing the glial marker 
GFAP in comparison to ATRA. This observation was quantified via flow cytometry (Fig. 
4.3.9). Flow cytometric analysis of the glial marker GF AP showed a 2 fold increase in 
". 
expression between O.I)J.M ATRA and O.l)J.M EC19 samples, with only ~20% cells 
expressing GFAP in ATRA-induced cultures and ~40% cells expressing GFAP in ECI9-
induced cultures. These results indicate that the synthetic retinoid EC 19 is able to induce 
differentiation within this adult neural progenitor cell system, however, the proportion of 
neural sub-types induced is different from the control natural retinoid ATRA and the 
synthetic retinoid EC23. It also appears as if the 'window' where this compound elicits 
an effect is smaller than A TRA, too low and nothing happens, too high and the cells die. 
120 
N 
nestin 
TW1 
GFAP 
Figure 4.3.8: Immunocytochemical staining of AHPCs exposed to varying concentration of ATRA or ECI9 for 7 days. Markers 
s tudied were nesti n, a neura I progen itor marker, TUJ I , a neuronal ma rker and GF AP, a glial marker. The highest concentrat ion of 
EC I9 studied, IflM , was toxic to the cells and elicited no differentiation. The lowest concentration studied , 0.01 flM , did not 
induce significant differentiation in this cell type, and cells continued to proliferate. When cells were cultured with 0.1 flM, 
differentiation was induced down the neural lineage, with more glial differentiation being noted compared to its ATRA 
counterpart control. Scale bars 50flm. n=3 
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Figure 4.3.9: Flow cytometric analysis of the glial marker GFAP on cultures of AHPCs incubated with 
0.1 ~lM ATRA or EC 19. In support of the morphological data, there is an increase in cell % expressing 
GFAP in O.IIlM EC 19 culture compared to its ATRA counterpart . . 0=3, error bars represent ± standard 
deviation of the mean. 
4.3.1. 5 Real time peR analysis of components of the retinoic acid receptor pathway 
Experiments so far have indicated the ability of both synthetic retinoids EC 19 and EC23 
to induce neural differentiation in the adult hippocampal ~rogenitor cell model system. It 
has yet to be shown whether this induced differentiation occurs via the retinoic acid 
receptor pathway. To address this, relative qRT-PCR was performed on two components 
of the retinoic acid receptor pathway, CYP26Al , a compound which is involved in the 
metabolism of A TRA within cells and which has been shown to be important in neural 
differentiation 173, and RAR-~ , a receptor sub-type which is known to be involved in 
neuronal differentiation 174 (Fig. 4.3.10). RNA was harvested from each culture exposed 
to the three different concentrations of A TRA, EC 19 and EC23 after 24hrs. All results 
obtained were set against the 24hr undifferentiated sample which was used as the relative 
control. 
In the control A TRA samples, expression levels of the enzyme CYP26A 1 increased as 
the retinoid concentration increased. This is as expected; if more A TRA is presented to 
cultures then the cells would have to work harder to keep cytostolic levels regulated to a 
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constant concentration; It is known that one of the mechanisms by which cells perform 
this is via the metabolism of A TRA to more polar compounds which are able to be 
excreted by the cell, a process which, as mentioned, is facilitated by the CYP26 
compounds. The expression of this gene in EC23 samples showed a different pattern 
(Fig. 4.3.10). It appears that gene expression of CYP26A1 had reached maximal levels 
with the lower two concentrations of EC23, as an increase does not induce a subsequent 
increase in expression. The level of CYP26A1 in the highest EC23 concentration tested, 
I/lM, was significantly lower than the other EC23 samples, and the ATRA counterpart. 
Taken together with the morphological analysis to date, it suggests that this highest 
concentration of EC23 is an amount that cells are unable to deal with effectively; 
therefore it remains within the cells, possibly resulting in the death of cells. Expression 
, profiles obtained in EC 19 cultures also reflect the morphological data obtained (Fig. 
4.3.10). No real differentiation is induced at the lowest concentration analysed, O.OI/lM, 
and it appears as if the CYP26Al is down regulated compared to undifferentiated sample. 
At 0.1 /lM, CYP26Al is up-regulated in relation to the undifferentiated control, but not up 
to levels seen in ATRA or EC23, however, it is at this concentration that we see ECI9-
induced activity. As in the EC23 samples, the highest concentration studied only elicited 
a small increase in CYP26A1 expression, probably due to the fact the cells were dying 
" 
with this level of retinoid. Therefore, at concentrations which elicited biological 
responses from the AHPCs a corresponding up-regulation of CYP26Al expression was 
visualised. These data adds more weight to the argument that our syrithetic retinoids, 
particularly EC23, are acting via the retinoic acid receptor pathway. 
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Figure 4.3.10: Quantitative analysis ofCYP26AI and RAR-~ mRNA expression in AHPCs cultured with 
a range of concentrations of either A TRA, EC23 or EC 19 for 24 hrs. Real time PCR analys is of the control 
ATRA concentration study revealed an increasing gradient of both genes, relative to an increase in ATRA 
concentration, 0.0 I, 0.1 and I ~M respectively. 80th the 0.0 I and 0.1 ~M EC23 cultures yielded the 
maximum amount of expression reached in ATRA cultures. The highest concentration of EC23 stud ied, 
I ~M, exhibited a decrease in expression compared to its ATRA counterpart for CYP26A I, this could be 
due to EC23 being toxic and killing cells at this concentration. Again, the highest concentration of EC 19 
was toxic to cells and no expression of the CYP26A I was seen . The lowest concentration of EC 19 showed 
a decrease in CYP26A I expression relative to the undifferentiated control, with the 0. 1 ~M cu lture showing 
some increase of expression of CYP26A I, but not to the same level as the other 2 retinoids. Relative 
quantification was carried out with the 24hr undifferentiated sample being set as the relat ive contro l fo r the 
coordinating retinoid samples. 
As observed with the CYP26Al gene, the expressIOn profile for RAR-f3 within the 
control A TRA samples showed an increase in expression level as the concentration of the 
natural retinoid also increased (Fig. 4.3.10). Again, this indicated that expression of thi s 
retinoic acid receptor pathway component, RAR-P, is concentration dependant with 
regard to A TRA incubation of cultures. As also witnessed with CYP26A 1 expression , 
this gene appeared to be already expressed at maximal levels at the lowest concentration 
of EC23 tested, as an increase in concentration (from 0.0 IIlM to O.IIlM), elicited no 
further increase in expression level. This maximal level of expression is also observed in 
the IIlM sample, indicating that cells which were still viable were responding to the 
retinoid as expected, however, as already discussed, not many cells remained viable at 
this concentration due to its higher potency/toxicity than A TRA (Fig. 4.3.1 0). EC 19 
samples showed a concentration dependent expression of this receptor, however, the 
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levels observed were lower than those witnessed with the other two retinoids, A TRA and 
EC23 (Fig. 4.3.10). Expression of RAR-~ at the lowest concentration tested was below 
the undifferentiated relative control, supporting evidence that at this concentration EC 19 
elicited no neural differentiation. In the O.1IlM EC19 condition an up.,.regulation of this 
gene was observed, again correlating with morphological data indicating neural 
differentiation had taken place. This level was significantly lower than that visualised 
with both ATRA and EC23 samples, which could be related to the differing proportions 
of neural cell-types seen in EC19 cultures compared to ATRA and EC23, however this 
would need further verification. There was an increase in expression of RAR-~ in the 
highest concentration of EC 19 tested compared to the lower EC 19 conditions, suggesting 
that at this concentration, EC 19 could be inducing an enhanced biological response, 
however, morphological analysis indicated that most cells were dying with this amount of 
retinoid and no differentiation analysis could be performed. 
To conclude this section, it is inferred that as an increase in CYP26Al and RAR~ 
expression occurs in cultures incubated with either EC23 or EC 19, they both are able to 
induce expression of components relating to the retinoic acid receptor pathway. Similar 
to morphological data, both EC23 and EC 19 are more potent/toxic than the natural 
retinoid A TRA, reflected in their expression profiles obtained at the lowest and highest 
concentrations tested. These data backs up earlier findings on EC cells indicating that our 
synthetic retinoids, particularly EC23 induce differentiation via the retinoic acid receptor 
pathway. The synthetic retinoid EC23 appears to mimic ATRA, albeit at a lower potency 
threshold, and EC 19 induces a different ratio of differentiation products. 
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4.3.2 Analysis of Natural and Synthetic Retinoid Induced Neural Differentiation of 
ReNcell VM Cultures: 
ReNcell VM is a commercially available model of human embryonic neural progenitor 
cells. Published data dictates that these cells can be induced to differentiate with removal 
of the growth factors bFGF and epidermal growth factor (EGF) from the culture media. 
This section investigates the differentiation induced, if any, with the addition of the 
natural retinoid A TRA or the synthetic retinoids EC23 and EC 19. As ATRA is a known 
embryonic morphogen it was hypothesised that it should elicit some effect from these cell 
types, however to the best of our knowledge, A TRA has not been used on this cell type 
before. 
4.3. 2.1 MTS cell viability analysis of ReNcel! VM cultures -exposed to the retinoids 
Cultures of ReNcell VM cells were initially spiked with 1 ~M of each retinoid, ATRA, 
EC23 and EC 19, for seven days then subjected to MTS cell viability/number analysis 
(Fig. 4.3.11). For retinoid-induced cultures, growth factors were removed from the media 
and retinoids were added at the correct concentration. Cell viability, therefore number, 
was compared against the undifferentiated control condition and cultures induced to 
differentiate with removal of growth factors alone, control differentiation. The sample 
inducing the least amount of colour change after addition of the MTS reagent, therefore 
containing the least number of cells was the A TRA sample. This was followed by both 
EC23 and EC 19 samples, which showed similar levels of absorbance, then control 
differentiation, and lastly the undifferentiated control. These data suggests that all the 
, ' 
retinoid conditions were attenuating the cell number in their respective cultures, therefore 
cell proliferation, in relation to the undifferentiated control, with the most enhanced effect 
being recorded in the A TRA culture. However, all cultures spiked with retinoids 
exhibited an enhanced effect compared to removal of growth factors alone, the 
differentiation protocol outlined for this cell type. It was not known at this stage whether 
the retinoids were inducing enhanced differentiation or were inducing cell death. This 
was verified in experiments outlined below. 
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Figure 4.3.11: MTS cell number analysis carried out on 197VM human embryonic neural progenitor cells 
after 7 days in culture. Cells were either cultured in control proliferative media, control differentiation 
media (removal of growth factors) , or exposed to 111M retinoid (ATRA, EC23 or EC 19) added to the 
control differentiation media. Under all differentiation conditions the cell number was attenuated compared 
to the proliferative control, with the most effect visualised in the A TRA condition . n=3, error bars represent 
±standard deviation. ** pSO.005 , *** pSO.0005, student 's t-test compared to the undifferentiated control. 
4.3.2.2 Morphological analysis of cultures exposed to retinoids 
To address whether cultures spiked with the retinoids were being induced to differentiate 
or were undergoing cell death, morphological analysis was carried out. Initially, cultures 
were visualised under a light microscope after 7 days of culture and phase images were 
captured (Fig. 4.3.12). Undifferentiated control cells retained their typical round 
homogenous appearance, as outlined in technical information obtained with the cells 
from the company. In all differentiation-induced conditions the cells had significantly 
changed shape. Cells were longer and thinner and cultures contained a very large 
proportion of cells possessing visible processes, inferring differentiation had been 
induced. These data suggests that in all differentiation cultures, cells had dropped out of 
the cell cycle and had differentiated. It was therefore concluded that spiking cultures with 
retinoids were not inducing solely cell death. 
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Figure 4.3.12: Phase images of 197VM human embryonal neural progenitor cells after 7 days in culture. 
Cells were either cultured in control proliferative media, control differentiation media (removal of growth 
factors), or exposed to 111M retinoid (ATRA, EC23 or EC 19) added to the control differentiation media. An 
abundance of neurite processes were seen in all differentiation conditions. n=3, scale bar represents 50l1m. 
4.3.2.3 Immunocytochemical analysis of cultures exposed to retinoids 
To determine the level of neural differentiation induced, immunocytochemical analysis 
was performed. A panel of neural markers was used, namely the neural progenitor marker 
nestin. the glial marker GF AP, the neuronal specific P-III-tubulin marker TUJl and the 
late neuronal marker neurofilament 200 (NF-200). Nestin appeared to be ubiquitously 
expressed throughout all of the culture conditions tested, with an elevated expression 
level visualised in ATRA samples (Fig. 4.3.13). It was noted that the morphology of the 
cells expressing nestin changed upon removal of growth factors and with media 
supplementation with the retinoids. Cultures showed similar changes to those visualised 
under phase microscopy, suggesting that cells were undergoing some form of cytoskeletal 
re-organisation, inferring the induction of differentiation. Again, GF AP appears to be 
ubiquitously expressed throughout all cultures (Fig 4.3.13), however, the level of 
expression of this marker was up-regulated in cultures supplemented with the retinoids. 
possibly indicating more mature, differentiated neural cultures. 
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Figure 4.3.13: lmmuno-cytochemically stained images of 197VM human embryonal neural progenitor 
cells after 7 days in culture. Cells were either cultured in control proliferative media, control differentiation 
media (removal of growth factors), or exposed to IIlM retinoid (A TRA, EC23 or EC 19) added to the 
control differentiation media. An abundance of neurite processes were seen in all differentiation conditions. 
However, mature neuronal differentiation was only seen in ATRA and EC23 cultures (NF-200 staining) 
n=3, scale bar represents 50llm. 
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Next, neuronal differentiation was investigated. As mentioned, two neuronal specific 
markers were studied, Tun and NF-200 (Fig. 4.3.14). Low level expression of Tun 
was noted in both the undifferentiated sample and the differentiation control. While the 
morphology of cells had changed significantly between the two sample groups, 
expression levels remained mostly constant, with a small number of cells expressing a 
higher level of the marker in the control differentiation sample. However, when the 
culture conditions were spiked with either the natural retinoid A TRA or the synthetic 
retinoid EC23, an increase in Tun expression was obserVed. Many cells throughout the 
cultures showed an enhanced expression level of this marker compared to the 
. undifferentiated and control differentiated conditions. These data suggests that a more 
mature level of neural differentiation was being achieved with the supplementation of 
these retinoids into the culture system. TUn expression levels in EC19 cultures remained 
comparable to control differentiated conditions, with a few individual cells -exhibiting the 
up-regulated expression of this marker. To investigate the theory that spiking with 
retinoids elicited more mature neural cell types ~he late neuronal marker NF-200 was 
examined (Fig. 4.3.14). This marker was not expressed in undifferentiated cultures, nor 
waS it expressed in cell induced to differentiate with removal of growth factors alone. 
These data backed up previous findings that removing only growth factors from media 
did appear to initiate neural differentiation, but was not conducive to obtaining mature 
neuronal phenotypes. After the addition of either A TRA or EC23 into the culture media, 
cells expressing the· late neuronal marker were visualised. An indication that mature 
neuronal phenotypes were being stimulated under these defined conditions. No NF-200 
positive cells were witnessed in EC19 cultures, again indicating the differing nature of 
this compound to the natural counterpart ATRA, and- synthetic retinoid EC23. To 
quantify the amount of mature neuronal differentiation visualised in the sample groups, 
ImageJ software was used. The number of positive NF-200 perikariaifield of view in 
eight randomly selected photomicrographs/condition was calculated and results were 
shown graphically (Fig. 4.3.15). As expected, both the A TRA and EC23 conditions 
contained the most NF-200 expressing cells, with a higher level being visualised in the 
EC23 condition. The number of cells expressing NF-200 in EC19 was comparable with 
the differentiation control condition, which were both slightly higher than the 
undifferentiated control. These data verifies that media supplementation with either 
A TRA or EC23 induced neural differentiation to a more mature level than just following 
. the standard protocol obtained with these commercially available embryonic neural 
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progenitor cells. It was noted that Ee23 was able to mimic A TRA induced biological 
responses within this cell model system. 
Figure 4.3.14: Immuno-cytochemically stained images of 197VM human embryonal neural progenitor 
cells after 7 days in culture. Cells were either cultured in control proliferative media, control differentiation 
media (removal of growth factors), or exposed to I ~M retinoid (A TRA, EC23 or EC 19) added to the 
control differentiation media. An abundance of neurite processes were seen in all differentiation conditions. 
However, mature neuronal differentiation was only seen in ATRA and EC23 cultures (NF-200 staining) 
n=3, scale bar represents 50~m . 
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Figure 4.3. t 5: Induction of neural differentiation in cultures of 197VM embryonic neural progenitor cells 
with 111M ATRA, EC23 , and ECI9. 7 day-differentiated cultures were immunocyto-stained for the late 
neuronal marker NF-200. Using ImageJ software the number of NF-200 positive cell bodies was counted 
on 8 random fields of view per condition. Results were averaged and represented graphically. When 
cultures were treated with either A TRA or EC23 the number of cells expressing the mature neuronal 
marker NF-200 increased. This was not the case with the EC 19 retinoid condition. Error bars represent 
standard deviation of the mean, n=8. *** pSO.OOOS, student's t-test compared to the undifferentiated 
control. 
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4.4 Discussion and Conclusions 
4.4. J Adult hippocampal neural progenitor cells 
The initial aim of this body of work was to establish a suitable adult neural progenitor 
cell model system to investigate the activity of synthetic analogues of retinoic acid. To 
qualify as a suitable model system, the chosen cell line had to demonstrate differentiation 
toward a neural lineage in response to media supplementation with natural retinoids. The 
AHPC line in question has been shown to respond to ATRA in previous experiments, 
differentiating down a neural lineage 168. Furthermore, hippocampal progenitor cells have 
. been used for high-throughput screening to identify neuro-active synthetic small 
molecules 175. 
Here, the addition of either A TRA or 13cisRA to _ cultures did indeed initiate 
differentiation, with expression of the neuronal marker TUJ1 and glial marker GF AP 
being up-regulated. In 13-cisRA cultures, cell number and immunological analysis 
confirmed there were consistently more TUJ1 positive cells than in A TRA counterparts, 
with also an increased total number of cells being present throughout the time course. 
One possible explanation for these findings could be the fact that 13-cisRA is thought to 
be a pro-form of ATRA and/or 9-cisRA 176, isomeHsing before it elicits an effect, as it is 
known that 13-cisRA is unable to bind effectively to either RARs or RXRs itself 177. 
Potentially, this phenomena could instigate a time-lag before cells become exposed to the 
biologically active forms, accounting for the increase in cell number (proliferation) 
witnessed. Consequently 13cisRA cultures would contain more cells over-all, whicp 
ultimately commit to the neural lineage, leading to increased final numbers of TUJ1 
positive cells (see Fig. 4.4.1 below). A similar phenomena was observed by Liu et al in 
2008 178. They reported that at specific concentrations, 13-cisRA induced an increased 
amount of neuronal cell survival in their primary hippocampal neuron cultures compared 
to standard media controls, whereas, while ATRA didn't induce cell death, it didn't 
enhance cell survival above the controls either. An increase of up to 44%.was observed in 
13cisRA cultures compared to vehicle controls, with no reported increase in the amount 
of glial cells. These results can be compared to those presented here, with the only 
difference being the concentration at which the effect was elicited, 100 fold lower. This 
difference could be due to the fact that cultures of primary explants were used, which 
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may be more sensitive than the established immortalised cell line used here. These 
findings are of interest, since they provide evidence that adult hippocampal cells respond 
differently to different isomers of retinoic acid. They also re-enforce the need for stable 
non-isomerisable A TRA alternatives to allow tightly controlled concentration and isomer 
studies to be performed. 
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Figure 4.4.1 Diagram depicting hypothesised delay of 13-cisRA action and possible explanation for the 
observation that more TUJ 1 positive cells are present in 13cisRA treated cultures compared to ATRA 
counterparts. 
Having shown that the AHPC line was a suitable cell model system with which to 
evaluate retinoid activity, the next aim was to investigate the synthetic retinoid analogue, 
EC23, to determine whether it elicited any biological response. Different concentrations 
and cell densities were analysed to establish the optimal culture conditions for further 
analysis. This was an important part of the investigative process, similar to the first 
published studies investigating the in vitro culture survival of primary hippocampal 
neurons. In these early studies, the optimal bFG F culture concentration suitable for 
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prolonged cell proliferation and survival was discovered by using a similar trial and error 
approach 179. After various EC23 concentrations and cell densities were evaluated, it was 
discovered that EC23 could elicit similar biological activity to A TRA providing the cells 
were seeded at a sufficiently high density. Cells exposed to EC23 appeared to 
differentiate down the neural lineage, with cells expressing the neuronal marker TUll 
after 7 days in culture. The highest concentration of EC23 tested, 1 JlM, appeared to be 
toxic to cultures as revealed by decreased neuronal survival, whereas A TRA was not, 
indicating an increased potency/toxicity of EC23 on these cultures. The toxic effect of 
high concentrations of A TRA on in vitro hippocampal neuron survival is published, and 
is similar to that observed here with EC23 178. Published data states that after cultures 
were exposed to high levels of ATRA, neuronal survival was decreased and cultures 
became sub-optimal for on-going neural differentiation with apoptosis/cell death 
becoming prevalent. The data obtained after EC23 toxicity fits with the fact that at high 
doses A TRA is toxic and is known to induce apoptosis in some cells, being used as a 
chemotherapeutic agent either alone or in combination with other drugs because of this 
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The apparent toxicity of EC23 at high concentrations may reflect its engineered stability. 
Not only is EC23 more chemically stable than ATRA, but it is possible that it is also 
more resistant to cellular metabolism. Both of these factors would contribute to EC23 
remaining intact in the media/cells for relatively long periods compared to ATRA. This 
in turn may contribute to the toxic effects observed. Another point to consider would be 
that it may not be that EC23 is more potent/toxic than A TRA, it may just be that due to 
the instability of ATRA that although cultures are supposedly being exposed to equal 
concentrations of the retinoids, this may not be the case due to A TRA degradation, the 
problem which is trying to be resolved in this investigation. These preliminary findings 
indicate that it is possible to synthesise a retinoid that is more stable than its natural 
counterpart and can also induce similar cell differentiation under defined culture 
conditions. Hence, EC23 appears to be an attractive alternative to ATRA for reproducible 
neuronal differentiation of adult neural progenitor cells. EC23 is non-isomerisable 
therefore there is no problem of trying to decipher which isomer is eliciting which effect. 
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AHPCs were also cultured with the synthetic retinoid EC 19. Again, a range of 
concentrations was tested with only one (O.IIlM) resulting in any differentiation of 
cultures. At higher concentrations the retinoid appeared toxic, killing cultures, while at 
lower concentrations no differentiation was induced. Compared to the natural control 
retinoid ATRA, EC19 appears to have a much smaller concentration 'window' for 
inducing differentiation within this particular cell system. At the concentration which did 
induce differentiation, O.IIlM, as was witnessed with all other systems tested, EC 19 
induced differing proportions of specific cell sub-types compared to the A TRA control. A 
higher level of glial differentiation was visualised, with almost a two-fold increase in 
marker expression for this cell type in EC 19 cultures. Therefore it was concluded that 
although EC 19 was able to induce differentiation, given the right culture conditions, the 
patterns of differentiation were distinctly different to those achieved with the A TRA 
counterpart. This could potentially provide interesting insights into the study of glial 
development in adult neural progenitor cell model systems. Experiments carried out on 
adult neural progenitor cells have reported that glial differentiation is the predominant 
cell type induced after media supplementation with the bone morphogenetic protein 4 
(BMP4) 181, 182. During neural development, BMPs exert their action by inhibiting the 
default neuro-ectodermal differentiation, inducing the differentiation of epithelial 
lineages. These reports indicate that applying BMPs to committed adult neural precursors 
induced specific glial subtypes, possibly blocking the action of other neuronal specific 
pathways. It could therefore be hypothesised that EC 19 is inducing similar glial effects, 
at the expense of neuronal differentiation. To confirm this hypothesis specific binding 
studies would need to be carried out to identify common EC 19 and BMP4 downstream 
binding partners, followed by antagonism of those elements and recording of the induced 
cellular responses. 
Real-time qPCR analysis of two specific components of the retinoic acid receptor 
pathway further revealed common functiomi1ity between A TRA and EC23. Genes 
studied were the ATRA metabolising agent CYP26AI, which has previously been shown 
to be involved in neural differentiation and regulation~ 173, and the nuclear receptor 
involved in neuronal differentiation, RAR-~ 174. Expression profiles obtained for both 
genes indicated that EC23 appeared to be inducing maximal levels of expression at the 
lowest concentration evaluated; backing up previous findings that EC23 appears to be 
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more potent than A TRA. Data also verifies that EC23 appears to be eliciting its effects 
via the retinoic receptor pathway. It is hypothesised that. reducing the concentration of 
EC23 to amounts lower than tested here would eventually elicit a concentration 
dependent expression profile. Further work here would be useful to evaluate the optimal 
supplementation concentration of EC23 into AHPC media for maximal neuronal 
differentiation . 
. ECl9-induced cultures also up-regulate the CYP26Al and RAR-P genes, but only under 
very defined culture conditions, and the expression levels reached were lower than those 
obtained with the other retinoids tested. Again, this indicates that this analogue may elicit 
its effects predominantly via a different pathway or by activating other retinoid receptor 
complexes not evaluated here. It would be interesting for future work to investigate the 
expression profiles of a larger group of retinoid-activated compounds to discover any 
which EC 19 is capable of inducing the expression of. It is important to note the vast 
difference in biological activity induced by EC23 and ECI9, especially since this must be 
attributed to the only difference between these molecules, namely, the position of the 
carboxylic acid group in the para- versus meta-position respectively. Again, this finding 
prompts the need for further structure/activity-based investigation into how these 
analogues are eliciting their effects. 
4.4: 2 Embryonic neural progenitor cells 
ReNcell VM is a commercially available embryonic neural progenitor cell line derived 
from the ventral mesencephalon of human foetuses. Cell lines and cells derived from this 
area of the embryonic brain are particularly important for therapeutic transplantation 
therapies for disorders associated with loss of dopaminergic neurons, such as Parkinson's 
disease 183 184. It is anticipated that the in vitro culture and subsequent controlled 
differentiation of neural progenitor cells derived from the ventral mesencephalon will 
-. ". 
limit the number of foetuses required per therapeutic transplantation into patients 185. 
However, the in vitro differentiation of these neural progenitors still needs to be 
optimised to increase the yield of the neuronal sub-types required for such 
transplantation. One such compound which could have an effect on the differentiation 
products induced is ATRA. It is known that during neurulation tn the early embryo, the 
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retinol dehydrogenase associated with the synthesis of retinoic acid has been localised to 
various areas of the developing CNS including cells within the ventral mesencephalon 
186, thereby indicating the ability of these cells to respond to endogenous ATRA. Indeed, 
in an investigation into the differentiation potential of ventral mesencephalon progenitors 
in vitro, carried out in 2004 187, the addition of ATRA into a defined dopamine-inducing 
differentiation protocol significantly increased the yield of dopamine neurons. Therefore, 
while it was predicted that media supplementation with A TRA should effect the 
differentiation of ReNcell VM cells, its effects had not been illustrated in the cell line 
before. 
Experiments were carried out to investigate what effect, -if any, the supplementation of 
A TRA would have when added to the standard differentiation media protocol. It was also 
investigated whether the addition of EC23 or EC 19 would induce similar or differing 
effects from the ATRA control. Immunological analysis of a panel of neural-related 
proteins revealed very interesting findings. It was discovered that the addition of either 
A TRA or EC23 into the culture media induced the differentiation of more mature 
neuronal phenotypes compared to the standard differentiation protocol. NF-200, (a 
marker of late neuronal development), positive neurons were only visualised in these two 
culture conditions. The supplementation with EC 19 did not induce these neuronal sub-
types, but it did induce an up-regulation of the glial marker GF AP, also witnessed with 
the other two retinoids. Yet again, these results support the hypothesis that EC23 is a 
--
more stable alternative to A TRA for in vitro investigations into neuronal differentiation 
processes. These results are in-line with those reported above. As a result of these data, a 
revised differentiation protocol is suggested for the production of mature neuronal 
phenotypes from cultures of ReNcell VM cells: 
Revised differentiation protocol: 
ReNcell VM cultures are incubated with trypsin to obtain a single cell suspension, and 
then 100,000 cells/well were seeded into 12 well plates. Plates were allowed to get 75% 
confluent then were switched to differentiation media. Differentiation media consists of 
DMEM:FI2 (1:1, Gibco) supplemented with 10mls B27 (Invitrogen), 2mM L-Glutamine 
(Sigma), 0.5ml Gentamycin (Gibco), Iml 50mg/ml Heparin solution (Sigma) and either 
1 flM ATRA or the more stable alternative EC23. Cultures are incubated for 7 days, with 
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a complete media change being performed on day 3. Following this protocol should 
induce the production of NF-200 positive neurons which were not found following the 
standard differentiation protocol issued with the cells from the selling company. 
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4.4.3 Conclusions 
The natural retinoid A TRA has been shown to be a vital component for both adult and 
embryonic neurogenesis (refer to Chapter 1). This chapter has dealt with evaluating the 
effects induced by supplementation of both adult and embryonic neural progenitor 
cultures with either the synthetic retinoid EC 19 or EC23, and comparing results with 
those obtained from A TRA cultures. It was hoped that one of the synthetic compounds 
would mimic ATRA-induced differentiation, and therefore present itself as a potential 
attractive alternative for use in in vitro neurogenesis research. Previous data has 
illustrated that the synthetic compounds are more stable than A TRA under standard 
laboratory conditions, and that EC23 appears to mimic A TRA in embryonic stem cell 
model systems, inducing induction of neural differentiation. EC 19 was also shown to 
induce differentiation in these cells, albeit down a different cell lineage. 
Cultures of adult hippocampal neural progenitor cells differentiated down a 
predominantly neuronal lineage in response to both A TRA and EC23 supplementation. 
However, it was noted that for EC23 to induce this differentiation, cells were required to 
be seeded at a higher density. The higher potency of EC23 compared to ATRA was also 
revealed during real time qPCR analysis, as outlined above. EC 19 was able to induce 
differentiation, albeit under very defined culture conditions. The differentiation induced 
was predominantly glial, different from control ATRAsamples, and as such EC19 may 
be an attractive new candidate for use in understanding glial cell development in the adult 
hippocampal system. It was concluded that both synthetic retinoids were able to induce 
differentiation in this adult neural progenitor model system, with EC23 closely 
resembling A TRA cultures. The effects of all three retinoids appeared to be elicited via 
activation of the retinoic acid receptor pathway, although induction of the components 
analysed was at relatively low levels in EC19 cultures. 
When cultures of ReNcell VM embryonic neural progenitors were supplemented with 
either ATRA or EC23, significantly more mature neuronal sub-types were visualised in 
culture, this was not seen with EC19 supplementation. It was therefore concluded that 
supplementation with either ATRA or EC23 greatly enhances the neuronal products 
obtained, therefore aiding future analysis of neurogenesis using this particular cell type. 
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In light of these findings an updated differentiation protocol is suggested for the 
induction of mature neuronal phenotypes. 
In both cell model systems EC23 was shown to induce differentiation in a similar 
manner to A TRA. Combining these data, also with knowledge that EC23 is a much more 
stable compound when used under standard laboratory conditions, it is concluded that 
this compound appears to be an attractive alternative to ATRA for use in in vitro 
investigations into both embryonic and adult neurogenesis. 
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5 Chapter 5: Natural and Synthetic Retinoid Action on SH-SY5Y 
Neuroblastoma Cells 
5.1 Introduction: 
Retinoids have a close link to cancer biology. They are recognised as teratogenetic agents 
when found in excess (Chapter 1), but can also be incorporated into therapy regimes as 
chemotherapeutic agents for certain types of cancer, including neuroblastoma, with 
varying success. Retinoids appear to inhibit tumour growth by two main biological 
processes, either causing cell differentiation or apoptosis. For example, ATRA can be 
used to successfully treat some types of acute promyelocytic leukaemia 188, where they 
induce apoptosis in the aberrant cell population, or in the case of neuroblastoma, retinoids 
also induce neural differentiation in the responding cell population 189. However, their use 
is assoCiated with many debilitating serious side effects such as hepatotoxicity, 
headaches, nausea, vomiting, abdominal pain and mucocutaneous dryness, collectively 
known as retinoic acid syndrome 190. Therefore, due to these limiting toxicities the 
maximum tolerated dose is often reduced to below therapeutically optimal levels. It also 
appears that cells become sensitised to ATRA very quickly during the treatment period 
due to an up-regulation of the CYP metabolising proteins 191, meaning that after time, a 
higher dose is required to elicit a comparable effect; however this dose increase is 
associated with the toxicity issues outlined above. Formation of synthetic retinoic acid 
metabolising blocking agents (RAMBAS) is an area of investigation which hopes to 
overcome this problem, as 'outlined in Chapter 1. 
One type of cancer that responds in part to retinoid therapy is neuroblastoma, a childhood 
cancer 192 which accounts for 7-10% of all childhood cancers. As already mentioned, 
administration of retinoids appears to cause differentiation of the aberrant stem cell 
population. However, not all neuroblastomas respond to treatment in the same way, and 
as outlined above, retinoid sensitivity regularly occurs throughout the treatment process, 
with some neuroblastomas being totally resistant to retinoid treatment from the start. It 
appears that certain factors contribute to the tumour's response to retinoid therapy, for 
example, over-expression of the Bcl-2 gene is one of the key mechanisms which instil 
142 
resistance in these cells to retinoid treatment 193. Several different approaches have been 
taken to try and optimise the use of retinoids for chemotherapeutic agents for 
neuroblastoma. For example the use of the ATRA isomer 13cisRA in clinical trials has 
proved more successful than ATRA therapy. even though it is thought to isomerise back 
to A TRA before it exerts its biological effect 194, 195. Two other interesting areas are the 
combining of A TRA and other compounds for joint treatment programmes, however so 
far. this has had limited success in clinical trials 196, or the development of synthetic 
retinoid analogues which have enhanced therapeutic potential 197, 198. It is this approach 
that we aimed to investigate here. The aim of this part of the investigation was to assess 
whether the synthetic retinoid compounds, EC 19 and EC23, were able to inhibit the 
growth of a neuroblastoma cancer cell line to a comparable or greater degree than the 
established natural retinoids, ATRA and 13cisRA. If the synthetic retinoids were found to 
inhibit tumour growth it would then be important for subsequent studies to deduce 
whether they induced the kind of debilitating side effects .,seen with their natural 
counterparts. This would need to be investigated via animal models and would therefore 
only be carried out once the basic science was in place. Clearly, if these synthetic 
analogous caused reduced side effects then they might be considered potential therapeutic 
replacements for ATRA and 13cisRA. Future strategies specifically aimed at side effect 
reduction could include the tailoring of compounds to selectively activate receptors 
associated with cell differentiation, apoptosis and cell death. 
5.1.1 SH-SY5Y Neuroblastoma cell line 
The neural tumour cell line SH-SY5Y has been used in this study. The SH-SY5Y cell 
line is a thrice cloned sub-clone of the SK-N-SH cellline·derived from neoplastic neural 
crest cells of a four-year old female child 199. The aberrant cells were collected and 
cultured from a bone-marrow biopsy. In previous investigations, the SH-SY5Y 
neuroblastoma cell line has been shown to differentiate in response to both ATRA and 
13CisRA 200, where it appears that 13cisRA is isomerised to ATRA before it elicits any 
effect. Although the SH-SY5Y cell line was initially cloned as a neuronal-specific N-type 
cell line, unless cultures undergo continual N-type selection, they have been shown to 
contain the three . different cell types normally associated with proliferating 
neuroblastoma cultures, namely the neuronal N-type cells, which are the cell type that 
differentiate down the neural lineage, the substrate-adherent S-type cells, which appear 
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non-neural in shape and are possibly linked to Schwann cells, and the intermediate I-type 
cells, which are thought to be an intermediate phenotype ,cells go through before turning 
into either N- or S-type cells 201. 
5.1.2 Aim and Objectives 
Aim 
The initial aim of this Chapter were to establish a valid neural tumour cell model system, 
and use this system to investigate retinoid action with a view to testing the biological 
activity of the synthetic retinoid compounds EC19 and EC23. 
Objectives 
• To represent a usable model, the cell line would be required to mimic a type of 
neural tumour that retinoid therapy is currently used on, and the cell line would 
need to show partial biological response to the natural retinoids. Biological 
activity of synthetic retinoids was investigated using a range of relevant biological 
techniques. 
• The ability of the synthetic retinoids EC 19 and EC23 to induce differentiation 
would be observed, and a range of concentrations studied to find a suitable 
'optimal' concentration at which all other experiments would be carried out at. 
• The ability of the synthetic retinoids EC 19 and EC23 to inhibit cell proliferation 
would be evaluated and compared with results obtained with the natural retinoids 
A TRA and 13cisRA. 
,. 
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5.2 Methods 
5.2.1 Tissue Culture 
5.2.1.1 SH-SY5 Y neuroblastoma cells 
Cells were cultured under standard laboratory conditions as described in Chapter 2. SH-
SY5Y cells were cultured in uncoated tissue culture T75 flasks (Nunc) or 12-well plates 
(Nunc). Proliferation media was MEM:F12 1:1 (Sigma), supplemented with 2mM L-
Glutamine (Sigma), 1% non-essential amino acids (Gibco), 15% foetal calf serum 
(Sigma) and 1000 active units of penicillin/streptomycin solution (Sigma). To maintain 
optimum cultures, media was changed every 3 days, and cultures were passaged when 
they reached ~80% confluencey. To passage, media was aspirated, 2ml trypsin-versene 
solution (Cambrex) added and rocked over cells and incubated at 37°C for up to 5 mins. 
Cells were dislodged from the plasticware by tapping, and resuspended in 10mls 
MEM/F12 media. The suspension was pelleted by centrifugation at 800rpm for 2 mins. 
The supernatant was removed and the pellet resuspended in 1ml proliferation media and 
triturated to gain a single cell suspension. Cells then underwent a 1:3 to 1:6 split 
depending on cell numbers and were transferred to new plasticware. 
5.2.1.2 Differentiation ojSH-SY5Y cells 
Cell cultures were induced to differentiate with the introduction of A TRA (Sigma, diluted 
in DMSO (Sigma)), 13-cisRA (Sigma, diluted in DMSO), EC19 (diluted in DMSO) or 
EC23 (diluted in DMSO) into the media. Unless stated, a concentration of I o 11M 
retinoids was used throughout. In preparation for differentiation, single cell suspensions 
were prepared as outlined above, and cells were counted using a haemocytometer under a 
light microscope. Unless otherwise stated, cells were seeded at 20,000 cells/well in a 12-
well plate. Cultures were maintained for up to 14 days with media being refreshed every 
3 days. 
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5.2.2 Flow cytometry 
For complete intracellular flow cytometry methods refer to Chapter 2, Section 2.4. 
For complete cell cycle analysis methods refer to Chapter 2, Section 2.5. 
Antibodies and stains used: 
Antibody Company Dilution Incubation Secondary 
time. 
TUJl Covance 1:600 Ihr Cy3 
Propidium Applied 1 :100 10mins N/A 
Iodide Biosystems 
5.2.3 Immunocytochemistry 
For complete immunocytochemical methods refer to Chapter 2, Section 2.6 
For complete BrdU pulsing and subsequent immunocytochemical staining methods refer 
to Chapter 2, Section 2.8. 
Antibodies used: 
I Antibody I Company Dilution Incubation Secondary 
time 
Vimentin Sigma 1:200 Ihr Alexafluor 488 
TUJl Covance 1:500 Ihr Cy3 
RAR-a Santa Cruz 1 :100 Ihr FITC 
RAR-~ Santa Cruz 1 :100 Ihr FITC 
RAR-y Santa Cruz 1 :100 _ Ihr FITC 
BrdU Molecular 1:100 Ihr Alexafluor 488 
Probes 
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5.3 Results 
5.3.1 Concentration study of natural and synthetic retinoids 
Initial experiments were carried out to establish a suitable concentration at which both 
synthetic retinoids appeared to be eliciting an effect in the SHSY-5Y cultures, at which 
all future analysis would be carried out. Initially a wide concentration range was tested 
incorporating I/-!M, 10/-!M and 100/-!M concentrations of each retinoid tested, namely 
A TRA, EC 19 and EC23. Cultures were set up and exposed to the retinoids for seven days 
before undergoing MTS viable cell number analysis (Fig. 5.3.1) and 
immunocytochemical analysis of markers of the two main cell sub-types found within the 
SH-SY5Y culture (Fig. 5.3.2). Two markers were used for immunocytochemical 
analysis, one for each of the specific cell types visualised within SH-SY5Y cultures. The 
P-III-tubulin antibody, TUll , was used as a marker of the neuronal N-type cells, and 
vimentin was used as a marker of the substrate-like S-type cells. All results were 
compared to both undifferentiated and vehicle-exposed (DMSO) controls. Cell number 
analysis indicated that exposure to the vehicle control, DMSO, alone did not inhibit cell 
number compared to the undifferentiated control, and can therefore be discounted as 
eliciting any effect on its ' own. 
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Figure 5.3.1: Concentration study of the synthetic retinoids EC23 and EC 19 on SH-SY5Y cell viability. 
MTS cell number analysis was carried out on 7 days samples incubated with either 1 ~M, I O~M or 1 OO~M 
retinoid. Undifferentiated and vehicle exposed cultures were treated as controls. 1 O~M concentration 
appears to be optimal for all retinoid compounds tested. n=2. * p:SO.05, student's t-test compared to the 
undifferentiated control. 
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Cell number analysis data revealed that as the concentration of the synthetic retinoid 
EC23 increased, the viable cell number decreased, with no viable cells visible in the 
highest concentration tested, 100)lM (Fig. 5.3.1A). Cell numbers also decreased as the 
concentration of EC 19 was increased (Fig. 5.3.1 B), however, at the lowest EC 19 
concentration (I )lM) the number of viable cells present was higher than that visualised in 
the undifferentiated control. IO)lM EC19 did induce a decrease in cell number compared 
to 1 )lM, however numbers remained higher than those observed for EC23 at the same 
concentration. Even when cells were exposed to the highest concentration tested of EC 19, 
lOO)lM, some viable cells were still present after 7 days in culture. Taken together these 
initial data suggested that EC23 is more potent/toxic to SH-SY5Y neuroblastoma cells 
than EC19. In addition, EC19 may act to induce an enhanced level of proliferation in 
these cancer model cells. 
Figure 5.3.2: Concentration study of the synthetic retinoids on SH-SY5Y cell differentiation . 
Immunocytochemical staining of SH-SY5Y cells after incubation with either I flM, IOflM , 100flM retinoid . 
Cells are stained for S-type marker vimentin (green), neuronal N-type marker TUJ 1 (red). At the highest 
concentration tested cells were sub-optimal and dying. At all concentrations the synthetic retinoid EC 19 
appears to induce predominantly S-type cells. Scale bars: 50pm. n=3. 
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To examine what effect EC19 and EC23 were having on the individual SH-SY5Y cell 
sub-types, immunological analysis was performed and compared against the control 
retinoid ATRA (Fig. 5.3.2). Undifferentiated cultures contained a high number of both N-
type and S-type cells, as did the vehicle control. After incubation with the control retinoid 
ATRA, the proportion of N- and S-type cells changed. The proportion of N-type cells 
decreased compared to control samples, and appeared to change shape, forming long 
processes indicating that differentiation into neuronal cell-types may have occurred, 
especially in the IOIlM sample. EC23 also appeared to attenuate the number of N-type 
cells, but not to the same extent as A TRA. The over-all number of S-type cells was also 
reduced compared to the undifferentiated controls. EC19 .appeared to inhibit N-type cell 
formation and increase S-type proliferation. To quantify the number of TUn-positive 
cells in ATRA and EC23 cultures, flow cytometry was performed (Fig. 5.3.3). It was 
noted that as the concentration of ATRA increased, from 1 IlM to IOIlM, the number of 
cells solely expressing the TUn N-type cell marker decreased, an indication that 
increased A TRA concentration increases the level of differentiation induced, therefore 
limiting proliferation of the N-type cells. The opposite was visualised with the synthetic 
retinoid EC23, in that an increase in concentration of the retinoid induced an increase in 
the number of cells solely expressing the N-type marker Tun. It was also noted that the 
vehicle control, DMSO alone, also appeared to be having an effect on the number of N-
type cells compared to the undifferentiated control, increasing the amount of cells solely 
expressing TUn. Since EC23 cultures contained an intermediate number ofN-type cells 
between control and ATRA counterpart cultures it was unclear whether this was due to 
either (a) increased neuronal effects or (b) general decreased potency associated with this 
retinoid. In order to try and resolve this point, it was decided to use a concentration of 
IOIlM throughout the investigation, and experimental emphasis was placed on reviewing 
biological responses. 
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Figure 5.3.3: Flow cytometric analysis of the percent ofSH-SY5Y cells solely expressing TUJI in cultures 
exposed to either 111M or IOIlM ATRA or EC23. Cells are stained for the S-type marker vimentin and the 
neuronal N-type marker TUn then analysed via flow cytometry. Using duel-gating the percent of cells 
exclusively expressing TUn is obtained. As the concentration of ATRA increases the number of TUJ 1 
positive cells decreases. The opposite is seen with EC23. The most TUn positive cells are observed in 
IOIlM EC23 cultures. n=2. * pSO.05, student's t-test compared to the undifferentiated control. 
5.3.2 Retinoic acid receptor expression in SH-SY5Y cultures exposed to retinoids 
Cultures were exposed to lO)lM retinoid for seven days, then fixed and immuno-
cytostained for the three different retinoic acid receptor (RAR) subtypes, alpha, beta and 
gamma (Fig. 5.3.4). All samples were counterstained with the nuclear dye Hoechst 33342 
to help visualise whether receptor expression was localised to the nuclei. Hoechst 
counterstaining is not shown here as the receptor expression was at low levels and would 
be masked, however all receptor expression was seen to be nuclear. Expression of RAR-a 
appeared to be increased in EC 19 cultures compared to the other retinoid-supplemented 
conditions and the undifferentiated control. RAR-~ expression appeared to be up-
regulated in cultures supplemented with ATRA and EC23 only. Non-specific staining 
was visualised in both undifferentiated and EC 19 conditions and was disregarded. RAR-y 
expression was slightly up-regulated in undifferentiated and EC 19-suplemented cultures. 
These expression profiles reinforce the differences seen between EC 19 and the other 
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retinoids, and indicate that the observed biological responses to EC 19 are elicited, in part 
at least, by activation of different RAR-dependent biological pathways. It is known that 
RAR-P activation is associated with neural development, and this receptor may therefore 
be important during the retinoid-activated differentiation of the neuroblastoma cells into 
neuronal derivatives. However, before any solid conclusions can be drawn, the 
verification of these data would need to be confirmed via western blot analysis. 
RAR-a 
RAR-P 
RAR-y 
Figure 5.3.4: Regulation of the nuclear retinoic acid receptors during differentiation of SH-SY5Y cells. 
Immunocytochemical staining of SH-SY5Y neuroblastoma cells cultured with IOIlM retinoid for 7 days. 
Retinoic acid receptor-a expression is increased in cultures exposed to EC 19. Retinoic acid recepror-p 
expression is slightly increased in cultures exposed to ATRA, EC23 and EC 19 after 7 days. The staining 
visible in the undifferentiated sample appears to be non-specific. Retinoic acid receptor-y expression is 
slightly increased in undifferentiated cultures and those exposed to EC 19 after 7 days. Scale bar: 50J.lm 
5.3.3 Potency analysis of synthetic retina ids at 10 J-LM concentration 
Viable cell number analysis was carried out over a time course on cultures exposed to 
10J.!M of either A TRA, 13cisRA, EC23 or EC 19 (Fig. 5.3.5). This analysis was 
performed to see how cell numbers changed over the time course, i.e. was cell number 
maintained at a constant level after retinoid supplementation or did it increase over time? 
The control conditions, undifferentiated cultures and OM SO-treated cultures, both 
exhibited an increase in cell number as the time course progressed, indicative of healthy, 
proliferating cultures. Supplementation with either natural retinoid A TRA or 13cisRA 
showed an attenuation of cell number after the 7 day time point, suggesting that both 
retinoids are inhibiting cell proliferation beyond this point, possibly causing cells to drop 
out of the cell cycle and differentiate. The synthetic retinoid EC23 also appeared to limit 
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cell proliferation after the 7 day time point, even showing a slight decrease in cell number 
compared to ATRA and 13cisRA conditions. The synthetic retinoid EC 19 was slightly 
more unpredictable in its induced responses. Cultures exposed to this retinoid did not 
show an attenuation of cell number over the time course, and the resulting cell number in 
the cultures was greatly variable compared to the other conditions tested, as revealed by 
the corresponding error bar in Figure 5. 
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Figure 5.3.5: MTS cell analysis of SH-SY5Y cell number after exposure to IOIlM A TRA, EC23 or EC 19 
over a specific time course. All retinoids are able to attenuate cell numbers over the time course in 
comparison to the control samples. EC 19 is less predictable in its ability to inhibit cell numbers as indicated 
by the large error bar. n=6. * p:SO.05, *** p:SO.0005, student's t-test compared to the relevant 
undifferentiated sample. 
Immunocytochemical analysis was carried out on cultures incubated with the retinoids 
after the 11 day time point (Fig. 5.3.6). Again, markers of the N- and S-type cell types 
were analysed by TUJ1 and vimentin immunostaining. As visualised in the concentration 
study, ATRA appeared to attenuate the number of N-type cells within the culture 
compared to control micrographs, and cells present appeared to have undergone 
differentiation with the presence of long neural processes. EC23 had also attenuated the 
number of N-type cells with regard to the undifferentiated control, but not to the same 
extent as A TRA, i.e. there was still a higher proportion of N-type cells to S-type cells 
compared to the A TRA samples. The N-type cells within this culture condition did not 
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appear to have undergone obvious neural differentiation; they did not appear to contain 
long neurites as seen in the A TRA condition. This could suggest that EC23 was not 
eliCiting as potent an effect on these cancer cells as A TRA. The cultures exposed to EC23 
appeared to resemble cultures exposed to the natural retinoid 13cisRAmore closely. 
13cisRA also did not induce neurite extension in the N-type component of its cultures, 
and the proportion of N - to S-type cells was also higher than in the A TRA control. EC 19 
cultures contained predominantly S-types cells, with very few cells solely expressing the 
N-type marker TUJl. Figure 6 also appeared to indicate an apparent increase in the total 
cell number present within EC 19 cultures compared with the undifferentiated control, 
however this would need to be verified via quantifiable methods. It appears that EC 19 
may be having some sort of enhanced proliferative effect on these model neuroblastoma 
cells, the opposite of the desired effect, but nonetheless an intriguing contrast to the 
closely related EC23 compound considering the only difference ·between the two 
analogues is the position of the carboxylic acid group. 
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Figure 5.3.6: Immuno-cytochemical analysis of the biological effect of the synthetic retinoids on SH-
SY5Y cell differentiation. Immunocytochemical staining of SH-SY5Y cells after incubation with IOIlM 
retinoid for II days. Cells are stained for S-type marker vimentin (green), and neuronal N-type marker 
TUJ I (red). EC23 cultures retain the most N-type cells followed by in turn 13cisRA, ATRA and EC 19. The 
synthetic retinoid EC 19 appears to induce predominantly S-type cells. Scale bars: 50llm . n=3. 
5.3.4 Cell cycle analysis ojSH-SY5Y cells incubated with retinoids 
To investigate the effect of retinoids on the cell cycle of SH-SY5Y neuroblastoma cells, 
flow cytometric analysis of the cell cycle was performed (Fig. 5.3.7). Cells that were in 
S-phase and G2/M-phase were considered to be undergoing cell division, and were 
therefore counted as dividing cells. Cell cycle analysis was performed at both three and 
seven day time points on cultures exposed to either A TRA, I3cisRA, EC 19 or EC23. 
Dean-Jett analysis and statistics were followed and results were presented in graphical 
form (Fig. 5.3.7). Undifferentiated control cultures retained the highest percentages of 
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cells entering cell division at both 3 day (-40%) and 7 day (-30%) time points, with 
fewer dividing cells present at 7 days. This could be due to cultures becoming more 
confluent and less optimal for cell proliferation, possibly due to contact inhibition. A TRA 
cultures had far fewer dividing cells at both 3 and 7 days compared to the 
undifferentiated control. By 7 days, on average only II % of cells within the A TRA 
cultures were still undergoing cell division/proliferation. 13cisRA cultures contained 
more proliferating cells than the A TRA differentiation control at both time points, with 
on average 17% of cells within the culture continuing to undergo cell division at the 
seven day time point. EC23 cultures contain less proliferating cells at both time points 
compared to the undifferentiated control, but the number of dividing cells was greater 
than those visualised in the A TRA counterpart. On average 17% of cells within the 
EC23-supplemented condition were undergoing cell division at the seven day time point, 
a figure which was comparable to 13cisRA cultures. EC 19-supplemented cultures 
showed very little attenuation of proliferating cells over the time course investigated, and 
the number of dividing cells appeared to actually increase compared to the 
undifferentiated control by the 7 day time point, though the margin was only very slight. 
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Figure 5.3.7: Cell cycle analysis in SH-SY5Y neuroblastoma cells exposed to either IO)lM ATRA, 
I3cisRA, EC23 or EC 19 for either 3 (A) or 7 days (8). Control undifferentiated cultures retain the highest 
percent of cells entering cell division at both 3 day and 7 day time points, with fewer dividing cells present 
at the 7 day time This could be due to cultures becoming more confluent and less optimal for cell 
proliferation. ATRA cultures had far fewer dividing cells at both 3 and 7 days. By 7 days not many 
proliferating cells are present at all . 13cisRA cultures contain more proliferating cells than ATRA controls 
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at both time points. EC23 cultures contain less proliferating cells at both time points than the controls, but 
the number of dividing cells is greater than the ATRA counterpart. EC 19 cultures show very little 
attenuation of proliferating cells and the number appears to actually increase compared to the controls by 
the 7 day time point. n=3. * p p:SO.05, ** p:SO.005, student ' s t-test compared to the relevant undifferentiated 
sample. 
5.3.5 BrdU analysis ojSH-SY5Y cells incubated with retinoids 
Now it had been established that supplementation of media with the retinoids did induce 
a decrease in cell proliferation in SH-SY5Y cells it was now investigated whether thi s 
attenuation of proliferation was linked to a particular cell type within the culture system. 
To analyse this, BrdU was spiked into cultures for 24 hours prior to fixation of cultures 
and immunocytochemical analysis. Figure 5.3.8, which shows cultures stained for BrdU 
expression, backs up previous cell cycle analysis data, indicating that after the seven day 
time course A TRA-supplemented cultures contained the lowest numbers of proliferating 
cells. Ee23 cultures contained the next lowest number of proliferating cells, followed by 
the undifferentiated and vehicle controls, with EC 19 supplemented cultures containing 
the highest level of cells which have continued to proliferate. 
Figure 5.3.8: BrdU expression in SH-SY5Y neuroblastoma cells exposed to either IO)lM ATRA, EC23 or 
EC 19 for up to 7 days. Control undifferentiated and vehicle (DMSO) exposed cultures (A,B,F,G) exhibited 
a high number of BrdU positive cells at both 3 day and 7 day time points, with slightly fewer positive cells 
at the 7 day time point. This could be due to cultures becoming more confluent and less optimal for cell 
proliferation. ATRA cultures (C, H) had far fewer BrdU positive cells at both 3 and 7 days. By 7 days not 
many proliferating cells are present at all. EC23 cultures (0,1) contain less proliferating cells at both time 
points than the controls, but the number of BrdU positive cells is greater than the ATRA counterpart. EC 19 
cultures (E, J) show no attenuation of BrdU positive cells and the number appears to actually increase 
compared to the controls by the 7 day time point. All micrographs are counterstained with the nuclear 
marker Hoechst 33342. Scale bar: 50)lm. n=3. 
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Samples were next dual stained with BrdU and the N-type cell marker TU] 1 (Fig. 5.3.9). 
In the undifferentiated and vehicle control cultures it was impossible to determine 
whether there was a particular cell type which had predominately undergone cell 
division, as so many cells were continuing to divide and therefore BrdU positi ve. There 
were many BrdU-positive cells within the EC 19-supplemented samples also, however, as 
seen throughout this chapter, N-type cells appeared to be inhibited within this culture, 
and although TUJ} positive cells were visualised, the level of expression was low, and no 
neurite extensions were seen. In both A TRA- and EC23 supplemented cultures, cell s 
which were BrdU positive at the three day time point were predominantly TU] I-negati ve 
(i.e. only had low level TU] 1 expression). Cells which were BrdU positi ve at the seven 
day time point in both conditions were also predominantly TU] I positive. These data 
suggests that both ATRA and EC23 inhibit the S-type cells from proliferating first , before 
they inhibit the N-type cell popUlation. Once again EC23 was able to mimic A TRA-
induced responses, albeit not to the same level. In fact EC23-induced biological 
responses visualised within this cancer cell model system appeared to more closely 
represent cultures supplemented with the natural retinoid 13cisRA, the retinoid of choice 
in therapeutic regimes for neuroblastoma. EC19 appeared to either elicit no response 
from this cell line, or at certain concentrations actually enhanced cell proliferation. These 
findings could potentially open the way for the use of these particular molecules as useful 
tools towards improving our understanding of neuroblastoma cancer biology. 
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Figure 5.3.9: Co-localisation of BrdU and TUJ I expression in SH-SY5Y neuroblastoma cells exposed to 
either IOIlM ATRA, EC23 or EC 19 for up to 7 days, It is difficult to distinguish at the 3 day time point if 
thee is any co-localisation of BrdU with a particular cell type, however, by the 7 day time point it becomes 
easier to see that BrdU predominantly appears to co-localise with the N-type cells, Scale bar: 50llm . n=3. 
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5.4Discussion and Conclusions: 
The aims of this Chapter were to evaluate the activity of the synthetic retinoids EC19 and 
EC23 to inhibit cell proliferation in a model of neural cancer. The cell system used was a 
model of childhood neuroblastoma, a neural tumour which treatment programmes 
incorporating retinoids is already in clinical use. For the cell system to be considered a 
suitable model they were required to demonstrate a leveI-'of response to the addition of 
natural retinoids into the culture system. The cell line SH-SY5Y has previously been 
shown to fit this criteria, with a portion of the cells dropping out of the cell cycle and 
differentiating down a neural lineage, extending neural processes199. Experiments 
performed in this study are consistent with these observations. Concentration studies 
revealed that the synthetic retinoids EC 19 and EC23 alsQ indu~ed a biological response 
from SH-SY5Y cells after media supplementation. EC19 appeared to inhibit N-type cell 
formation and enhance S-type proliferation, whereas EC23 appeared to mimic ATRA-
induced responses and induce neural differentiation in the N-type cell component. Ee23 
appeared to be more potent than the synthetic retinoid EC 19, which did not inhibit cell 
numbers to the same extent. In fact, EC 19 appeared to actually increase cell numbers at 
the lowest concentration tested, 1 j..lM. Further analysis was carried out at 10j..lM as this 
appeared to be optimal in terms of all retinoids clearly eliciting some level of biological 
response. 
RAR expression analysis revealed that EC19 appeared tojnduc,e differenCRAR sub-sets 
compared to both A TRA and EC23. EC 19 induced an up-regulation of the alpha receptor 
whereas A TRA and EC23 induced localised nuclear beta receptor ef(pression. It has been 
observed with all cell types investigated throughout this thesis that EC 19 elicits differing 
effects to ATRA and EC23, and these expression profiles may go part way to explaining 
these differences. The differential expression of the specific RAR sub-types has been the 
focus of many different neuroblastoma investigations. It is now understood that an up-
regulation of RAR-B often occurs after successful retinoid supplementation and is 
associated with proliferation inhibition and differentiation of cells 202,203. For example, 
retinoid supplementation induces a RAR-B mediated activation of the HOX5A gene via a 
retinoic acid response element located in the 3' end of the gene, and has been shown to 
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induce corresponding apoptosis in breast cancer cells 204. Indeed, it has also been reported 
that the level of RAR-~ expression is an important indicator of retinoid sensitivity of 
primary neuroblastoma samples, the higher the expression level the better the prognosis 
205. Therefore the small ~ncrease in RAR-~ expression after ATRA and EC23 exposure 
observed in this investigation could be interpreted as an indication that the cells were 
responding to the retinoid treatment, as a corresponding decrease in total cell 
number/culture and differentiation was observed in these samples. Therefore it can be 
concluded that EC23 appears to induce a similar response in SH-SY5Y cells as ATRA. 
The increase in expreSSIOn of RAR-a in cultures supplemented with ECl9 is very 
interesting. While there are no papers specifically reporting the outcome of over-
expression of RAR-a in neuroblastoma cultures, there are papers reporting the effects in 
other cancer models. For example, the over-expression of RAR-a fusion proteins 
inhibited cell differentiation of mouse bone marrow progenitor cells, leading to 
immortalisation of the myeloid progenitors, and creating cells similar to those seen in 
acute promyelocytic leukaemia 206. It is possible to hypothesise that EC 19 triggers 
enhanced proliferation in the SH-SY5Y cultures, somehow involving RAR-a-mediated 
activity, which would be of interest to investigate further from a cancer point of view. It 
would be interesting to investigate what effect treatment with an antagonist of RAR-a 
would have on neuroblastoma proliferation. It would be tempting to hypothesis that 
profileration would become decreased compared to controls. These are potentially 
important findings, and will contribute to the future development of more specific RAR 
orientated chemotherapeutic agents. 
To investigate whether the synthetic compounds were more potently active than the 
natural retinoids on this neuroblastoma cell line, experiments were tailored to examining 
what effect media supplementation had on the cell cycle and markers of proliferation. 
Specifically this focussed on the two cell types found within healthy cultures, namely the 
N-type neuronal cells and S-type substrate-adherent like cells. Cell cycle analysis 
revealed that after the 7 day time point EC23 did not cause as many cells to stop dividing 
as ATRA. In fact, EC23 results were more in line with the other natural retinoid tested, 
13-cisRA. As expected EC 19 did not inhibit cell division to any extent compared with the 
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undifferentiated control. BrdU analysis was carried out to investigate which cell type was 
being affected by retinoid supplementation. It appeared that within A TRA and EC23 
cultures S-type cell proliferation was being inhibited first, followed by the N-type cells. It 
was again noted that Ee23 was found to be less effective at inhibiting cell proliferation as 
A TRA, although it did mimic its effects. EC 19 appeared to be acting differently from the 
other retinoids tested which was consistent with its pattern of activity. The fact that EC23 
did not appear as effective an inhibitor of proliferation as ATRA, indicates that it is not a 
viable alternative for further study in a chemotherapeutic context in the neuroblastoma 
cell line. 
Other studies have also shown that synthetic arotinoids induce biological activity, 
however they have also shown that these compounds appear to have an increased level of 
toxicity 207, signifying them as inappropriate for use as therapeutic agents. This data ties 
in with findings reported in Chapter 2 concerning their use in adult progenitor cells, 
where they appeared toxic when used at concentrations recommended and commonly 
used for ATRA supplementation. However, the chemical stability achieved with these 
molecules remains very desirable, and reports of modifications to their basic structure 
have proved promising. For example, the incorporation of a heteroatom into one of the 
cyclic rings drastically reduced the toxicity observed, whilst retaining the ability to 
induce differentiation or apoptosis in cancer cell models 207. One such compound, 
Tazarotene, which IS already available as a treatment for psoriasis and acne, was 
subjected to phase 1 clinical trials on adult patients with advanced cancer 208. It was 
shown to be tolerated well over a period of 12 weeks with fewer toxicity issues than 
associated with A TRA and 13cisRA, making it a promising compound requiring further 
investigation. Other chemical variations of arotinoids, namely flexible heteroarotinoids, 
also have potential as chemotherapeutic agents, by inducing the differentiation of cancer 
cells, Interestingly, however, these compounds do not activate any of the RARs or RXRs, 
prompting further investigation into their modes of action 209. Novel retinoid compounds 
have also been evaluated with some success in the field of neuroblastoma research. The 
synthetic atypical retinoid STI926 does not induce the differentiation of neuroblastoma 
cells but does induce apoptosis. STI926 is able to function in this way in cell lines which 
have been shown to be ATRA-resistant, again making this a very interesting candidate 
requiring further evaluation 198. All of these studies have indicated that while arotinoids 
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theinselves are not conducive for use in chemotherapeutic therapies they have formed a 
solid base from which more viable chemical compounds have been created. 
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5.4.1 Conclusions 
SH-SY5Y neuroblastoma cells are a suitable model for testing retinoid-induced inhibition 
of growth of cancer cells. The ability of the synthetic retinoids EC 19 and EC23 to inhibit 
neural cancer cell growth was tested here. EC23 did induce neural differentiation within 
this cell model system and was able to limit cell proliferation in a manner similar to that 
witnessed with the natural retinoid A TRA; albeit not to the same extent. Therefore it was 
concluded that EC23 does not appear to be an effective alternative to ATRA for limiting 
neuroblastoma growth according to this particular cell model system. 
EC 19 did elicit biological responses after media supplementation. However, these were 
distinctly different to those witnessed with the control test retinoid ATRA. EC 19 
inhibited N-type cells, with very few being visible using immunocytochemical analysis. 
EC 19 also appeared to enhance cell proliferation of the S-type component within the 
cultures. It can be concluded that while EC 19 is not effective at inhibiting neuroblastoma 
cell growth it may be a valuable tool for use in the study of why cancer cells are 
proliferative. One tentative hypothesis may be that an up-regulation of the RAR-a sub-
type is involved in this aberrant cell proliferation, as discussed above. 
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6 Chapter 6: Thesis Discussion and Final Concluding Comments 
6.1 Summary and Discussion of Thesis Data 
This thesis has investigated the biological activity of the retinoic acid analogues EC 19 
and EC23, specifically their ability to induce neural differentiation in a range of stem and 
progenitor cell model systems. EC 19 and EC23 are arotinoids which have been shown to 
have enhanced chemical stability due to the insertion of a triple bond and an aromatic 
ring into the polyene linker region. 
The main aim of this body of work was to establish whether either EC 19 or EC23 would 
be viable as an attractive alternative to A TRA for in vitro experimental use. A TRA has 
been shown to be unstable when used under standard laboratory conditions, isomerising 
readily when exposed to heat and light. For example, when ATRA was exposed to UV 
light for 3 days only 37% of the compound remained in the intact un-degraded form 123. 
This is likely to cause problems when an exact concentration of A TRA is required, i.e. 
for developmental studies, as outlined in Chapter 1. It has also been shown in this thesis 
how the different isomers of retinoic acid can elicit dramatically different results, again 
indicating the need for a non-isomerisable alternative to ATRA. Throughout the course of 
this investigation the biological activity of EC 19 and EC23 was tested on stem cells, 
adult and embryonic neural progenitor cells and a model of neuroblastoma. 
In all the cell model systems tested, the biological activity of EC23 closely mimicked that 
of A TRA, whereas EC 19 did not. Work carried out in Chapter 3 illustrated the ability of 
both compounds to induce differentiation in stem cells systems. In both EC and ES cells, 
EC23 was able to induce neuronal differentiation in a similar manner to A TRA, up-
regulating specific components of the retinoic acid receptor pathway. EC 19 also induced 
cellular differentiation under specific conditions, but induced epithelial-like 'plaques' of 
cells at the expense of neural differentiation. Similar findings were reported in Chapter 4, 
where the two compounds were cultured with adult and embryonic neural progenitor 
celis. In the adult model system, EC23 was able to induce mainly neuronal 
differentiation, similar to ATRA, whereas EC 19 induceci an increased amount of glial 
differentiation. Interestingly, in the embryonic neural progenitor system retinoids had not 
previously been used as part of the differentiation protocol. It was noted that after either 
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ATRA or EC23 media supplementation more mature, NF-200 positive, neuronal sub-
types were observed compared with the established differentiation protocol. Again this 
was not the case with EC 19. Chapter 5 dealt with the ability of the synthetic retinoids to 
inhibit proliferation of a neuroblastoma cell model system. While EC23 was able to 
induce a degree of neural differentiation, the ability of this compound to inhibit 
proliferation was less than that of A TRA. It appeared that low level supplementation of 
media with EC 19 actually enhanced the proliferation of this cancer . model. This 
phenomenon could be exploited to aid in the understanding of the mechanisms behind 
cancer cell proliferation, if the downstream activation partners were identified. 
It is important to relate how these data fit in with other published retinoid biological data. 
As outlined in the introduction to this thesis, there have been many novel synthetic 
retinoids synthesised and their associated RARJRXR binding capacities reported. Indeed, 
EC23 has been shown to activate all of the retinoic acid receptors 122, and data in this 
thesis suggests that the biological activity elicited by both EC 19, and to a greater extent 
EC23 are mediated via the nuclear retinoic acid receptor pathway. However, it must be 
noted that some retinoids appear to act in non-nuclear modes. Retinoids which have this 
ability include a sub-group of arotinoids, the heteroarotinoids. As these compounds have 
a similar chemical structure to the arotinoids tested in this thesis it is relevant to explore 
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these findings. For example, the synthetic heteroarotinoid SHetA2 induces apoptosis in 
head and neck squamous carcinoma cells through a receptor-independent and 
mitrochondria-dependent pathway 210. The retinoid does not activate any of the retinoic 
acid receptors and appears to induce apoptosis by increasing the production of reactive 
oxygen species within the mitochondria. This RARJRXR independent retinoid action has 
been demonstrated to overcome much of the toxicity and'teratogenicity normally 
associated with the clinical use of retinoids 207. As a result of this, non-receptor mediated 
retinoid activity could prove very beneficial for treatments of cancers. Another example 
showed that synthetic heteroarotinoids could induce apoptosis in A TRA -resistant HL60 
myeloid leukemia cells' 211. As far as this thesis is concerned, although it is known that 
EC23 activates the RARs, it cannot be ruled out that· some, of its activity may be 
associated with non-receptor mediated events. To better understand this, more 
experimentation would have to be performed, perhaps looking at the levels of reactive 
oxygen species released by the mitochondria, and also blocking the activity of the 
receptors via an antagonist and investigating whether any biological activity still occurs 
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after EC 19/23 supplementation. As it is not known which receptors EC 19 activates it 
would also be interestirig to evaluate the possibility that some- of the results observed 
could be induced via non-receptor mediated pathways. 
Proteomic analysis of retinoid-induced proteins revealed that after exposure of EC cells 
to EC23 for 7 days, an increase in CRABP-I was observed compared to the ATRA 
differentiation control. This could indicate that EC23 is either lllore biologically potent, 
and/or the cell finds it harder to break down this more stable synthetic compound. 
However, it must also be noted that differences in activity between EC23 and ATRA are 
also liable to arise from alternative active breakdown products. For example it has been 
shown that the breakdown products resulting from A TRA metabolism also elicit their 
own biological activity. In 1993 a paper published in Nature revealed that 4-oxo-retinoic 
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acid is a highly active modulator of positional specification during xenopus development, 
and not just an excretable bi-product of ATRA metabolism 212. However, they did also 
note that the activity of this compound on ES cells was less than A TRA. It is not known 
what, if any, active cellular breakdown products derive from EC23. Nonetheless the 
apparent resistance to cellular breakdown suggests that such molecules would be 
generated at lower rates and hence be present at lower concentrations than those arising 
from ATRA. Furthermore any breakdown products of EC23 would be structurally, and 
by inference, functionally different from their natural counterparts. Again, this is an area 
which requires further investigation. 
Finally it must also be acknowledged that the retinoic acid receptor pathway is by no 
means the only pathway influencing the neuronal differentiation of cells in vitro or in 
vivo. Many of the well known and studied signalling pathways are involved in neural 
development and CNS axis orientation, both working independently and interacting with 
the retinoic acid receptor pathway. Recent published data has indicated distinct roles for 
FGF, Wnt and retinoic acid in posteriorizing the neural e~toderm 2\3. In this study of the 
"~ . 
anterior/postior patterning of the late blastula to gastrula embryo of the zebrafish, they 
revealed how FGF and Wnt signals suppress expression of anterior genes, such as the 
retinoid activated cyp26 gene. This suppression allowed posteriorization of the neural 
tissue to occur, regulated by retinoic acid. Therefore it was discovered that the cyp26 
gene played an important role in linking FGF, Wnt and retinoic acid signals. Other papers 
have also revealed links between the retinoic acid receptor pathway and the nerve growth 
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factor and sonic hedgehog signalling pathways during neurite outgrowth (extensively 
reviewed in 214). It has been shown that sonic hedgehog is one of the downstream targets 
of the RAR~2 signalling pathway 215, and it is expressed in the injured dorsal root ganglia 
neuronal subtypes that extend neurites in response to retinoic acid 216. Therefore, while 
studying the biological effects of our synthetic retinoids on neural differentiation it is 
important to aknowledge that other pathways may be being influenced, and better yields 
of neuronal differentiation could be obtained if these pathways were manipulated also. 
6.2 Possible future directions 
While the findings reported here, answered the main questions set out at the beginning of 
this piece of work, new questions have arisen which are deserving of attention. Three 
main questions and areas for future work are outlined below. 
6.2.1 Structure of synthetic retinoids relates to function 
The importance of retinoid structure and how this can have a great influence on 
biological outcome has been clearly demonstrated throughout this investigation. The only. 
chemical difference between the two synthetic retinoid compounds EC 19 and EC23 is the 
position of the carboxyl group either in the meta- (ECI9) or para-position (EC23). This 
seemingly small chemical modification appears to alter the structure of the molecule 
enough to interrupt interaction with specific receptor subsets. EC19 does not appear to be 
as biologically active as EC23 when tested on any of the. cell model systems. Its effects 
tend to be different from those induced by ATRA or EC23, again an indication that 
different retinoic acid receptors, or indeed other receptors, are being activated. The 
importance of structure/activity relationships between retinoids have already been 
realised, for example, 9cisRA, which differs from ATRA only by a cis configuration at 
the 9 carbon position is able to induce both differentiation and apoptosis in the N-type 
cells of neuroblastoma, whereas ATRA is only able to i~duce differentiation 217. This 
outcome is obviously desirable from a therapeutic standing and as such, has been 
exploited for therapeutic applications. Research and development has focussed on 
creating novel structures containing the cis- configuration with some success. For 
example, a novel synthetic heterocycle retinoid based on the structure of TTNBP, 
contains a cis-bond isomerisation and has been shown ~to induce enhanced levels of 
apoptotic activity in a culture model of APL. Furthermore, the compound has further 
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been shown to induce apoptosis in culture models of APL which are apparently non-
responsive to ATRA treatment 218. These studies exemplify the importance of 
understanding structure/activity relationships, and how to use these for 
therapeutic/research gain. In the context of this thesis; understanding how structure 
ultimately effects cellular differentiation is very important, and will build on the existing 
knowledge base for use in the future synthesis of more selective retinoid structures. 
6.2.2 Preliminary analysis of a novel fJ-selective synthetic retinoid 
EC 19 and EC23 were designed to activate all of the RAR sub-types; however it is known 
that specific receptors are important for different biological developmental processes, and 
some are linked to the side-effects observed when these compounds are used 
therapeutically. As outlined in Chapter 1, it is well known that the beta retinoic acid 
receptor is involved in neuronal differentiation 174,219, specifically the RAR-~2 subtype 
174. As part of an on-going research initiative, receptor-specific synthetic retinoids are 
being generated which need to be tested biologically. A novel synthetic compound was 
synthesised in the Chemistry Department, Durham University, modelled on published 
data pertaining to a selective ~-retinoic acid receptor agonist compound 220. In terms of 
neuronal development, the ~-receptor plays an important role. Therefore it is 
hypothesised that a ~-selective receptor agonist may enhance the neuronal differentiation 
induced in stem cell models. Experiments could be carried out as before to verify this 
biological activity of the ~-agonist. 
6.2.3 Manipulation of Ee2 3 synthesis and storage for commercialisation 
One of the main aims of this investigation was to evaluate whether synthetic retinoid 
compounds synthesised in the Durham University Chemistry Department, would act as 
an attractive alternative to ATRA for in vitro use. Specifically, ATRA alternatives are 
required which are stable since ATRA is extremely heat- and photo-labile, isomerising 
readily under standard laboratory conditions (see Chapter 1). One of the main 
conclusions resulting from this thesis was that EC23 appeared to mimic ATRA-induced 
activity, inducing neuronal differentiation within the various cell model systems tested. 
This molecule therefore possesses potential as a commercial product, and as the work 
obtained for this thesis is linked to the commercial entity ReInnervate Ltd, 
commercialisation of the product needs to be evaluated. Before EC23 could be 
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considered for validation by prospective commercial partners, further investigative 
experimentation would be required relating to the possibility for bulk production and 
accurate dispensing into commercial vials. Subsequently, biological activity of this 
product would need to be assessed before the product can be put forward for the next 
stage of the commercialisation process. 
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6.3 Final concluding comments 
In conclusion, all results obtained throughout this thesis indicate the feasibility of the 
synthetic arotinoid, EC23, being used as a more stable alternative to ATRA in in vitro 
investigations into retinoid modes of action and neurogenesis. EC23 has been able to 
induce neuronal differentiation in a diverse range of cell model systems, covering 
embryonic stem, and neural progenitor cells through to models of adult neural progenitor 
cells. Up-regulation of key retinoic acid receptor components has strengthened arguments 
that EC23 elicits its effects via this retinoic acid receptor pathway. Novel findings have 
been established along the way, including new methods to induce more mature neuronal 
phenotypes with retinoid media supplementation in the embryonic neural progenitor cell 
line ReNcell VM. Links between profilin and stathmin regulation and retinoid-induced 
differentiation have been discovered during proteomic analysis of Tera2.sp12 EC cells 
cultured with either ATRA or EC23 for seven days. Finally, it was shown that EC23 was 
able to induce motor neuron phenotypes when used under defined culture conditions in 
human embryonic stem cell cultures. The bulk production and dispensing of EC23 in 
commercially viable quantities was shown to not affect its biological activity, making this 
a very attractive commercial product which is now being taken to the next step of the 
commercialisation process via ReInnervate Ltd, a Durham University Spin-out 
biotechnology company. 
EC 19 was not as biologically effective as EC23 in inducing differentiation in the cell 
model systems tested. Structural analysis revealed that the conformation of this synthetic 
retinoid did not favour activation of the retinoic acid receptors, however when it did elicit 
a response it was invariably different from that witnessed with either ATRA or EC23. In 
the neuroblastoma model system, EC 19 appeared to actually enhance cell proliferation, 
potentially making this retinoid an interesting compound for use in cancer research. The 
inclusion of a methyl group into this compound greatly enhanced its biological activity. 
However this subtle modification did not alter the structural alignment of the compound, 
and must therefore influence its activity in some other way, possibly by altering its 
lipophilic nature, or by enhancing its selective protein binding capacity by some other 
means. This was an interesting finding and requires further experimentation to address 
these possibilities. 
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Work obtained throughout this thesis can be used as a base for future synthesis and 
structural modelling of novel synthetic retinoids. It has been established that proteomic 
analysis can be performed after only seven days of culture with the retinoids and gives a 
good indication of retinoid action. Work carried out on the novel beta-agonist and the 3-
Me-EC 19 compound indicated that chemical modelling has a valuable contribution to 
make to the process of novel retinoid synthesis. However, modelling alone is not 
sufficient to fully predict the induced biological outcome, due to the complicated nature 
of retinoid modes of action. 
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